OMEGA HEALTHCARE INVESTORS INC 10-K

Item 9A – Controls and Procedures Evaluation of Disclosure Controls and Procedures In connection with the preparation of our Form 10-K as of and for the year ended December 31, 2025, management evaluated the effectiveness of the design and operation of disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) of the Company as of December 31, 2025. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer of the Company concluded that the disclosure controls and procedures of the Company were effective at the reasonable assurance level as of December 31, 2025. Management’s Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that: ● Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; ● Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and ● Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements. All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. In connection with the preparation of this Form 10-K, our management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2025. In making that assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (“2013 framework”). Based on management’s assessment, management believes that, as of December 31, 2025, the Company’s internal control over financial reporting was effective based on those criteria. The independent registered public accounting firm’s attestation reports regarding the Company’s internal control over financial reporting is included in the 2025 financial statements under the caption entitled Report of Independent Registered Public Accounting Firm and is incorporated by reference herein. Changes in Internal Control Over Financial Reporting There were no changes in the Company’s internal control over financial reporting during the quarter ended December 31, 2025 identified in connection with the evaluation of their disclosure controls and procedures (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) described above that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting. 51 Table of Contents Item 9B – Other Information Rule 10b5-1 Trading Plans No officers or directors, as defined in Rule 16a-1(f), adopted , modified and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the fourth quarter of 2025. Item 9C – Disclosure Regarding Foreign Jurisdictions that Prevent Inspections Not Applicable. ​ ​ 52 Table of Contents PART III Item 10 – Directors, Executive Officers of the Registrant and Corporate Governance For information regarding executive officers of our Company, see Item 1 – Business – Information about our Executive Officers. The other information required by this item is incorporated herein by reference to the “Proposal 1 – Election of Directors,” “Board Committees and Corporate Governance” and “Audit Committee and Independent Auditor Matters” sections of Company’s definitive proxy statement for the 2026 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation 14A. Code of Business Conduct and Ethics We have adopted a written Code of Business Conduct and Ethics (“Code of Ethics”) that applies to all of our directors and employees, including our chief executive officer, chief financial officer, chief accounting officer and controller. A copy of our Code of Ethics is available on our website at www.omegahealthcare.com. Any amendment to our Code of Ethics or any waiver of our Code of Ethics that is required to be disclosed will be provided on our website at www.omegahealthcare.com promptly following the date of such amendment or waiver. Insider Trading Policy We have adopted an Insider Trading Policy that governs the purchase, sale and/or other dispositions of our securities by our directors, officers and employees, as well as the Company, that is reasonably designed to promote compliance with insider trading laws, rules and regulations, and the New York Stock Exchange listing standards applicable to us. A copy of our Insider Trading Policy is incorporated by reference as Exhibit 19.1 to this Annual Report on Form 10-K. Equity Award Grant Policy The Compensation Committee of our Board of Directors approves all equity awards granted to the executive officers. Approval of the equity awards for the executive officers generally occurs at the Compensation Committee’s regularly scheduled quarterly meeting for the fourth quarter of each year, although the Compensation Committee retains the right to approve them at any time. The Company has not historically issued stock options or stock appreciation awards. Item 11 – Executive Compensation The information required by this item is incorporated herein by reference to the “Compensation Discussion and Analysis” and “Executive Compensation Tables and Related Information” sections of our Company’s definitive proxy statement for the 2026 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation 14A. Item 12 – Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters The information required by this item is incorporated herein by reference to the “Stock Ownership Information” section of our Company’s definitive proxy statement for the 2026 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation 14A, except as set forth below. 53 Table of Contents The following table provides information about shares available for future issuance under our equity compensation plans as of December 31, 2025: Equity Compensation Plan Information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (c) ​ ​ ​ ​ ​ ​ ​ Number of securities ​ ​ (a) ​ (b) ​ remaining available for ​ ​ Number of securities to ​ Weighted-average ​ future issuance under ​ ​ be issued upon exercise ​ exercise price of ​ equity compensation plans ​ ​ of outstanding options, ​ outstanding options, ​ excluding securities Plan category ​ ​ ​ warrants and rights (1) ​ ​ ​ warrants and rights (2) ​ ​ ​ reflected in column (a) (3) Equity compensation plans approved by security holders 6,776,302 ​ $ — 3,061,381 Equity compensation plans not approved by security holders — ​ — — Total 6,776,302 ​ $ — 3,061,381 (1) Reflects (i) 523,258 time-based restricted stock units (“RSUs”) and profit interest units (“PIUs”), (ii) 5,572,204 shares related to performance-based RSUs ( “PRSUs”) and performance-based PIUs that could be issued if certain performance conditions are achieved and (iii) 680,840 shares in respect of outstanding deferred stock units. (2) No exercise price is payable with respect to the RSUs and PRSUs. (3) Reflects (i) 2,621,601 shares of common stock under our 2018 Stock Incentive Plan and (ii) 439,780 shares of common stock under the Omega Healthcare In vestors, Inc. Employee Stock Purchase Plan. ​ Item 13 – Certain Relationships and Related Transactions, and Director Independence The information required by this item is incorporated herein by reference to the “Proposal 1 – Election of Directors” and “Board Committees and Corporate Governance” sections of our Company’s definitive proxy statement for the 2026 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation 14A. Item 14 – Principal Accountant Fees and Services The information required by this item is incorporated herein by reference to the “Audit Committee and Independent Auditor Matters” section of our Company’s definitive proxy statement for the 2026 Annual Meeting of Stockholders, to be filed with the SEC pursuant to Regulation 14A. ​ 54 Table of Contents PART IV Item 15 – Exhibits and Financial Statement Schedules (a)(1) Listing of Consolidated Financial Statements ​ ​ ​ Title of Document ​ ​ ​ Page Number Reports of Independent Registered Public Accounting Firm (PCAOB ID: 42 ) ​ F-1 ​ ​ ​ Consolidated Balance Sheets as of December 31, 2025 and 2024 ​ F-4 Consolidated Statements of Operations for the three years ended December 31, 2025 ​ F-5 Consolidated Statements of Comprehensive Income for the three years ended December 31, 2025 ​ F-6 Consolidated Statements of Equity for the three years ended December 31, 2025 ​ F-7 Consolidated Statements of Cash Flows for the three years ended December 31, 2025 ​ F-8 Notes to Consolidated Financial Statements ​ F-9 ​ (a)(2) Financial Statement Schedules. The following consolidated financial statement schedules are included herein: ​ ​ ​ Schedule III – Real Estate and Accumulated Depreciation ​ F-63 ​ ​ ​ Schedule IV – Mortgage Loans on Real Estate ​ F-65 ​ All other schedules for which provision is made in the applicable accounting regulation of the Securities and Exchange Commission are not required under the related instructions or are inapplicable or have been omitted because sufficient information has been included in the notes to the Consolidated Financial Statements. (a)(3) Exhibits — See “ Index to Exhibits ” beginning on Page I-1 of this report. Item 16 – Form 10-K Summary None. ​ ​ 55 Table of Contents Report of Independent Registered Public Accounting Firm ​ To the Stockholders and the Board of Directors of Omega Healthcare Investors, Inc. ​ Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Omega Healthcare Investors, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive income, equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes and financial statement schedules listed in the Index at Item 15(a)(2) (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 9, 2026 expressed an unqualified opinion thereon. Basis for Opinion These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matter The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. F-1 Table of Contents Collectibility of future lease payments Description of the Matter During 2025, the Company recognized rental income of $1,002.0 million and has recorded straight-line rent and lease inducement receivables of $278.6 million at December 31, 2025. As described in Note 2 to the consolidated financial statements, the timing and pattern of rental income recognition for operating leases is affected by the Company’s determination as to whether the collectibility of substantially all lease payments is probable. Auditing the Company's accounting for rental income is complex due to the judgment involved in the Company’s determination of the collectibility of future lease payments for certain operators. The determination involves consideration of the lessee’s payment history, an assessment of the financial strength of the lessee and any guarantors, where applicable, historical operations and operating trends, current and future economic conditions, and expectations of performance (which includes known substantial doubt about an operator’s ability to continue as a going concern). How We Addressed the Matter in Our Audit We obtained an understanding, evaluated the design and tested the operating effectiveness of the Company’s controls over the recognition of rental income, including controls over management’s assessment of the collectibility of future lease payments. For example, we tested controls over management’s consideration of the factors used in assessing collectibility and controls over the completeness and accuracy of the data used in management’s analyses. To test the rental income recognized, we performed audit procedures that included, among others, evaluating the collectibility of future lease payments. For example, we assessed the lessee’s payment history, historical operating results of the properties, and factors contributing to the financial strength of the lessee, including current and future economic conditions, as well as management’s assessment of the expectation of performance of a sample of operators. We also considered whether other information obtained throughout the course of our audit procedures corroborated or contradicted management’s analysis. In addition, we tested the completeness and accuracy of the data that was used in management’s analyses. ​ ​ ​ ​ ​ ​ /s/ Ernst & Young LLP We have served as the Company’s auditor since 1992. Baltimore, Maryland February 9, 2026 ​ ​ F-2 Table of Contents Report of Independent Registered Public Accounting Firm ​ To the Stockholders and Board of Directors of Omega Healthcare Investors, Inc. ​ Opinion on Internal Control over Financial Reporting We have audited Omega Healthcare Investors, Inc.’s internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control —Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Omega Healthcare Investors, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on the COSO criteria. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive income, equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes and financial statement schedules listed in the Index at Item 15(a)(2) and our report dated February 9, 2026 expressed an unqualified opinion thereon. Basis for Opinion The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Definition and Limitations of Internal Control Over Financial Reporting A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. /s/ Ernst & Young LLP Baltimore, Maryland February 9, 2026 ​ F-3 Table of Contents ​ OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except per share amounts) ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2025 ​ ​ ​ 2024 ​ ​ ​ ​ ​ ​ ASSETS ​ ​ ​ ​ ​ Real estate assets ​ ​ ​ ​ Buildings and improvements $ 7,901,652 $ 7,342,497 Land ​ 1,179,463 ​ ​ 996,701 Furniture and equipment ​ 539,775 ​ ​ 510,106 Construction in progress ​ 12,492 ​ ​ 210,870 Total real estate assets ​ 9,633,382 ​ ​ 9,060,174 Less accumulated depreciation ( 2,930,611 ) ( 2,721,016 ) Real estate assets – net 6,702,771 6,339,158 Investments in direct financing leases – net — 9,453 Real estate loans receivable – net 1,380,949 1,428,298 Investments in unconsolidated entities 414,127 88,711 Assets held for sale 4,000 56,194 Total real estate investments ​ 8,501,847 ​ ​ 7,921,814 Non-real estate loans receivable – net 330,322 332,274 Total investments 8,832,169 8,254,088 ​ ​ ​ ​ ​ ​ Cash and cash equivalents 27,024 518,340 Restricted cash 27,539 30,395 Contractual receivables – net 9,723 12,611 Other receivables and lease inducements ​ 278,570 ​ ​ 249,317 Goodwill 644,626 643,664 Other assets 229,408 189,476 Total assets $ 10,049,059 $ 9,897,891 ​ ​ ​ ​ ​ ​ LIABILITIES AND EQUITY ​ ​ Revolving credit facility $ 242,000 $ — Secured borrowings — 243,310 Senior notes and other unsecured borrowings – net 4,014,011 4,595,549 Accrued expenses and other liabilities 352,549 328,193 Total liabilities 4,608,560 5,167,052 ​ ​ ​ ​ ​ ​ Preferred stock $ 1.00 par value authorized – 20,000 shares, issued and outstanding – none ​ — ​ ​ — Common stock $ 0.10 par value authorized – 700,000 shares , issued and outstanding – 295,539 shares as of December 31, 2025 and 279,129 shares as of December 31, 2024 29,553 ​ 27,912 Additional paid-in capital 8,693,033 ​ 7,915,873 Cumulative net earnings 4,677,092 ​ 4,086,907 Cumulative dividends paid ( 8,297,416 ) ​ ( 7,516,750 ) Accumulated other comprehensive income 79,037 ​ 22,731 Total stockholders’ equity 5,181,299 ​ 4,536,673 Noncontrolling interest 259,200 ​ 194,166 Total equity 5,440,499 ​ 4,730,839 Total liabilities and equity $ 10,049,059 $ 9,897,891 ​ See accompanying notes. ​ F-4 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2025 ​ ​ ​ 2024 ​ ​ ​ 2023 Revenues ​ ​ ​ ​ ​ ​ ​ ​ Rental income $ 1,001,965 ​ $ 887,910 ​ $ 826,394 Interest income 175,112 ​ 157,207 ​ 119,888 Miscellaneous income 13,022 ​ 6,273 ​ 3,458 Total revenues 1,190,099 ​ 1,051,390 949,740 ​ ​ ​ ​ ​ ​ ​ ​ ​ Expenses ​ ​ ​ ​ Depreciation and amortization 325,247 ​ 304,648 ​ 319,682 General and administrative 104,137 ​ 88,001 ​ 81,504 Real estate taxes ​ 14,438 ​ ​ 14,561 ​ ​ 15,025 Acquisition, merger and transition related costs 4,219 ​ 11,615 ​ 5,341 Impairment on real estate properties 22,610 ​ 23,831 ​ 91,943 Provision (recovery) for credit losses 2,336 ​ ( 15,483 ) ​ 44,556 Interest expense 215,035 ​ 221,716 ​ 235,529 Total expenses 688,022 ​ 648,889 793,580 ​ ​ ​ ​ ​ ​ ​ ​ ​ Other income (expense) ​ ​ ​ ​ Other income – net 50,058 ​ 6,826 ​ 20,297 Gain (loss) on debt extinguishment 4,995 ​ ( 1,749 ) ​ ( 492 ) Gain on assets sold – net ​ 67,303 ​ ​ 13,168 ​ ​ 79,668 Total other income ​ 122,356 ​ ​ 18,245 ​ ​ 99,473 ​ ​ ​ ​ ​ ​ ​ ​ ​ Income before income tax expense and income from unconsolidated entities 624,433 ​ 420,746 255,633 Income tax expense ( 14,748 ) ​ ( 10,858 ) ​ ( 6,255 ) (Loss) income from unconsolidated entities ( 218 ) ​ 7,916 ​ ( 582 ) Net income 609,467 ​ 417,804 248,796 Net income attributable to noncontrolling interest ( 19,282 ) ​ ( 11,478 ) ​ ( 6,616 ) Net income available to common stockholders $ 590,185 ​ $ 406,326 $ 242,180 ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnings per common share available to common stockholders: ​ ​ ​ ​ Basic: ​ ​ ​ ​ Net income available to common stockholders $ 1.96 ​ $ 1.57 ​ $ 1.01 Diluted: ​ ​ ​ ​ ​ Net income available to common stockholders $ 1.94 ​ $ 1.55 ​ $ 1.00 ​ See accompanying notes. ​ F-5 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ ​ ​ 2023 Net income ​ $ 609,467 ​ $ 417,804 ​ $ 248,796 Other comprehensive income (loss) ​ ​ ​ ​ ​ ​ Foreign currency translation ​ 67,771 ​ ( 8,373 ) ​ 20,531 Cash flow hedges ​ ( 9,797 ) ​ 1,602 ​ ( 11,245 ) Total other comprehensive income (loss) ​ 57,974 ​ ( 6,771 ) ​ 9,286 Comprehensive income ​ 667,441 ​ 411,033 ​ 258,082 Comprehensive income attributable to noncontrolling interest ​ ( 20,950 ) ​ ( 11,314 ) ​ ( 6,889 ) Comprehensive income attributable to common stockholders ​ $ 646,491 ​ $ 399,719 ​ $ 251,193 ​ See accompanying notes. ​ ​ F-6 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF EQUITY (in thousands, except per share amounts) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common ​ Additional ​ Cumulative ​ ​ ​ ​ Other ​ Total ​ ​ ​ ​ ​ ​ ​ Stock ​ Paid ‑ in ​ Net ​ Cumulative ​ Comprehensive ​ Stockholders’ ​ Noncontrolling ​ Total ​ ​ ​ ​ Par Value ​ ​ ​ Capital ​ ​ ​ Earnings ​ ​ ​ Dividends ​ ​ ​ Income (Loss) ​ ​ ​ Equity ​ ​ ​ Interest ​ ​ ​ Equity Balance at December 31, 2022 ​ ​ 23,425 ​ ​ 6,314,203 ​ ​ 3,438,401 ​ ​ ( 6,186,986 ) ​ ​ 20,325 ​ ​ 3,609,368 ​ ​ 193,914 ​ ​ 3,803,282 Stock related compensation ​ — ​ ​ 35,276 ​ ​ — ​ ​ — ​ ​ — ​ 35,276 ​ — ​ 35,276 Issuance of common stock ​ 1,100 ​ ​ 335,302 ​ ​ — ​ ​ — ​ ​ — ​ 336,402 ​ — ​ 336,402 Common dividends declared ($ 2.68 per share) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 644,075 ) ​ ​ — ​ ​ ( 644,075 ) ​ ​ — ​ ​ ( 644,075 ) Issuance of Omega OP Units ​ ​ — ​ ​ ( 14,570 ) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 14,570 ) ​ ​ 14,570 ​ ​ — Exchange and redemption of Omega OP Units ​ 3 ​ ​ 1,018 ​ ​ — ​ ​ — ​ ​ — ​ 1,021 ​ ( 1,098 ) ​ ( 77 ) Omega OP Units distributions ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ — ​ ( 26,397 ) ​ ( 26,397 ) Net change in noncontrolling interest holder in consolidated JV ​ ​ — ​ ​ ( 31 ) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 31 ) ​ ​ ( 171 ) ​ ​ ( 202 ) Other comprehensive income ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 9,013 ​ 9,013 ​ 273 ​ 9,286 Net income ​ — ​ ​ — ​ ​ 242,180 ​ ​ — ​ ​ — ​ 242,180 ​ 6,616 ​ 248,796 Balance at December 31, 2023 ​ ​ 24,528 ​ ​ 6,671,198 ​ ​ 3,680,581 ​ ​ ( 6,831,061 ) ​ ​ 29,338 ​ ​ 3,574,584 ​ ​ 187,707 ​ ​ 3,762,291 Stock related compensation ​ ​ — ​ ​ 36,940 ​ ​ — ​ ​ — ​ ​ — ​ ​ 36,940 ​ ​ — ​ ​ 36,940 Issuance of common stock ​ ​ 3,383 ​ ​ 1,232,274 ​ ​ — ​ ​ — ​ ​ — ​ ​ 1,235,657 ​ ​ — ​ ​ 1,235,657 Common dividends declared ($ 2.68 per share) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 685,689 ) ​ ​ — ​ ​ ( 685,689 ) ​ ​ — ​ ​ ( 685,689 ) Issuance of Omega OP Units ​ ​ — ​ ​ ( 25,011 ) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 25,011 ) ​ ​ 25,011 ​ ​ — Exchange and redemption of Omega OP Units ​ ​ 1 ​ ​ 472 ​ ​ — ​ ​ — ​ ​ — ​ ​ 473 ​ ​ ( 1,157 ) ​ ​ ( 684 ) Omega OP Units distributions ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 29,254 ) ​ ​ ( 29,254 ) Net change in noncontrolling interest holder in consolidated JV ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 545 ​ ​ 545 Other comprehensive loss ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 6,607 ) ​ ​ ( 6,607 ) ​ ​ ( 164 ) ​ ​ ( 6,771 ) Net income ​ ​ — ​ ​ — ​ ​ 406,326 ​ ​ — ​ ​ — ​ ​ 406,326 ​ ​ 11,478 ​ ​ 417,804 Balance at December 31, 2024 ​ ​ 27,912 ​ ​ 7,915,873 ​ ​ 4,086,907 ​ ​ ( 7,516,750 ) ​ ​ 22,731 ​ ​ 4,536,673 ​ ​ 194,166 ​ ​ 4,730,839 Stock related compensation ​ ​ — ​ ​ 43,878 ​ ​ — ​ ​ — ​ ​ — ​ ​ 43,878 ​ ​ — ​ ​ 43,878 Issuance of common stock ​ ​ 1,635 ​ ​ 605,133 ​ ​ — ​ ​ — ​ ​ — ​ ​ 606,768 ​ ​ — ​ ​ 606,768 Common dividends declared ($ 2.68 per share) ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 780,666 ) ​ ​ — ​ ​ ( 780,666 ) ​ ​ — ​ ​ ( 780,666 ) Issuance of Omega OP Units ​ ​ — ​ ​ 125,780 ​ ​ — ​ ​ — ​ ​ — ​ ​ 125,780 ​ ​ 96,595 ​ ​ 222,375 Exchange and redemption of Omega OP Units ​ ​ 6 ​ ​ 2,369 ​ ​ — ​ ​ — ​ ​ — ​ ​ 2,375 ​ ​ ( 8,623 ) ​ ​ ( 6,248 ) Omega OP Units distributions ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 43,888 ) ​ ​ ( 43,888 ) Other comprehensive income ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 56,306 ​ ​ 56,306 ​ ​ 1,668 ​ ​ 57,974 Net income ​ ​ — ​ ​ — ​ ​ 590,185 ​ ​ — ​ ​ — ​ ​ 590,185 ​ ​ 19,282 ​ ​ 609,467 Balance at December 31, 2025 ​ $ 29,553 ​ $ 8,693,033 ​ $ 4,677,092 ​ $ ( 8,297,416 ) ​ $ 79,037 ​ $ 5,181,299 ​ $ 259,200 ​ $ 5,440,499 ​ See accompanying notes. ​ F-7 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2025 ​ ​ ​ 2024 ​ ​ ​ 2023 Cash flows from operating activities ​ ​ ​ ​ ​ ​ Net income $ 609,467 ​ $ 417,804 ​ $ 248,796 Adjustment to reconcile net income to net cash provided by operating activities: ​ ​ ​ ​ ​ ​ Depreciation and amortization ​ 325,247 ​ 304,648 ​ 319,682 Impairment on real estate properties ​ 22,610 ​ 23,831 ​ 91,943 Straight-line rent and other write-offs ​ 27,983 ​ 4,174 ​ 20,633 Provision (recovery) for credit losses ​ 2,336 ​ ( 15,483 ) ​ 44,556 Amortization of deferred financing costs and loss on debt extinguishment ​ 968 ​ 12,146 ​ 14,189 Stock-based compensation expense ​ 44,189 ​ 36,696 ​ 35,068 Gain on assets sold – net ​ ( 67,303 ) ​ ( 13,168 ) ​ ( 79,668 ) Straight-line rent and effective interest receivables ​ ( 50,261 ) ​ ​ ( 43,018 ) ​ ​ ( 41,849 ) Interest paid-in-kind ​ ( 13,590 ) ​ ​ ( 11,463 ) ​ ​ ( 11,365 ) Loss from unconsolidated entities ​ 6,134 ​ ​ 1,947 ​ ​ 182 Other non-cash items ​ ( 26,281 ) ​ ( 1,538 ) ​ ( 9,336 ) Change in operating assets and liabilities – net: ​ ​ ​ ​ ​ ​ Contractual receivables ​ 2,888 ​ ( 845 ) ​ ( 3,660 ) Lease inducements ​ ( 9,043 ) ​ ( 61 ) ​ ( 15,210 ) Other operating assets and liabilities ​ 3,207 ​ 33,760 ​ 3,775 Net cash provided by operating activities ​ 878,551 ​ 749,430 ​ 617,736 Cash flows from investing activities ​ ​ ​ ​ ​ ​ Acquisition of real estate ​ ( 683,029 ) ​ ( 408,628 ) ​ ( 262,453 ) Net proceeds from sale of real estate investments ​ 282,776 ​ 95,045 ​ 585,031 Investments in construction in progress ​ ( 33,589 ) ​ ( 68,980 ) ​ ( 44,495 ) Investment in loan receivables and other ​ ( 173,570 ) ​ ( 470,011 ) ​ ( 420,626 ) Collection of loan principal ​ 246,593 ​ 207,617 ​ 165,191 Investments in unconsolidated entities ​ ( 122,088 ) ​ ​ ( 971 ) ​ ​ ( 12,350 ) Distributions from unconsolidated entities in excess of earnings ​ 12,913 ​ 1,017 ​ 8,807 Capital improvements to real estate investments ​ ( 80,869 ) ​ ( 37,757 ) ​ ( 38,011 ) Proceeds from foreign currency forward contracts ​ 4,240 ​ 8,429 ​ 11,378 Receipts from insurance proceeds ​ 6,831 ​ 3,075 ​ 6,758 Net cash used in investing activities ​ ( 539,792 ) ​ ( 671,164 ) ​ ( 770 ) Cash flows from financing activities ​ ​ ​ ​ ​ ​ Proceeds from long-term borrowings ​ 1,311,708 ​ 657,819 ​ 507,072 Payments of long-term borrowings ​ ( 1,896,758 ) ​ ( 1,145,301 ) ​ ( 734,991 ) Payments of financing related costs ​ ( 27,251 ) ​ ( 7,018 ) ​ ( 3,827 ) Net proceeds from issuance of common stock ​ 606,768 ​ 1,235,657 ​ 336,402 Dividends paid ​ ( 780,387 ) ​ ( 685,445 ) ​ ( 643,867 ) Net payments to noncontrolling members of consolidated joint venture ​ — ​ 545 ​ ​ ( 202 ) (Payments for) proceeds from derivative instruments ​ ( 2,200 ) ​ ​ — ​ ​ 92,577 Redemption of Omega OP Units ​ ( 6,248 ) ​ ​ ( 684 ) ​ ​ ( 77 ) Distributions to Omega OP Unit Holders ​ ( 43,888 ) ​ ( 29,254 ) ​ ( 26,397 ) Net cash (used in) provided by financing activities ​ ( 838,256 ) ​ 26,319 ​ ( 473,310 ) Effect of foreign currency translation on cash, cash equivalents and restricted cash ​ 5,325 ​ ( 580 ) ​ 430 (Decrease) increase in cash, cash equivalents and restricted cash ​ ( 494,172 ) ​ 104,005 ​ 144,086 Cash, cash equivalents and restricted cash at beginning of period ​ 548,735 ​ 444,730 ​ 300,644 Cash, cash equivalents and restricted cash at end of period $ 54,563 ​ $ 548,735 ​ $ 444,730 ​ See accompanying notes. ​ ​ ​ F-8 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 - ORGANIZATION Omega Healthcare Investors, Inc. (“Parent”), is a Maryland corporation that, together with its consolidated subsidiaries (collectively, “Omega”, the “Company”, “we”, “our”, “us”) invests in healthcare-related real estate properties located in the United States (“U.S.”), the United Kingdom (“U.K.”) and Canada. Our core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (“SNFs”), assisted living facilities (“ALFs”), including care homes in the U.K., and to a lesser extent, independent living facilities (“ILFs”), rehabilitation and acute care facilities (“specialty facilities”) and continuing care retirement communities (“CCRCs”). Our core portfolio consists of our long-term “triple-net” leases and real estate loans with healthcare operating companies and affiliates (collectively, our “operators”). Additionally, during the fourth quarter of 2025, we began utilizing the structure authorized by the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as “RIDEA”), whereby we own and operate healthcare facilities through third-party managers (collectively, our “managers”). In addition to our core investments, we make loans to operators and/or their principals. From time to time, we also acquire equity interests in joint ventures or entities that support the long-term healthcare industry and our operators, which may include ancillary service or technology companies, and in operating companies. Omega has elected to be taxed as a real estate investment trust (“REIT”) for federal income tax purposes and is structured as an umbrella partnership REIT (“UPREIT”) under which all of Omega's assets are owned directly or indirectly by, and all of Omega's operations are conducted directly or indirectly through, its operating partnership subsidiary, OHI Healthcare Properties Limited Partnership (collectively with subsidiaries, “Omega OP”). Omega has exclusive control over Omega OP’s day-to-day management pursuant to the partnership agreement governing Omega OP. As of December 31, 2025, Parent owned approximately 95 % of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and other investors owned approximately 5 % of the outstanding Omega OP Units. The number of Omega OP Units owned by Parent is equivalent to the number of outstanding common shares of beneficial interest in Parent. As of December 31, 2025 and 2024, there were 14,698,225 and 7,898,425 Omega OP Units outstanding, respectively, that were held by other investors. NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Consolidation The consolidated financial statements include the accounts of Omega Healthcare Investors, Inc, its wholly-owned subsidiaries, joint ventures (“JVs”) and variable interest entities (“VIEs”) that it controls, through voting rights or other means. All intercompany transactions and balances have been eliminated in consolidation. GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise, if any, is the primary beneficiary of VIEs. A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. We may change our original assessment of a VIE upon subsequent events such as the modification of contractual arrangements that affects the characteristics or adequacy of the entity’s equity investments at risk and the disposition of all or a portion of an interest held by the primary beneficiary. F-9 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Our variable interests in VIEs may be in the form of equity ownership, leases and/or loans with our operators. We analyze our agreements and investments to determine whether our operators or unconsolidated JVs are VIEs and, if so, whether we are the primary beneficiary. We consolidate a VIE when we determine that we are its primary beneficiary. We identify the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. Factors considered in determining whether we are the primary beneficiary of an entity include: (i) our voting rights, if any; (ii) our involvement in day-to-day capital and operating decisions; (iii) our risk and reward sharing; (iv) the financial condition of the operator or JV and (iv) our representation on the VIE’s board of directors. We perform this analysis on an ongoing basis. As of December 31, 2025 and 2024, we have one JV that is a consolidated VIE as we have concluded that we are the primary beneficiary through our equity investment in the entity. Revenue Recognition Rental Income Rental income from operating leases is recognized on a straight-line basis, inclusive of fixed annual escalators, over the lease term when we have determined that the collectibility of substantially all of the lease payments is probable. Certain of our operating leases contain provisions for an increase based on the change in pre-determined formulas from year to year (e.g., increases in the Consumer Price Index). We do not include in our measurement of our lease receivables these variable increases until the specific events that trigger the variable payments have occurred. Certain payments made to operators are treated as lease inducements and are amortized as a reduction of revenue over the lease term. Our leased real estate properties are leased under provisions of single or master leases with initial terms typically ranging from 5 to 15 years . Some of our leases have options to extend, terminate or purchase the facilities, which are considered when determining the lease term. We assess the probability of collecting substantially all payments due under our leases on several factors, including, among other things, payment history, the financial strength of the lessee and any guarantors, as applicable, historical operations and operating trends, current and future economic conditions, and expectations of performance (which includes known substantial doubt about an operator’s ability to continue as a going concern). If our evaluation of these factors indicates it is not probable that we will be able to collect substantially all rents, we recognize a charge to rental income to write off straight-line rent receivables, contractual receivables and lease inducements and limit our rental income to the lesser of lease income on a straight-line basis plus variable rents when they become accruable or cash collected. Provisions for uncollectible lease payments are recognized as a direct reduction to rental income. If we change our conclusion regarding the probability of collecting rent payments required by a lessee, we may recognize an adjustment to rental income in the period we make a change to our prior conclusion, potentially resulting in increased volatility of rental income. From time to time, we may allow certain operators to defer contractual rent and/or interest or to apply collateral, such as security deposits or letters of credit, to contractual rent and/or interest amounts owed. During the years ended December 31, 2025, 2024 and 2023, these amounts were immaterial. Under the terms of our leases, the lessee is responsible for all maintenance, repairs, taxes and insurance on the leased properties. Certain of our operating leases require the operators to reimburse us for property taxes and other expenditures that are not considered components of the lease and therefore no consideration is allocated to them as they do not result in the transfer of a good or service to the operators. We have determined that all of our leases qualify for the practical expedient, under Accounting Standards Codification (“ASC”) 842, Leases (“Topic 842”), to not separate the lease and non-lease components because (i) the lease components are operating leases and (ii) the timing and pattern of recognition of the non-lease components are the same as the lease components. Certain operators are obligated to pay directly their obligations under their leases for real estate taxes, insurance and certain other expenses. These obligations, which have been assumed by the tenants under the terms of their respective leases, are not reflected in our consolidated financial statements. To the extent any tenant responsible for these obligations under their respective lease defaults on its lease or if it is deemed probable that the tenant will fail to pay for such costs, we would record a liability for such obligation. F-10 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ We have elected to exclude sales and other similar taxes from the measurement of lease revenue and expense. Loan Interest Income Interest income is recognized as earned over the term of the related real estate and non-real estate loans receivable. Interest income is recorded on an accrual basis to the extent that such amounts are expected to be collected using the effective interest method. In applying the effective interest method, the effective yield on a loan is determined based on its contractual payment terms, adjusted for prepayment terms. Real Estate Sales We recognize gains on the disposition of real estate when the recognition criteria have been met, generally at the time the risks and rewards and title have transferred, and we no longer have substantial continuing involvement with the real estate sold. Gains on the sale of real estate are recognized pursuant to provisions under Accounting Standards Codification (“ASC”) 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets. Under ASC 610-20, we determine whether the transaction is a sale to a customer or non-customer. As a REIT, we do not sell real estate within the ordinary course of our business and therefore expect that our sale transactions will not be contracts with customers. ASC 610-20 refers to the revenue recognition principles under ASC 606, Revenue from Contracts with Customers. Under ASC 610-20, if we determine we do not have a controlling financial interest in the entity that holds the asset and the arrangement meets the criteria to be accounted for as a contract, we will dispose of the asset and recognize a gain or loss on the sale of the real estate when control of the underlying asset transfers to the buyer. If we determine a sale has not occurred under ASC 610-20, we continue to record the asset on the Consolidated Balance Sheets and related depreciation expense on the Consolidated Statements of Operations. Fair Value Measurement The Company measures and discloses the fair value of nonfinancial and financial assets and liabilities utilizing a hierarchy of valuation techniques based on whether the inputs to a fair value measurement are considered to be observable or unobservable in a marketplace. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. This hierarchy requires the use of observable market data when available. These inputs have created the following fair value hierarchy: ● Level 1 - quoted prices for identical instruments in active markets; ● Level 2 - quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and ● Level 3 - fair value measurements derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The Company measures fair value using a set of standardized procedures that are outlined herein for all assets and liabilities which are required to be measured at fair value. When available, the Company utilizes quoted market prices from an independent third-party source to determine fair value and classifies such items in Level 1. In some instances where a market price is available, but the instrument is in an inactive or over-the-counter market, the Company consistently applies the dealer (market maker) pricing estimate and classifies such items in Level 2. If quoted market prices or inputs are not available, fair value measurements are based upon valuation models that utilize current market or independently sourced market inputs, such as interest rates, option volatilities, credit spreads and/or market capitalization rates. Items valued using such internally-generated valuation techniques are classified according to the lowest level input that is significant to the fair value measurement. As a result, these items could be classified in either Level 2 or Level 3 even though there may be some significant inputs that are readily observable. Internal fair value models and techniques used by the Company include discounted cash flow and Monte Carlo valuation models. F-11 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Real Estate Acquisitions Upon acquisition of real estate properties, we evaluate the acquisition to determine if it is a business combination or an asset acquisition. Our real estate acquisitions are generally accounted for as asset acquisitions as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the acquisition is determined to be an asset acquisition, the Company records the purchase price and other related costs incurred to the acquired tangible assets and identified intangible assets and liabilities on a relative fair value basis. In addition, costs incurred for asset acquisitions, including transaction costs, are capitalized. If the acquisition is determined to be a business combination, we record the purchase of properties to net tangible and identified intangible assets acquired and liabilities assumed at fair value. Goodwill is measured as the excess of the fair value of the consideration transferred over the fair value of the identifiable net assets. Transaction costs are expensed as incurred as part of a business combination. In making estimates of fair value for purposes of recording asset acquisitions and business combinations, we utilize a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company determines the fair value of acquired assets and liabilities as follows: ● Land is determined based on third-party appraisals which typically include market comparables. ● Buildings and site improvements acquired are valued using a combination of discounted cash flow projections that assume certain future revenues and costs and consider capitalization and discount rates using current market conditions as well as the residual approach. ● Furniture and fixtures are determined based on third-party appraisals which typically utilize a replacement cost approach. ● Real estate loans and non-real estate loans are valued using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings. ● Investments in JVs are valued based on the fair value of the JV’s assets and liabilities. Differences, if any, between the Company’s basis and the JV’s basis are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of earnings (losses) of the JV. ● Intangible assets and liabilities acquired are valued using a combination of discounted cash flow projections as well as other valuation techniques based on current market conditions for the intangible asset or liability being acquired. When evaluating below market leases we consider extension options controlled by the lessee in our evaluation. ● Other assets acquired and liabilities assumed are typically valued at stated amounts, which approximate fair value on the date of the acquisition. ● Assumed debt balances are valued by discounting the remaining contractual cash flows using a current market interest rate. ● Noncontrolling interests are valued using a stock price, if available, or by other methods to estimate the fair value on the acquisition date. Real Estate Properties Real estate properties are carried at initial recorded value less accumulated depreciation. The costs of significant improvements, renovations and replacements, including interest are capitalized. Our interest expense reflected in the Consolidated Statements of Operations has been reduced by the amounts capitalized. For the years ended December 31, 2025, 2024 and 2023, we capitalized $ 1.1 million, $ 7.3 million and $ 4.3 million, respectively, of interest to our projects under development. In addition, we capitalize leasehold improvements when certain criteria are met, including when we supervise construction and will own the improvement. Expenditures for maintenance and repairs are expensed as they are incurred. F-12 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Depreciation is computed on a straight-line basis over the estimated useful lives ranging from 20 to 40 years for buildings, eight to 15 years for site improvements, and three to ten years for furniture and equipment. Leasehold interests are amortized over the shorter of the estimated useful life or term of the lease. Management evaluates our real estate properties for impairment indicators at each reporting period, including the evaluation of our assets’ useful lives. The judgment regarding the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance including the current payment status of contractual obligations and expectations of the ability to meet future contractual obligations, legal structure, as well as our intent with respect to holding or disposing of the asset. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to management’s estimate of future undiscounted cash flows of the underlying facilities. Impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows based on our intended use of the property are determined to be less than the carrying values of the assets, with a corresponding adjustment to the net carrying value of the real estate investments. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset. Management’s impairment evaluation process, and when applicable, impairment calculations involve estimation of the future cash flows from management’s intended use of the property as well as the fair value of the property. Changes in the facts and circumstances that drive management’s assumptions may result in an impairment to our assets in a future period that could be material to our results of operations. Lessee Accounting Omega leases real estate (corporate headquarters and certain other facilities), office equipment and is party to certain ground leases on our owned facilities. We determine if an arrangement is or contains a lease at inception. Leases are classified as either finance or operating at inception of the lease. Short-term leases, defined as leases with an initial term of 12 months or less that do not contain a purchase option, are not recorded on the balance sheet. Lease expense for short-term leases is recognized on a straight-line basis over the lease term. As of December 31, 2025 and 2024, all our leases were classified as operating leases. We have leases that contain both lease and non-lease components and have elected, as an accounting policy, to not separate lease components and non-lease components. Operating and finance lease right-of-use ("ROU") assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. Our ROU assets and lease liabilities are included in other assets and accrued expenses and other liabilities, respectively, on our Consolidated Balance Sheets. The lease liability is calculated as the present value of the remaining minimum rental payments for existing leases using either the rate implicit in the lease or, if none exists, the Company's incremental borrowing rate, as the discount rate. Certain leases have options to extend, terminate or purchase the asset and have been considered in our analysis of the lease term and the measurement of the ROU assets and lease liabilities. On a quarterly basis, we record our lease liabilities at the present value of the future lease payments using the discount rate determined at lease commencement. Rental expense from operating leases is generally recognized on a straight-line basis over the lease term. Lease expense derived from our operating leases is recorded in general and administrative in our Consolidated Statements of Operations. We do not include in our measurement of our lease liability certain variable payments, including changes in an index until the specific events that trigger the variable payments have occurred. We record rental income and ground lease expense on a straight-line basis for those assets we lease and are reimbursed by our operators and/or are paid for directly by our operators. F-13 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Allowance for Credit Losses The allowance for credit losses reflects our current estimate of the potential credit losses on our real estate loans, non-real estate loans, and our investment in direct financing leases and is recorded as a valuation account as a direct offset against these financial instruments on our Consolidated Balance Sheets. Expected credit losses inherent in non-cancelable unfunded loan commitments are accounted for as separate liabilities included in accrued expenses and other liabilities on the Consolidated Balance Sheets. The Company has elected to not measure an allowance for credit losses on accrued interest receivables related to all of its real estate loans and non-real estate loans because we write off uncollectible accrued interest receivable in a timely manner pursuant to our non-accrual policy, described below. Changes to the allowance for credit losses on loans resulting from quarterly evaluations are recorded through provision for credit losses on the Consolidated Statements of Operations. We assess the creditworthiness of our borrowers on a quarterly basis. For purposes of determining our allowance for credit loss, we pool financial assets that have similar risk characteristics. We aggregate our financial assets by financial instrument type (i.e. real estate loan, non-real estate loan, etc.) and by our internal risk rating. Our internal credit ratings consider several factors including the collateral and/or security, the performance of borrowers underlying facilities, if applicable, available credit support (e.g., guarantees), borrowings with third parties, and other ancillary business ventures and real estate operations of the borrower. Our internal ratings range between 1 and 7. An internal rating of 1 reflects the lowest likelihood of loss and a 7 reflects the highest likelihood of loss. The characteristics associated with each risk rating is as follows: ● Risk Rating 1 through 3 – Instruments with minimal to marginally acceptable risk. ● Risk Rating 4 – Instruments with potential weaknesses identified (Special mention). ● Risk Rating 5 – Instruments with well-defined weaknesses that may result in possible losses (Substandard). ● Risk Rating 6 – Instruments that are unlikely to be repaid in full and will probably result in losses (Doubtful). ● Risk Rating 7 – Instrument that will not be repaid in full and losses will occur (Loss). We have a limited history of incurred losses and consequently have elected to employ external data to perform our expected credit loss calculation. We utilize a probability of default (“PD”) and loss given default (“LGD”) methodology. Our model’s historic inputs consider PD and LGD data for residential care facilities published by the Federal Housing Administration along with Standards & Poor’s one-year global corporate default rates. Our historical loss rates revert to historical averages after 36 months. Our model’s current conditions and supportable forecasts consider internal credit ratings, current and projected U.S. unemployment rates published by the U.S. Bureau of Labor Statistics and the Federal Reserve Bank of St. Louis and the weighted average life to maturity of the underlying financial asset. Periodically, the Company may identify an individual loan for impairment. A loan is considered impaired when, based on current information and events, it is probable that we will be unable to collect all amounts due as scheduled according to the contractual terms of the loan agreements. Our assessment of collectibility considers several factors, including, among other things, payment history, the financial strength of the borrower and any guarantors, historical operations and operating trends, current and future economic conditions, expectations of performance (which includes known substantial doubt about an operator’s ability to continue as a going concern) and the fair value of the underlying collateral of the agreement, a Level 3 measurement, if any. Consistent with this definition, all loans on non-accrual status may be deemed impaired. To the extent circumstances improve and the risk of collectibility is diminished, we will return these loans to full accrual status. When we identify a loan impairment, the loan is written down to the present value of the expected future cash flows or to the fair value of the underlying collateral. Financial instruments are charged off against the allowance for credit losses when collectibility is determined to be permanently impaired. We account for impaired loans using (a) the cost-recovery method, and/or (b) the cash basis method. We generally utilize the cost-recovery method for impaired loans for which impairment reserves were recorded. Under the cost-recovery method, we apply cash received against the outstanding loan balance prior to recording interest income. Under the cash basis method, we apply cash received to principal or interest income based on the terms of the agreement. F-14 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Investments in Unconsolidated Entities We account for our investments in unconsolidated entities using the equity method of accounting as we exercise significant influence over, but do not control, the entities. Under the equity method of accounting, the net equity investments of the Company are reflected in the accompanying Consolidated Balance Sheets, and the Company’s share of net income and comprehensive income from the entities are included in the accompanying Consolidated Statements of Operations and Consolidated Statements of Comprehensive Income, respectively. On a periodic basis, management assesses whether there are any indicators that the value of the Company’s investments in the unconsolidated entities may be other-than-temporarily-impaired. An investment is impaired only if management’s estimate of the value of the investment is less than the carrying value of the investment, and such a decline in value is deemed to be other than-temporary. To the extent impairment has occurred, the loss is measured as the excess of the carrying amount of the investment over the estimated fair value of the investment. The estimated fair value of the investment is determined using a discounted cash flow model which is a Level 3 valuation. We consider a number of assumptions that are subject to economic and market uncertainties including, among others, rental rates, operating costs, capitalization rates, holding periods and discount rates. In Substance Real Estate Investments We provide loans to third parties for the acquisition, development and construction of real estate. Under these arrangements, it is possible that we will participate in the expected residual profits of the project through the sale, refinancing or acquisition of the property. We evaluate the characteristics of each arrangement, including its risks and rewards, to determine whether they are more similar to those associated with a loan or an investment in real estate. Arrangements with characteristics implying loan classification are presented as real estate loans receivable and result in the recognition of interest income. Arrangements with characteristics implying real estate JVs are treated as in substance real estate investments and presented as investments in unconsolidated entities and are accounted for using the equity method. The classification of each arrangement as either a real estate loan receivable or investment in unconsolidated entity involves judgment and relies on various factors, including market conditions, amount and timing of expected residual profits, credit enhancements in the form of guarantees, estimated fair value of the collateral, and significance of borrower equity in the project, among others. The classification of such arrangements is performed at inception, and periodically reassessed when significant changes occur in the circumstances or conditions described above. Cash and Cash Equivalents and Restricted Cash Cash and cash equivalents consist of cash on hand and highly liquid investments with a maturity date of three months or less when purchased. Restricted cash consists primarily of liquidity deposits escrowed for tenant obligations required by us pursuant to certain contractual terms and other deposits required by our lenders in connection with financing arrangements. The majority of our cash, cash equivalents and restricted cash are held at major commercial banks. Certain cash account balances exceed FDIC insurance limits of $ 250,000 per account and, as a result, there is a concentration of credit risk related to amounts in excess of the insurance limits. Deposits We obtain liquidity deposits and other deposits, security deposits and letters of credit from certain operators pursuant to our lease and mortgage agreements. These generally represent the rental and/or mortgage interest for periods ranging from three to six months with respect to certain of our investments or the required deposits in connection with our HUD borrowings. At December 31, 2025 and 2024, we held $ 22.9 million and $ 15.5 million, respectively, in liquidity and other deposits and $ 80.8 million and $ 52.7 million, respectively, in security deposits. We also had the ability to draw on $ 24.2 million and $ 29.1 million of letters of credit at December 31, 2025 and 2024, respectively. F-15 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ The liquidity deposits and other deposits, security deposits and the letters of credit may be used in the event of lease and/or loan defaults, subject to applicable limitations under bankruptcy law with respect to operators filing under Chapter 11 of the U.S. Bankruptcy Code. Liquidity deposits and other deposits are recorded as restricted cash on our Consolidated Balance Sheets with the offset recorded as a liability in accrued expenses and other liabilities on our Consolidated Balance Sheets. Security deposits related to cash received from the operators are primarily recorded in cash and cash equivalents on our Consolidated Balance Sheets with a corresponding offset in accrued expenses and other liabilities on our Consolidated Balance Sheets. Additional security for rental and loan interest revenue from operators is provided by covenants regarding minimum working capital and net worth, liens on accounts receivable and other operating assets of the operators, provisions for cross-default, provisions for cross-collateralization and by corporate or personal guarantees. Goodwill We test goodwill for potential impairment at least annually in the fourth quarter, or more frequently if an event or other circumstance indicates that we may not be able to recover the carrying amount of the net assets of the reporting unit. An impairment loss is recognized to the extent that the carrying amount, including goodwill, exceeds the reporting unit’s fair value. Goodwill is not deductible for tax purposes. We have had no goodwill impairment charges for the last three fiscal years. Income Taxes Omega and its wholly-owned subsidiaries were organized to qualify for taxation as a REIT under Section 856 through 860 of the Internal Revenue Code (“Code”). As long as we qualify as a REIT, we will not be subject to federal income taxes on the REIT taxable income that we distributed to stockholders, subject to certain exceptions. However, with respect to certain of our subsidiaries that have elected to be treated as taxable REIT subsidiaries (“TRSs”), we record income tax expense or benefit, as those entities are subject to federal income tax similar to regular corporations. Omega OP is a pass-through entity for U.S. federal income tax purposes. We account for deferred income taxes using the asset and liability method and recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our financial statements or tax returns. Under this method, we determine deferred tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Any increase or decrease in the deferred tax liability that results from a change in circumstances, and that causes us to change our judgment about expected future tax consequences of events, is included in the tax provision when such changes occur. Deferred income taxes also reflect the impact of operating loss and tax credit carry-forwards. A valuation allowance is provided if we believe it is more likely than not that all or some portion of the deferred tax asset will not be realized. Any increase or decrease in the valuation allowance that results from a change in circumstances, and that causes us to change our judgment about the realizability of the related deferred tax asset, is included in the tax provision when such changes occur. We are subject to certain state and local income tax, franchise taxes and foreign taxes. The expense associated with these taxes are included in income tax expense on the Consolidated Statements of Operations. Stock-Based Compensation We recognize stock-based compensation expense to employees and directors, in general and administrative in our Consolidated Statements of Operations on a straight-line basis over the vesting period. Forfeitures of share-based awards are recognized as they occur. F-16 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Deferred Financing Costs, Discounts and Premiums External costs incurred from the placement of our debt are capitalized and amortized on a straight-line basis over the terms of the related borrowings which approximates the effective interest method. Deferred financing costs related to our revolving line of credit are included in other assets on our Consolidated Balance Sheets and deferred financing costs related to our other borrowings are included as a direct deduction from the carrying amount of the related liability on our Consolidated Balance Sheets. Original issuance premium or discounts reflect the difference between the face amount of the debt issued and the cash proceeds received and are amortized on a straight-line basis over the term of the related borrowings. Any difference between fair value and stated value of debt, assumed in an assets acquisition or business combination, is recorded as a discount or premium and amortized over the remaining term of the loan. All premiums and discounts are recorded as an addition to or reduction from debt on our Consolidated Balance Sheets. Net amortization of deferred financing costs and premiums or discounts totaled $ 6.0 million, $ 10.4 million and $ 13.7 million for the years ended December 31, 2025, 2024 and 2023, respectively, and are recorded in interest expense on our Consolidated Statements of Operations. Earnings Per Share The computation of basic earnings per share/unit (“EPS”) is computed by dividing net income (loss) available to common stockholders allocable to unrestricted common shares by the weighted-average number of unrestricted shares of common stock outstanding during the relevant period after allocating undistributed earnings between common stockholders and participating securities under the two-class method. Our participating securities include restricted stock and profit interest units, performance restricted stock and profit interest units and deferred shares. The computation of diluted EPS is similar except that the denominator is increased to include the effect of dilutive potential common shares outstanding, including restricted stock and profit interest units, performance restricted stock and profit interest units, the assumed issuance of additional shares related to Omega OP Units held by outside investors, using the if-converted or treasury stock methods. The diluted numerator is adjusted to add back any changes in income or loss that would result from the conversion of potential shares into common shares that are added to the dilutive denominator. Noncontrolling Interests Noncontrolling interests is the portion of equity not attributable to the respective reporting entity. We present the portion of any equity that we do not own in consolidated entities as noncontrolling interests and classify those interests as a component of total equity, separate from total stockholders’ equity on our Consolidated Balance Sheets. We include net income attributable to the noncontrolling interests in net income in our Consolidated Statements of Operations. As our ownership of a controlled subsidiary increases or decreases, any difference between the aggregate consideration paid to acquire the noncontrolling interests and our noncontrolling interest balance is recorded as a component of equity in additional paid-in capital, so long as we maintain a controlling ownership interest. The noncontrolling interest for Omega primarily represents the outstanding Omega OP Units held by outside investors. Each of the Omega OP Units (other than the Omega OP Units owned by Omega) is redeemable at the election of the Omega OP Unit holder for cash equal to the then-fair market value of one share of Omega common stock, par value $ 0.10 per share (“Omega Common Stock”), subject to Omega’s election to exchange the Omega OP Units tendered for redemption for unregistered shares of Omega Common Stock on a one -for-one basis, subject to adjustment as set forth in Omega OP’s partnership agreement. Foreign Operations The U.S. dollar (“USD”) is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound (“GBP”). Total revenues from our consolidated U.K. operating subsidiaries were $ 180.1 million, $ 93.6 million and $ 56.8 million for the years ended December 31, 2025, 2024 and 2023, respectively. Our consolidated U.K. operating subsidiaries held long-lived assets of $ 1.6 billion and $ 1.1 billion as of December 31, 2025 and 2024, respectively. As discussed in Note 20, in December 2025, we entered into a $ 87.6 million Canadian dollar denominated loan agreement with a borrower to fund the development of several long-term care facilities in Canada. As of December 31, 2025, no advances had been made on the loan. F-17 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ For our consolidated subsidiaries whose functional currency is not the USD, we translate their financial statements into the USD. We translate the balance sheet accounts at the exchange rate in effect as of the financial statement date. The income statement accounts are translated using an average exchange rate for the period. Gains and losses resulting from translation are included in accumulated other comprehensive income (loss) (“AOCI”), as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interests, if applicable. We and certain of our consolidated subsidiaries may have intercompany and third-party debt that is not denominated in the entity’s functional currency. When the debt is remeasured against the functional currency of the entity, a gain or loss can result. The resulting adjustment is reflected in results of operations within other income (expense) - net, unless it is intercompany debt that is deemed to be long-term in nature in which case the adjustments are included in AOCI and a proportionate amount of gain or loss is allocated to noncontrolling interests, if applicable. Derivative Instruments To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. We formally document all relationships between hedging instruments and hedged items, as well as our risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific forecasted transactions as well as recognized liabilities or assets on the Consolidated Balance Sheets. In addition, at the inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with the Company’s related assertions. The Company recognizes all derivative instruments, including embedded derivatives required to be bifurcated, as assets or liabilities on the Consolidated Balance Sheets at fair value which is determined using a market approach and Level 2 inputs. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in the Consolidated Statements of Operations. For derivatives designated in qualifying cash flow hedging relationships, the gain or loss on the derivative is recognized in AOCI as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest, if applicable. If it is determined that a derivative instrument ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, the Company discontinues its cash flow hedge accounting prospectively and records the appropriate adjustment to earnings based on the current fair value of the derivative instrument. For net investment hedge accounting, upon sale or liquidation of our U.K. investment, the cumulative balance of the remeasurement value is reclassified to the Consolidated Statements of Operations. Reclassifications Certain line items in our Consolidated Statements of Cash Flows have been combined to conform to the current period presentation. Recent Accounting Pronouncements ASU – 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-03, which requires disclosure of certain costs and expenses on an interim and annual basis in the notes to the financial statements. The guidance is effective for the first annual reporting period beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The amendments in this update are to be applied on a prospective basis, with the option for retrospective application. Early adoption is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and disclosures. F-18 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ ASU – 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures In December 2023, the FASB issued ASU 2023-09, which modifies the rules on income tax disclosures to require entities to disclose (i) specific categories in the rate reconciliation, (ii) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (iii) income tax expense or benefit from continuing operations (separated by federal, state and foreign). The guidance also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions. We have adopted the guidance in the fourth quarter of 2025 and have included the required disclosures for all periods presented within Note 17 – Taxes. The adoption of the new guidance and related codification improvements did not have a material impact to the Company’s financial position, results of operations or cash flows. NOTE 3 – REAL ESTATE ASSET ACQUISITIONS AND DEVELOPMENT 2025 Acquisitions The following table summarizes the significant asset acquisitions that occurred in 2025: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Facilities ​ ​ ​ ​ ​ ​ ​ Total Real Estate ​ ​ ​ ​ ​ ​ ​ Specialty ​ ​ ​ Assets Acquired (1) ​ Period ​ SNF ALF and Other ​ Country/State ​ (in millions) ​ Q1 ​ — 2 — TX ​ $ 10.6 ​ Q1 ​ — 4 — ​ U.K. ​ ​ 47.7 ​ Q2 ​ — 45 — ​ U.K. & Jersey ​ ​ 344.2 (2) Q2 ​ — 1 — ​ CA ​ ​ 11.6 ​ Q2 ​ — 2 — ​ NM ​ ​ 32.0 ​ Q2 ​ — 1 — ​ SC ​ ​ 8.5 ​ Q2 ​ 8 — — ​ TX ​ ​ 105.8 ​ Q3 ​ — 1 — ​ U.K. ​ ​ 8.6 ​ Q3 ​ — 1 — ​ U.K. ​ ​ 10.3 (3) Q3 ​ — — 1 (4) NJ ​ ​ 58.6 ​ Q4 ​ — 4 — ​ WI, NJ, IN ​ ​ 36.9 (5) Q4 ​ — 1 — ​ U.K. ​ ​ 15.6 ​ Total 8 62 1 ​ ​ $ 690.4 (1) Represents the acquisition cost that was allocated to our real estate assets on a relative fair value basis. This also represents the total cost of the acquisition unless specifically noted within the table, as the assets acquired in our acquisitions typically consist of only real estate assets. From time to time we may have acquisitions in which additional assets and liabilities are assumed. (2) In April 2025, the Company acquired 45 facilities in the U.K. and the Bailiwick of Jersey (“Jersey”) for $ 344.2 million and leased the facilities to four existing and two new operators. (3) Relates to a non-cash acquisition of one facility previously subject to a mortgage loan with Omega in which the principal amount under the loan agreement was settled in exchange for title to the facility (see Note 7 – Real Estate Loans Receivable) and $ 0.2 million of transaction costs incurred related to the non-cash acquisition. (4) Relates to a CCRC. (5) Relates to facilities that we will own and operate utilizing a RIDEA structure. Total consideration paid for this acquisition was $ 36.1 million. We allocated $ 0.1 million of the consideration to other assets and $ 0.7 million to accrued expenses. ​ F-19 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ 2024 Acquisitions The following table summarizes the significant asset acquisitions that occurred in 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ ​ ​ Total Real Estate ​ ​ ​ ​ ​ Facilities ​ ​ ​ ​ ​ ​ ​ Assets Acquired (1) ​ ​ ​ Period ​ SNF ALF ​ Country/State ​ (in millions) ​ Q1 1 — WV ​ $ 8.1 ​ Q1 ​ — 1 ​ U.K. ​ ​ 5.2 ​ Q2 ​ 1 — ​ MI ​ ​ 31.0 ​ Q2 ​ — 32 ​ U.K. ​ ​ 50.8 (2) Q2 ​ 1 — ​ LA ​ ​ 21.0 ​ Q3 ​ — 63 ​ U.K. ​ ​ 421.0 (3) Q3 ​ — 1 ​ U.K. ​ ​ 5.1 ​ Q3 ​ 1 — ​ NC ​ ​ 8.8 ​ Q3 ​ — 1 ​ U.K. ​ ​ 10.8 ​ Q4 ​ — 3 ​ U.K. ​ ​ 39.7 ​ Q4 ​ — 1 ​ OR ​ ​ 8.0 ​ Q4 ​ 2 — ​ TX ​ ​ 19.5 ​ Q4 ​ — 6 ​ U.K. ​ ​ 111.5 ​ Total 6 108 ​ ​ $ 740.5 (1) Represents the acquisition cost that was allocated to our real estate assets on a relative fair value basis. This also represents the total cost of the acquisition unless specifically noted within the table, as the assets acquired in our acquisitions typically consist of only real estate assets. From time to time we may have acquisitions in which additional assets and liabilities are assumed. (2) Total consideration paid for this acquisition was $ 62.7 million. We allocated $ 11.9 million of the purchase consideration to a deferred tax asset related to net operating losses acquired in the transaction. See Note 17 – Taxes for additional information. (3) Relates to our acquisition of the remaining 51 % ownership interest in the Cindat Joint Venture, as defined and discussed below under “Cindat Portfolio Acquisition.” Total costs to be allocated for this acquisition was $ 461.9 million, inclusive of our previously held equity interest of $ 97.0 million. We allocated $ 53.8 million of the costs to be allocated to other assets acquired in the transaction and we allocated $ 13.0 million of the costs to be allocated to other liabilities assumed in the transaction. Cindat Portfolio Acquisition As of December 31, 2023, we held a 49 % interest in an unconsolidated real estate JV owning 63 facilities in the U.K. (the “Cindat Joint Venture”) accounted for using the equity method of accounting. As of December 31, 2023, our equity interest was $ 97.6 million. The 63 facilities are subject to leases with two operators that have contractual rent of $ 43.6 million per annum with minimum escalators between 1.0 % to 2.0 % that can escalate further based on certain inflationary measures. In July 2024, we acquired the remaining 51 % interest in the Cindat Joint Venture for total consideration of $ 364.9 million inclusive of: (i) $ 98.9 million of cash consideration including direct transaction costs, (ii) the assumption of a £ 188.6 million mortgage loan (the “2026 Mortgage Loan”) with an estimated fair value of $ 264.0 million and (iii) deferred contingent consideration of $ 2.0 million that was paid in December 2024. The fair market value of the mortgage debt assumed was determined by discounting the remaining contractual cash flows using a current market interest rate of comparable debt instruments. Following the acquisition, we own 100 % of the equity interests in the entity that owns the Cindat portfolio, and accordingly, we will consolidate its results in our consolidated financial statements going forward. The acquired interest was accounted for as an asset acquisition as substantially all of the fair value of the gross assets acquired is concentrated in a group of similar identifiable assets. Under our existing accounting policy election, we follow the asset acquisition cost accumulation and allocation model. Accordingly, we did not remeasure our previously held $ 97.0 million equity interest, as of the acquisition date, at fair value. F-20 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ The following table summarizes the assets and liabilities recorded as part of the acquisition as of the date of the acquisition: ​ ​ ​ ​ ​ ​ (in thousands) Costs to be allocated: ​ ​ ​ 49 % equity method investment in Cindat Joint Venture ​ $ 96,971 Consideration for additional 51 % interest in Cindat Joint Venture ​ ​ 100,921 Fair market value of debt assumed ​ ​ 263,990 Total acquisition cost to be allocated ​ $ 461,882 ​ ​ ​ ​ Net assets acquired: ​ ​ ​ Real estate assets ​ $ 421,044 Non-real estate loans receivable ​ ​ 1,632 Cash and cash equivalents ​ ​ 6,866 Restricted cash ​ ​ 14,050 Contractual receivables ​ ​ 8 Other assets ​ ​ 31,278 Total assets ​ ​ 474,878 Accrued expenses and other liabilities ​ ​ ( 12,996 ) Net assets acquired ​ $ 461,882 ​ 2023 Acquisitions The following table summarizes the significant asset acquisitions that occurred in 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ ​ ​ Total Real Estate ​ ​ ​ ​ ​ Facilities ​ ​ ​ ​ ​ ​ ​ Assets Acquired (1) ​ ​ ​ Period ​ SNF ALF ​ Country/State ​ (in millions) ​ Q1 — 6 U.K. ​ $ 26.4 (2) Q2 ​ 4 — ​ WV ​ ​ 114.8 (3) Q2 ​ 1 — ​ WV ​ ​ 13.7 ​ Q3 ​ 1 — ​ VA ​ ​ 15.6 ​ Q3 ​ — 14 ​ U.K. ​ ​ 39.5 ​ Q4 ​ 1 — ​ MD ​ ​ 22.5 ​ Q4 ​ — 1 ​ U.K. ​ ​ 3.8 ​ Q4 ​ 2 — ​ LA ​ ​ 24.9 ​ Total 9 21 ​ ​ $ 261.2 ​ (1) Represents the acquisition cost that was allocated to our real estate assets on a relative fair value basis. This also represents the total cost of the acquisition unless specifically noted within the table, as the assets acquired in our acquisitions typically consist of only real estate assets. From time to time we may have acquisitions in which additional assets and liabilities are assumed. (2) In connection with this acquisition, the Company recorded $ 9.9 million of right-of-use assets and lease liabilities associated with ground leases assumed in the acquisition. (3) In connection with this acquisition, the Company also provided $ 104.6 million of mezzanine financing discussed further in Note 7 – Real Estate Loans Receivable and Note 8 – Non-Real Estate Receivable. Construction in progress and Capital Expenditure Investments We invested $ 114.5 million, $ 106.7 million and $ 82.5 million, respectively under our construction in progress and capital improvement programs during the years ended December 31, 2025, 2024 and 2023. As of December 31, 2025, four projects were included construction in progress, consisting of developments of SNFs in Virginia, Florida, Maryland and Kansas. F-21 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ In February 2025, we placed the $ 201.8 million Inspir Embassy Row construction in progress project into service and began recognizing rental income from the facility. For accounting purposes, the new lease commenced in February 2025 upon the substantial completion of construction of the ALF. The lease provides for an annual cash yield of 6 % in the first year following the completion of construction, increasing to 7 % in year two and 8 % in year three with 2.5 % annual escalators thereafter. Rent can be deferred by the operator for months in which certain operating metrics are not met. Deferred rent bears interest at 5 % per annum and is required to be repaid in any month in which certain operating metrics are met. We recognized full contractual rental income of $ 11.9 million related to the lease for the new facility for the year ended December 31, 2025. NOTE 4 – ASSETS HELD FOR SALE, DISPOSITIONS AND IMPAIRMENTS We periodically sell facilities to reduce our concentration in certain operators, geographies and non-strategic assets or due to the exercise of a tenant purchase option. The following is a summary of our assets held for sale: ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ 2025 ​ 2024 Number of facilities held for sale ​ N/A (1) ​ 12 Amount of assets held for sale (in thousands) $ 4,000 ​ $ 56,194 (1) Relates to a property adjacent to one of our existing facilities. Asset Sales 2025 Activity During the year ended December 31, 2025, we sold 49 facilities ( 45 SNFs and four ALFs) for approximately $ 282.8 million in net cash proceeds, recognizing a net gain of approximately $ 67.3 million. 2024 Activity During the year ended December 31, 2024, we sold 21 facilities ( 14 SNFs, six ALFs and one specialty facility) for $ 95.0 million in net cash proceeds, recognizing a net gain of approximately $ 13.2 million. 2023 Activity During the year ended December 31, 2023, we sold 69 facilities ( 64 SNFs, two ALFs, one ILF and two specialty facilities) for $ 585.0 million in net cash proceeds, recognizing net gains of $ 79.7 million. Our 2023 facility sales were primarily driven by restructuring transactions and negotiations related to our lease agreements with LaVie Care Centers, LLC (“LaVie”) and Guardian Healthcare (“Guardian”). During 2023, we sold 37 facilities subject to operating agreements with LaVie for $ 402.3 million in aggregate consideration, which included cash proceeds of $ 119.4 million and $ 282.9 million of pay-offs of the outstanding principal and accrued interest on 29 HUD mortgages on the sold properties made by the buyer, on Omega’s behalf. The sales resulted in an aggregate net gain of $ 1.0 million. Also in the third quarter of 2023, we recognized the sale of 11 facilities, previously leased to LaVie, related to a December 2022 transaction, that did not meet the contract criteria to be recognized under ASC 610-20 at the legal sale date. During the third quarter of 2023, Omega received an aggregate $ 104.8 million of principal prepayments for the mortgage from the seller. As a result of the principal prepayments, the Company determined the transaction met the contract criteria under ASC 610-20 and recognized the sale, resulting in a $ 50.2 million gain during the year ended December 31, 2023, which includes a $ 25 million contract liability and $ 5.7 million of deferred interest income received to date. F-22 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ During 2023, we sold five facilities that were previously leased to Guardian for net cash proceeds of $ 23.8 million, with no gain or loss on the sale as the facilities had already been impaired down to the estimated fair value less costs to sell. We legally sold one additional facility during 2023, also previously leased to Guardian, that did not meet the contract criteria to be recognized under ASC 610-20. Sales Not Recognized As of December 31, 2025 and 2024, we had one and three facility sales, respectively, that were not recognized as a result of not meeting the contract criteria under ASC 610-20 at the legal sale date. During the years ended December 31, 2025 and 2024, we received interest of $ 5.6 million and $ 1.7 million, respectively, related to seller financing provided in connection with sales that were not recognized at the legal sale date. The interest received was deferred and recorded as a contract liability within accrued expenses and other liabilities on our Consolidated Balance Sheets. Real Estate Impairments 2025 Activity During the year ended December 31, 2025, we recorded impairments of approximately $ 22.6 million on eight facilities. Of the $ 22.6 million, $ 6.3 million related to two facilities that were classified as held for sale and $ 16.3 million related to six held for use facilities. 2024 Activity During the year ended December 31, 2024, we recorded impairments of approximately $ 23.8 million on 14 facilities. Of the $ 23.8 million, $ 10.9 million related to six facilities that were classified as held for sale and $ 12.9 million related to eight held for use facilities. 2023 Activity During the year ended December 31, 2023, we recorded impairments of approximately $ 91.9 million on 25 facilities. Of the $ 91.9 million, $ 2.6 million related to two facilities that were classified as held for sale and $ 89.3 million related to 23 held for use facilities. To estimate the fair value of the facilities, for the impairments noted above, we utilized a market approach which considered binding sale agreements (a Level 1 input) or non-binding offers from unrelated third parties and/or broker quotes (a Level 3 input). NOTE 5 – CONTRACTUAL RECEIVABLES AND OTHER RECEIVABLES AND LEASE INDUCEMENTS Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line rent receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception, modification or renewal of the lease, and are amortized as a reduction of rental income over the non-cancellable lease term. F-23 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ A summary of our net receivables by type is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ ​ (in thousands) Contractual receivables – net ​ $ 9,723 ​ $ 12,611 ​ ​ ​ ​ ​ ​ ​ Effective yield interest receivables ​ $ 2,363 ​ $ 1,839 Straight-line rent receivables ​ 268,688 ​ 238,690 Lease inducements ​ 7,519 ​ 8,788 Other receivables and lease inducements ​ $ 278,570 ​ $ 249,317 ​ Cash basis operator leases and straight-line rent receivable write-offs We review our collectibility assumptions related to our operator leases on an ongoing basis. If we determine that it is no longer probable that substantially all rents over the life of a lease are collectible, rental revenue related to the operator lease will be recognized only to the extent of payments received (“cash basis of revenue recognition”), and all related receivables associated with the lease will be written off. Write-offs of contractual and straight-line receivables are recorded as adjustments to rental revenue. We recognized straight-line rent receivable write-offs of $ 15.5 million, $ 2.8 million, and zero for the years ended December 31, 2025, 2024, and 2023, respectively, in connection with placing certain operator leases on a cash basis of revenue recognition. We placed three , four and three operators on a cash basis of revenue recognition for the years ended December 31, 2025, 2024, and 2023, respectively. Several of the operator leases placed on a cash basis of revenue recognition in the comparative years related to new operator leases, so there were no related straight-line rent receivable write-offs associated with these operator leases. As of December 31, 2025, we had 20 operator leases on a cash basis for revenue recognition, which represent 19.0 %, 19.9 % and 21.4 % of our total revenues for the years ended December 31, 2025, 2024 and 2023, respectively. As of December 31, 2024, we had 21 operator leases on a cash basis for revenue recognition, which represent 20.5 % and 22.1 % of our total revenues for the years ended December 31, 2024 and 2023, respectively. During the year ended December 31, 2023, we transitioned the portfolios of four cash basis operators with an aggregate of 48 facilities to new or amended leases with five operators. We recognized revenue on a straight-line basis for the leases associated with these five operators. The aggregate initial contractual rent related to the 48 facilities transitioned to these five operators is $ 48.0 million per annum. The transitioned facilities included 14 facilities of which Omega made or agreed to make termination payments of $ 15.5 million in aggregate that were recorded as initial direct costs related to the lease with the new operator of the 14 transitioned facilities in the first quarter of 2023. These termination payments are deferred and recognized within depreciation and amortization expense on a straight-line basis over the term of the master lease. During the years ended December 31, 2025, 2024 and 2023, we also wrote-off $ 2.5 million, $ 1.4 million and $ 8.1 million of straight-line rent receivable balances through rental income as a result of transitioning facilities between existing operators. Operator updates Agemo After Agemo Holdings, LLC (“Agemo”), an operator on a cash basis of revenue recognition, failed to pay contractual rent and interest due under its lease and loan agreements throughout 2022, in the first quarter of 2023, Omega and Agemo entered into a restructuring agreement, an amended and restated master lease and a replacement loan agreement for two replacement loans. As part of the restructuring agreement and related agreements, Omega agreed to, among other things: ● forgive and release Agemo from previously written off past due rent and interest obligations related to certain periods prior to the 2018 Restructuring and from August 2021 through January 2023, with contractual rent under the lease agreement and contractual interest under the loan agreements scheduled to resume on April 1, 2023; F-24 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ ● reduce monthly contractual base rent from $ 4.8 million to $ 1.9 million following the sales of the 22 facilities, previously leased and operated by Agemo, that occurred in the third and fourth quarters of 2022 (See Note 4 – Assets Held For Sale, Dispositions and Impairments); ● extend the initial Agemo lease term from December 31, 2030 , to December 31, 2036 , with three consecutive tenant 10-year extension options; and ● refinance and restructure the $ 25.0 million secured working capital loan (the “Agemo WC Loan”) and the $ 32.0 million term loan (the “Agemo Term Loan”) as discussed in further detail in Note 8 – Non-Real Estate Loans Receivable. Agemo resumed making contractual rent and interest payments during the second quarter of 2023 in accordance with the restructuring terms discussed above. We recorded rental income of $ 24.4 million, $ 23.8 million and $ 17.4 million for the years ended December 31, 2025, 2024 and 2023, respectively, for the contractual rent payments that were received. No interest income was recognized during the years ended December 31, 2025, 2024 and 2023 on the two loans with Agemo because these loans are on non-accrual status and we are utilizing the cost recovery method, under which any payments are applied against the principal amount. LaVie During 2023, we continued the process of restructuring our portfolio with LaVie by amending the lease agreements with LaVie to allow for a partial rent deferral of $ 19.0 million for the first four months of 2023, transitioning two facilities previously subject to the master lease with LaVie to another operator during the second quarter of 2023 and selling seven facilities previously subject to the master lease with LaVie to a third party during the third quarter of 2023. In the fourth quarter of 2023, Omega sold an additional 30 facilities and amended the master lease with LaVie to further reduce monthly rent to $ 3.3 million. Despite our efforts to restructure the portfolio, LaVie began to short pay contractual rent during the third quarter of 2023, which continued for the remainder of 2023. For the year ended December 31, 2023, LaVie paid total contractual rent of $ 37.0 million, a total short pay of $ 21.1 million of the $ 58.1 million due under the lease agreement after reflecting the deferral discussed above. As LaVie was placed on a cash basis of revenue recognition for lease purposes in the fourth quarter of 2022, only the $ 37.0 million of contractual rent payments that were received from LaVie were recorded as rental income during the year ended December 31, 2023. In June 2024, LaVie commenced voluntary cases under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Northern District of Georgia, Atlanta Division. We provided $ 10.0 million of a $ 20.0 million junior secured debtor-in-possession (“DIP”) financing loan to LaVie, as further discussed in Note 8 – Non-Real Estate Loans Receivable. As a condition of the DIP financing, LaVie was required to pay Omega full contractual rent under its lease agreement. We determined LaVie was a VIE after it became a debtor-in-possession and following the issuance of the DIP financing loan. Omega is not the primary beneficiary of LaVie because we do not have the power to control the activities that most significantly impact LaVie’s economic performance. See Note 10 – Variable Interest Entities, for additional disclosures surrounding our VIEs. On December 5, 2024, a plan of reorganization was confirmed by the Bankruptcy Court, pursuant to which the LaVie master lease agreement was to be assumed and assigned by the reorganized debtor upon the effective date of the plan. Prior to its bankruptcy filing, LaVie short paid contractual rent under its lease agreement by $ 8.8 million. Following the bankruptcy filing, LaVie resumed making full contractual rent payments due under its lease agreement. As LaVie was on a cash basis of revenue recognition for lease purposes, rental income recorded was equal to cash received of $ 28.6 million during the year ended December 31, 2024 . The plan of reorganization was effective as of June 1, 2025, which resulted in the LaVie master lease agreement being assumed by and assigned to ENDMT LLC (“Avardis”) and amended and restated. The amended master lease has a lease term ending December 31, 2037 and requires monthly rent payments of $ 3.1 million, which escalate 2.5 % annually. F-25 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ During the first and second quarters of 2025, LaVie paid full contractual rent of $ 15.5 million through the date the plan of reorganization became effective. We did no t recognize any interest income related to LaVie during the years ended December 31, 2025, 2024 and 2023, as the three loans that were outstanding during the periods have interest paid-in-kind (“PIK”) and were on non-accrual status. Following the June 1, 2025 effective date of the plan of reorganization, Avardis paid full contractual rent of $ 21.9 million during the year ended December 31, 2025. Avardis is on a straight-line basis for rental income recognition, and we recognized $ 25.5 million of rental income related to Avardis during the year ended December 31, 2025. Maplewood In the first quarter of 2023, we agreed to a formal restructuring agreement, master lease amendments and loan amendments with Maplewood Senior Living (along with affiliates, “Maplewood”). As part of the restructuring agreement and related agreements, Omega agreed to, among other things: ● extend the maturity date of the master lease from December 2033 to December 2037 with two consecutive 5-year tenant extension options; ● fix contractual rent at $ 69.3 million per annum (December 2022 rent annualized) and defer the 2.5 % annual escalators under our lease agreement through December 31, 2025, with mandatory repayments to be made subject to certain metrics and due in full by the maturity date; ● fund $ 22.5 million of capital expenditures through December 31, 2025; ● extend the maturity date of the secured revolving credit facility (the “Maplewood Revolver”) from June 2030 to June 2035 with one borrower 2-year extension option; ● increase the capacity of the Maplewood Revolver from $ 250.5 million to $ 320.0 million, inclusive of PIK interest applied to principal ; ● convert the 7 % per annum cash interest due on the Maplewood Revolver to all PIK interest in 2023, 1 % cash interest and 6 % PIK interest in 2024, and 4 % cash interest and 3 % PIK interest in 2025 and through the maturity date; ● pay a one-time option termination fee of $ 12.5 million to Maplewood; and ● reduce Maplewood’s share of any future potential sales proceeds (in excess of our gross investment) by the unpaid deferred rent balance, the $ 22.5 million of capital expenditures and the $ 12.5 million option termination fee payment. Shortly after the restructuring was completed, on March 31, 2023, Greg Smith, the principal and chief executive officer of Maplewood, passed away. Mr. Smith had been a guarantor of Maplewood’s contractual obligations pursuant to a $ 40.0 million limited unconditional guaranty agreement. Maplewood began to short pay contractual rent under its lease agreement during the second quarter of 2023. F-26 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ In June 2024, Omega executed a non-binding term sheet with the key members of the existing Maplewood management team (the “Key Principals”) and the Greg Smith estate (the “Estate”) which outlined the terms of a proposed transition, in which the Key Principals would become the new majority equity holders in the Maplewood entities. The proposed transition included maintaining the Maplewood lease agreement and the Maplewood Revolver provided by Omega. On July 31, 2024, we entered into a settlement agreement (the “Settlement Agreement”) with the Estate and submitted it to the probate court for approval. The Settlement Agreement, among other things, grants Omega the right to direct the assignment of Mr. Smith’s equity to the Key Principals or their designee(s) or another designee of Omega’s choosing, with the Estate remaining liable under Mr. Smith’s guaranty until August 2025, and required Omega to refrain from exercising contractual rights or remedies in connection with the defaults. On August 26, 2024, the probate court approved the Settlement Agreement. In the fourth quarter of 2025, we received the final regulatory approvals related to the licensure of Maplewood’s operating assets, and the transition of the equity to the Key Principals was completed. Concurrently with the transition of the equity to the Key Principals, on December 11, 2025, Omega entered into a restructuring agreement and amended its master lease agreement for 17 facilities (the “Maplewood Master Lease”) and the Maplewood Revolver. The single facility lease for the Inspir Embassy Row property in Washington D.C. was not modified as part of the restructuring. As part of the restructuring agreement and related agreements, Omega and Maplewood agreed, among other things: ● to reinstate the 2.5 % annual contractual rent escalators that were allowed to be deferred as part of the 2023 restructuring agreement terms, resulting in contractual rent of $ 76.5 million for 2026 for the 17 facilities under the Maplewood Master Lease, increasing annually by 2.5 % thereafter; ● allow for the deferral of monthly rent (with 5 % interest if outstanding longer than 18 months) if certain conditions are met, but require a minimum amount of contractual rent to be paid annually including $ 62.1 million for 2026 and $ 70.0 million for 2027, increasing annually by 2.5 % thereafter; ● provide up to $ 43.0 million of incentive payments to Maplewood based on achievement of certain metrics and conditions ( $ 8.0 million of which was paid upon execution of the restructuring agreement as targets had already been achieved); ● extend the maturity date of the Maplewood Revolver from June 2035 to June 2037 ; ● retrospectively allow the interest due on the Maplewood Revolver dating back to January 1, 2023 to be paid-in-kind; and ● reduce Maplewood’s share of any future potential sales proceeds (in excess of our gross investment) by any incentive payments made to Maplewood. For the year ended December 31, 2023, Maplewood paid total contractual rent of $ 57.8 million, a total short pay of $ 11.5 million of the $ 69.3 million due under the lease agreement for the year after reflecting the impact of deferred escalators. Omega applied all $ 4.8 million of Maplewood’s security deposit towards the total year to date shortfall and recognized rental income of $ 62.6 million for the year ended December 31, 2023. The $ 12.5 million option termination fee payment made in the first quarter of 2023 in connection with the restructuring agreement was accounted for as a lease inducement. As Maplewood is on a cash basis of revenue recognition, the inducement was immediately expensed and was recorded as a reduction to the $ 62.6 million of rental income recognized for the year ended December 31, 2023. For the year ended December 31, 2024, Maplewood paid total contractual rent of $ 47.5 million, a total short pay of $ 21.8 million of the $ 69.3 million of contractual rent due under the lease agreement for the year after reflecting the impact of deferred escalators. For the year ended December 31, 2025, Maplewood paid total contractual rent of $ 58.9 million compared to the $ 69.3 million of contractual rent due under the lease agreement for the year after reflecting the impact of deferred escalators. These amounts exclude contractual rent and payments related to Inspir Embassy Row in Washington D.C. of $ 11.9 million for the year ended December 31, 2025, which were paid in full and are separately discussed in Note 3– Real Estate Asset Acquisitions and Development. As discussed further in Note 7 – Real Estate Loans Receivable, we recorded interest income of zero , zero and $ 1.5 million on the Maplewood Revolver during the years ended December 31, 2025, 2024 and 2023, respectively. Following the restructuring and transition of the equity to the Key Principals, the lease remains on a cash basis of revenue recognition and the Maplewood Revolver remains on a non-accrual basis. F-27 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ In January 2026, Maplewood paid $ 6.3 million under its lease agreements, $ 1.1 million of which relates to Inspir Embassy Row in Washington D.C. Genesis In March 2025, Genesis Healthcare, Inc. (“Genesis”), an operator on a cash basis of rental revenue recognition, failed to make a rent payment due under its lease agreement and interest payment due under one of its three loan agreements. In July 2025, Genesis commenced voluntary cases under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Northern District of Texas, Dallas Division. Genesis will continue to operate, as a DIP, the 31 facilities subject to a master lease agreement with Omega, unless and until Genesis’ leasehold interest under the master lease agreement is rejected or assumed and assigned. We provided $ 8.0 million of a $ 30.0 million junior secured DIP financing, along with other lenders, to Genesis to support sufficient liquidity to, among other things, operate its facilities during bankruptcy, as further discussed in Note 8 – Non-Real Estate Loans Receivable. As a condition of the DIP financing, Genesis is required to pay Omega full contractual rent under its lease agreement. On January 14, 2026, 101 W State Street Holdings, LLC (“WSSH”) was named the winning bidder in the auction to acquire Genesis’ assets, and on January 26, 2026, the Bankruptcy Court approved the sale to WSSH, subject to satisfaction of the terms and conditions of the purchase and sale agreement between Genesis and WSSH. To the extent that the transaction is consummated, closing is not expected in the next 90-120 days. Genesis has not yet elected to assume and assign the Omega lease to WSSH. If the transaction closes, it is anticipated that the cash proceeds of the sale will be sufficient to repay the DIP and Omega term loans. As discussed in Note 20 – Commitments and Contingencies, the Statutory Unsecured Claimant’s Committee has filed a proposed Complaint and Preliminary Objection regarding the collateral supporting our term loans (discussed in Note 8 – Non-Real Estate Loans Receivable) and regarding payments received by Omega under its lease and loan obligations in the 90 days prior to the Genesis bankruptcy filing date. Since commencing the bankruptcy process in July 2025, Genesis made all required contractual rent and interest payments through the end of 2025. As Genesis is on a cash basis of revenue recognition, we recognized rental income of $ 51.2 million, $ 48.1 million, and $ 51.4 million for the years ended December 31, 2025, 2024 and 2023, respectively. The $ 51.2 million recognized in 2025 includes $ 47.0 million for contractual rent payments received and $ 4.2 million from the application of proceeds from the letter of credit in March 2025 that was held as collateral from Genesis. In addition, we recognized interest income of $ 17.1 million (which includes $ 0.1 million from the application of proceeds from the letter of credit) related to loans with Genesis during the year ended December 31, 2025. After the application of proceeds from the letter of credit, there is $ 3.5 million remaining under the letter of credit. In January 2026, Genesis paid full contractual rent and interest of $ 4.5 million. Guardian In August 2023, Guardian, an operator on a cash basis of revenue recognition, failed to make the contractual rent payment due under its lease agreement and continued to fail to make the required contractual rent payments due under its lease agreement throughout the remainder of 2023. We applied $ 6.3 million of Guardian’s security deposit to fund the unpaid rent for payment missed in the third and fourth quarters. As Guardian is on a cash basis of revenue recognition, we recorded rental income of $ 16.8 million for the year ended December 31, 2023 for the contractual rent payments that were received from Guardian and through the application of Guardian’s security deposit. Guardian continued to fail to make the contractual rent payment due under its lease agreement during the first quarter of 2024. As such, we only recorded rental income of $ 0.1 million related to our lease with Guardian for the three months ended March 31, 2024 for the application of Guardian’s remaining security deposit to fund a portion of the unpaid rent. In April 2024, we transitioned the remaining six facilities previously included in Guardian’s master lease to a new operator for minimum initial contractual rent of $ 5.5 million per annum with the potential to increase contractual rent dependent on revenue received by the operator. Additionally, no mortgage interest income was recognized on the Guardian mortgage loan (discussed in Note 7 – Real Estate Loans Receivable) during the year ended December 31, 2023 as we were accounting for this loan under the cost recovery method. F-28 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Lease Inducements We funded $ 10.0 million, $ 1.0 million and $ 15.9 million of lease inducements or incentives to operators during the years ended December 31, 2025, 2024 and 2023, respectively. Lease inducements are deferred and amortized as a reduction to rental income over the remaining contractual term of the related lease if the operator’s lease is recognizing revenue on a straight-line basis. To the extent the related operator lease is on a cash basis of revenue recognition, the full lease inducement is recorded as a reduction to rental income in the period it was paid. NOTE 6 – LEASES Lease Income The following table summarizes the Company’s rental income: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2025 ​ 2024 ​ 2023 ​ (in thousands) Fixed income from operating leases $ 985,894 ​ $ 871,189 ​ $ 811,123 Variable income from operating leases ​ 15,891 ​ ​ 15,718 ​ ​ 14,257 Interest income from direct financing leases ​ 180 ​ ​ 1,003 ​ ​ 1,014 Total rental income $ 1,001,965 ​ $ 887,910 ​ $ 826,394 ​ Our variable lease income primarily represents the reimbursement of real estate taxes by operators that Omega pays directly. Lessor – Operating Leases The following amounts reflect the future minimum lease payments due to us for the remainder of the initial terms of our operating leases as of December 31, 2025: ​ ​ ​ ​ (in thousands) 2026 $ 1,034,973 2027 ​ 1,030,128 2028 ​ 1,010,023 2029 ​ 1,003,679 2030 ​ 989,436 Thereafter ​ 6,937,245 Total $ 12,005,484 ​ Lessor – Direct Financing Leases During the first quarter of 2025, we terminated our one direct financing lease, along with several operating leases with the same operator, and entered into a new consolidated operating lease for all facilities leased to the operator. In connection with the termination of the direct financing lease, we reclassified $ 9.4 million from investment in direct financing lease to real estate assets. In connection with the execution of the new consolidated lease agreement, we paid $ 10.0 million to the operator, which was treated as lease inducement. As this operator is on a cash basis of revenue recognition, the inducement was immediately expensed and was recorded as a reduction to the rental income recognized for the year ended December 31, 2025. See additional discussion within Note 5 – Contractual Receivables and Other Receivables and Lease Inducements. F-29 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Lessee – Operating Leases As of December 31, 2025, the Company is a lessee under ground leases and/or facility leases related to 10 SNFs, four ALFs, one specialty facility and our corporate headquarters. For the years ended December 31, 2025, 2024 and 2023, the expenses associated with these operating leases were $ 3.3 million, $ 3.2 million and $ 2.8 million, respectively, and are included within general and administrative expense on the Statements of Operations. In connection with a 6-facility asset acquisition in the first quarter of 2023, the Company recorded $ 9.9 million of right-of-use assets and lease liabilities associated with ground leases assumed in the acquisition. The following table summarizes the balance sheet information related to leases where the Company is a lessee: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2025 ​ 2024 ​ ​ (in thousands) Other assets - right of use assets ​ $ 27,283 ​ $ 28,302 ​ ​ ​ ​ ​ ​ ​ Accrued expenses and other liabilities – lease liabilities ​ $ 29,512 ​ $ 30,328 ​ ​ NOTE 7 – REAL ESTATE LOANS RECEIVABLE Real estate loans consist of mortgage loans and other real estate loans which are primarily collateralized by a first, second or third mortgage lien or a leasehold mortgage on, or an assignment of the partnership interest in the related properties. As of December 31, 2025, our real estate loans receivable consists of 20 fixed rate mortgages on 91 operating long-term care facilities and 20 other real estate loans. The facilities subject to the mortgage notes are operated by 15 independent healthcare operating companies and are located in 9 states and within the U.K. The other real estate loans are with 16 of our operators as of December 31, 2025. We monitor compliance with the loans and when necessary have initiated collection, foreclosure and other proceedings with respect to certain outstanding real estate loans. A summary of our real estate loans receivable by loan type and by borrower and/or guarantor is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2025 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ Average Years ​ ​ December 31, ​ December 31, ​ ​ ​ ​ Interest Rate ​ to Maturity ​ ​ 2025 ​ ​ ​ 2024 ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Mortgage notes receivable – gross ​ 10.9 % ​ 3.9 (1) ​ $ 931,616 ​ $ 982,327 Allowance for credit losses on mortgage notes receivable ​ ​ ​ ​ ​ ​ ​ ​ ( 33,298 ) ​ ​ ( 39,562 ) Mortgage notes receivable – net ​ ​ ​ ​ ​ ​ ​ ​ 898,318 ​ ​ 942,765 Other real estate loans – gross ​ 9.0 % ​ 7.6 (2) ​ ​ 524,169 ​ ​ 517,220 Allowance for credit losses on other real estate loans ​ ​ ​ ​ ​ ​ ​ ( 41,538 ) ​ ​ ( 31,687 ) Other real estate loans – net ​ ​ ​ ​ ​ ​ ​ ​ 482,631 ​ ​ 485,533 Total real estate loans receivable – net ​ ​ ​ ​ ​ ​ ​ $ 1,380,949 ​ $ 1,428,298 (1) Consists of mortgage notes with maturity dates ranging from 2026 through 2037 (with $ 196.9 million maturing in 2026). One of the mortgage notes with an aggregate principal balance of $ 6.4 million is past due and has been written down, through our allowance for credit losses, to the estimated fair value of the underlying collateral of $ 1.5 million. (2) Consists of other real estate loans with maturity dates ranging from 2026 through 2037 (with $ 16.6 million maturing in 2026). F-30 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ ​ Interest income on real estate loans is included within interest income on the Consolidated Statements of Operations and is summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2025 ​ 2024 ​ 2023 ​ (in thousands) Mortgage notes – interest income $ 104,987 ​ $ 91,434 ​ $ 68,340 Other real estate loans – interest income ​ 29,616 ​ ​ 35,366 ​ ​ 29,426 Total real estate loans interest income $ 134,603 ​ $ 126,800 ​ $ 97,766 ​ The following is a summary of advances and principal repayments under our real estate loans: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2025 ​ 2024 ​ 2023 ​ (in thousands) Advances on new real estate loans receivable (1) $ 65,447 ​ $ 370,248 ​ $ 224,121 Advances on existing real estate loans receivable ​ 17,300 ​ ​ 7,922 ​ ​ 20,836 Principal repayments on real estate loans receivable (2) ​ ( 115,687 ) ​ ​ ( 77,882 ) ​ ​ ( 51,884 ) Net cash advances (repayments) on real estate loans receivable $ ( 32,940 ) ​ $ 300,288 ​ $ 193,073 ​ (1) Consists of advances under 19 , 29 and 12 new real estate loans originated during 2025, 2024 and 2023, respectively, with a weighted average interest rate of 10.3 % , 10.5 % and 10.9 % during the years ended December 31, 2025, 2024 and 2023, respectively. (2) Excludes principal recoveries on loans written off in prior periods and cash recoveries related to interest payments received on loans that are written down to fair value and are being accounted for under the cost recovery method in which any payments received are applied directly against the principal balance outstanding. Included below is additional discussion on any significant new loans issued and/or significant updates to any existing loans. Ciena Healthcare Management, Inc (“Ciena”) Mortgage Loans As of December 31, 2025 and 2024, Omega had $ 480.0 million and $ 525.5 million, respectively, of mortgage notes with Ciena secured by 34 and 38 facilities, respectively. The mortgage loans bear interest at a weighted average interest rate of 11.8 % and mature on June 30, 2030 . During the year ended December 31, 2025, Ciena made $ 40.6 million of early repayments on mortgage notes with a weighted average interest rate of 11.6 % as of the repayment date, subject to the master mortgage agreement with Ciena. U.K. Mortgage Loans In May 2024, we funded an aggregate $ 71.7 million under two new mortgage loans to an existing U.K. operator secured by first mortgage liens on two parcels of land that the U.K. operator intends to develop into two facilities. Both mortgage loans bear interest at 10.0 % per annum and had original maturity dates of October 28, 2024 . During the fourth quarter of 2024, the $ 18.5 million mortgage loan was extended to February 28, 2025 prior to being refinanced into a mezzanine loan in the first quarter of 2025. Through multiple amendments in 2024 and 2025, the maturity date of the $ 53.2 million mortgage loan was extended to January 31, 2026 . During the fourth quarter of 2024, we funded an additional $ 61.7 million and $ 39.1 million, respectively, under two new mortgage loans to the same existing U.K. operator discussed above that originally bore interest at 11.0 % per annum. The $ 61.7 million mortgage loan had an original maturity date of October 29, 2025 , and the $ 39.1 million mortgage loan had an original maturity date of November 27, 2025 . Both mortgage loans contain a purchase option, whereby Omega can purchase the facilities that secure the applicable mortgage loan. The purchase options can be exercised upon the occurrence of certain conditions. During the fourth quarter of 2025, both of these mortgage loans were amended to extend the maturity dates to April 30, 2026 and reduce the interest rate to 10 % per annum. As of December 31, 2025 and 2024, the outstanding principal balance on the four loans discussed above was $ 172.5 million. F-31 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ $60.0 million Mortgage Loan In December 2023, we funded a $ 50.0 million mortgage loan to a new operator secured by a first mortgage lien on the operator’s four facilities. The mortgage loan bears interest at 10 % per annum and matures on December 28, 2028 . During the fourth quarter of 2024, the mortgage loan was amended to increase the maximum principal to $ 60.0 million. As of December 31, 2025 and 2024, the outstanding principal balance of this mortgage note was $ 53.8 million. Guardian Mortgage Loan As of January 1, 2023, we had an $ 82.0 million four-facility first mortgage loan outstanding with Guardian that was on non-accrual status and being accounted for under the cost recovery method as a result of ongoing liquidity issues. During the year ended December 31, 2023, we received $ 3.9 million of interest payments that we applied against the outstanding principal balance of the loan and recognized a recovery for credit loss equal to the amount of payments applied against principal. In the second quarter of 2023, Guardian sold the four facilities subject to the mortgage note with Omega. Guardian used $ 35.2 million of proceeds from the sale of the facilities to make a principal repayment to Omega, in the same amount, against the mortgage note. Following the repayment, Omega agreed to release the mortgage liens on these facilities and forgive the remaining $ 46.8 million of outstanding principal due under the mortgage note. We had previously established an allowance for credit loss to reserve this loan down to $ 35.2 million in anticipation of this settlement. Following the sale in the second quarter of 2023, we wrote off the outstanding principal and related allowance associated with the mortgage loan. As a result, Guardian no longer has any outstanding loan obligations to us. Maplewood Revolving Credit Facility In July 2020, we entered into the Maplewood Revolver as a part of an overall restructuring with this operator. Loan proceeds under the Maplewood Revolver may be used to fund Maplewood’s working capital needs. The loan is secured by a leasehold mortgage and Maplewood’s share of any future potential sales proceeds of facilities subject to the Maplewood Master Lease. Advances made under the Maplewood Revolver bear interest at a fixed rate of 7 % per annum. The loan is on non-accrual status for interest income recognition. Maplewood was determined to be a VIE when this loan was originated in 2020. Our balances and risk of loss associated with Maplewood are included within our disclosures in Note 10 – Variable Interest Entities. In the first quarter of 2023, Omega entered into a restructuring agreement and a loan amendment that modified the Maplewood Revolver. As part of the restructuring agreement and loan amendment, Omega agreed to extend the maturity date to June 2035, increase the capacity of the Maplewood Revolver to $ 320.0 million, including PIK interest applied to the principal, and to convert the 7 % cash interest due on the Maplewood Revolver to all PIK interest in 2023, 1 % cash interest and 6 % PIK interest in 2024, and 4 % cash interest and 3 % PIK interest in 2025 and through the maturity date. The maximum PIK interest allowable under the Maplewood Revolver, as amended, was $ 52.2 million. This amendment was treated as a loan modification provided to a borrower experiencing financial difficulty. In the fourth quarter of 2025, we received the final regulatory approvals related to the licensure of Maplewood’s operating assets, and the transition of the equity to the key management team members was completed. Concurrently with the transition of the equity to the new management team, on December 11, 2025, Omega entered into a restructuring agreement and amended the Maplewood Master Lease and the Maplewood Revolver. The loan amendment extended the maturity date of the Maplewood Revolver from June 2035 to June 2037. In addition, the amendment also allows for the payment of interest due on the Maplewood Revolver to be paid-in-kind through maturity, effective retroactively beginning January 1, 2023. For the years ended December 31, 2025 and 2024, prior to the amendment, Maplewood missed cash interest payments of $ 11.9 million and $ 2.7 million, respectively. As the loan is on non-accrual status, the previously missed cash interest payments due under the loan were never recognized as interest income. Therefore, subsequent to the amendment, the missed cash interest payments will increase the principal balance of the loan but will not be included in the amortized cost basis of the loan. The interest rate remains at 7 % per annum. Omega has no obligation to make any additional cash advances under the loan, but additional PIK interest added to the principal is allowable with no limit. This amendment was treated as a loan modification provided to a borrower experiencing financial difficulty. F-32 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ We adjusted the internal risk rating on the Maplewood Revolver, utilized as a component of our allowance for credit loss calculation, from a 3 to a 4 in the second quarter of 2023 when Maplewood began to short-pay contractual rent under its lease agreement. In the first quarter of 2024, we again adjusted the internal risk rating from a 4 to 5 to reflect the increased risk of the Maplewood Revolver as a result of the missed interest payments in the first quarter of 2024, discussed below, and due to Maplewood continuing to pay interest in kind on the loan. We believe the internal risk rating of a 5 appropriately reflects the risks as of December 31, 2025. See the allowance for credit losses attributable to real estate loans with a 5 internal risk rating within Note 9 – Allowance for Credit Losses. During the year ended December 31, 2023, we recorded interest income of $ 1.5 million on the Maplewood Revolver for the contractual interest payment received related to December 2022, as the loan was placed on non-accrual status for interest recognition during the fourth quarter of 2022. We did no t record any interest income related to the PIK interest during the years ended December 31, 2025, 2024 and 2023. As of December 31, 2025 and 2024, the outstanding principal balance of the Maplewood Revolver was $ 323.8 million and $ 301.7 million, respectively, and the amortized cost basis of the Maplewood Revolver was $ 263.6 million, which represents 18.1 % and 17.6 %, respectively, of the total amortized cost basis of all real estate loan receivables. $68.0 million Mezzanine Loan In April 2023, we entered into a mezzanine loan with a principal balance of $ 68.0 million with an existing operator and its affiliates in connection with the operator’s acquisition of 13 SNFs in West Virginia. The loan matures on April 13, 2029 and bears interest at a variable rate that results in a blended interest rate of 12 % per annum across this loan and three other existing loans with the operator. The loan requires quarterly principal payments of $ 1.0 million commencing on July 1, 2023 and additional payments contingent on certain metrics. The loan is secured by a leasehold mortgage and a pledge of the operator’s equity interest in subsidiaries of the operator. As of December 31, 2025 and 2024, the amortized cost basis of the mezzanine loan is $ 53.8 million and $ 57.2 million, respectively. NOTE 8 – NON-REAL ESTATE LOANS RECEIVABLE Our non-real estate loans consist of fixed and variable rate loans to operators or principals. These loans may be either unsecured or secured by the collateral of the borrower, which may include the working capital of the borrower and/or personal guarantees. As of December 31, 2025, we had 40 loans with 27 different borrowers. A summary of our non-real estate loans by borrower and/or guarantor is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2025 ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ ​ ​ Average ​ Average Years ​ ​ December 31, ​ ​ ​ December 31, ​ Interest Rate ​ to Maturity ​ ​ 2025 ​ ​ ​ 2024 ​ ​ ​ ​ ​ ​ ​ (in thousands) Working capital loans receivable 9.6 % ​ 0.8 (1) ​ $ 55,010 ​ $ 57,071 Other loans receivable 10.3 % ​ 3.3 (2) ​ 375,574 ​ ​ 397,998 Non-real estate loans receivable – gross ​ ​ ​ ​ ​ ​ ​ 430,584 ​ ​ 455,069 Allowance for credit losses on non-real estate loans receivable ​ ​ ​ ​ ​ ​ ​ ( 100,262 ) ​ ​ ( 122,795 ) Total non-real estate loans receivable – net ​ ​ ​ ​ ​ ​ $ 330,322 ​ $ 332,274 (1) Consists of revolving working capital loans receivable collateralized by the accounts receivable of the applicable borrower with maturity dates ranging from 2026 to 2029 (with $ 47.1 million maturing in 2026 ). (2) Consists of other loans receivable with maturity dates ranging from 2026 to 2037 (with $ 219.6 million maturing in 2026 ). One of the other notes outstanding with an aggregate principal balance of $ 6.4 million is past due and has been reserved down to the estimated fair value of the underlying collateral of zero through our allowance for credit losses. For the years ended December 31, 2025, 2024 and 2023, non-real estate loans generated interest income of $ 40.5 million, $ 30.4 million and $ 22.1 million, respectively. Interest income on non-real estate loans is included within interest income on the Consolidated Statements of Operations. F-33 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ The following is a summary of advances and principal repayments under our non-real estate loans: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2025 ​ 2024 ​ 2023 ​ (in thousands) Advances on new non-real estate loans receivable $ 17,517 ​ $ 60,618 ​ $ 147,437 Advances on existing non-real estate loans receivable ​ 37,863 ​ ​ 14,801 ​ ​ 18,700 Principal repayments on non-real estate loans receivable (1) ​ ( 68,058 ) ​ ​ ( 119,736 ) ​ ​ ( 23,000 ) Net cash advances (repayments) on non-real estate loans receivable $ ( 12,678 ) ​ $ ( 44,317 ) ​ $ 143,137 ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) Consists of advances under seven , 13 and 19 new non-real estate loans originated during 2025, 2024 and 2023, respectively, with weighted average interest rates of 11.9 % , 8.4 % and 10.5 % for the years ended December 31, 2025, 2024 and 2023, respectively. (2) Excludes principal recoveries on loans written off in prior periods and cash recoveries related to interest payments received on loans that are written down to fair value and are being accounted for under the cost recovery method in which any payments received are applied directly against the principal balance outstanding. Included below is additional discussion on any significant new loans issued and significant updates to any existing loans. Genesis Non-Real Estate Loans Omega has two secured term loans with Genesis with initial borrowings of $ 48.0 million and $ 16.0 million at issuance that previously were included as real estate loans receivables within our Consolidated Balance Sheets. The $ 48.0 million term loan was issued in July 2016 (the “2016 Term Loan”), with subsequent amendments in 2018, 2019, 2021, 2023 and 2024 (discussed below), and currently bears interest at a fixed rate of 14 % per annum. The $ 16.0 million secured term loan was issued on March 6, 2018 (the “2018 Term Loan,” together with the 2016 Term Loan, the “Genesis Term Loans”), with subsequent amendments in 2021, 2023 and 2024 (discussed below), and bears interest at a fixed rate of 10 % per annum. On September 30, 2024, the loans were amended to (i) modify the priority of certain real estate collateral securing the loans so that they are primarily collateralized by a first priority lien on the equity of several ancillary businesses of Genesis, (ii) extend the maturity date from June 30, 2025 to June 30, 2026 and (iii) keep the existing interest rates but reduce the portion of contractual interest permitted to be paid in kind from 9.0 % to 3.5 % per annum on the 2016 Term Loan and from 5.0 % to 2.5 % per annum on the 2018 Term Loan beginning September 1, 2025. Following the modification to the priority of certain real estate collateral available to us under the loan agreements, we adjusted our presentation of these loans from real estate loans receivable to non-real estate loans receivable as of September 30, 2024. As of December 31, 2025 and 2024, there was $ 104.4 million and $ 93.4 million, respectively, of principal outstanding on the 2016 Term Loan and $ 24.2 million and $ 22.5 million, respectively, of principal outstanding on the 2018 Term Loan. As discussed in Note 5 – Contractual Receivables and Other Receivables and Lease Inducements, in July 2025, Genesis commenced voluntary cases under Chapter 11 of the U.S. Bankruptcy Code in the Bankruptcy Court for the Northern District of Texas, Dallas Division. As described in Genesis’ filings with the Bankruptcy Court, we provided, $ 8.0 million of a $ 30.0 million DIP financing, along with other lenders, to Genesis to support sufficient liquidity to, among other things, operate its facilities during bankruptcy. The DIP financing loan bears PIK interest at 14.0 % per annum, payable monthly in arrears. The principal is due upon maturity. The DIP loan matures on the earlier of (i) February 4, 2026 , (ii) the effective date of a plan of reorganization or liquidation in the Chapter 11 cases or (iii) upon an event of default as defined in the DIP loan agreement. Prior to its maturity on February 4, 2026, the DIP loan was in default. Upon maturity, the DIP loan was not paid, which is another event of default. The DIP loan Agent, on behalf of the DIP lenders, has issued a default notice and reserved all rights and remedies under the DIP loan documents. Omega, along with other DIP and term loan lenders, have agreed to forbear from exercising remedies, except for charging default interest on the DIP and term loans, until February 13, 2026. The DIP lenders hold a third and fourth priority security interest in all of Genesis’ assets, which includes a third priority security interest in cash and accounts receivable, other than (i) certain claims and causes of action arising under the US. Bankruptcy Code and (ii) any causes of action that are not accounts receivable or accounts ((i) and (ii), collectively, the “Excluded Claims”). Proceeds of any future asset sales, claims and causes of action other than the Excluded Claims and debt or equity issuances will all serve as collateral for the DIP loans. The interim DIP order approved, as part of the bankruptcy process, the DIP budget, which allows interest payments due under Omega’s Genesis Term Loans to be satisfied in kind during the bankruptcy, except for budgeted adequate protection payments that will be applied as interest on the 2016 Term Loan. During the year ended December 31, 2025, we received $ 0.4 million of adequate protection payments. F-34 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ As part of our ongoing credit loss procedures, we evaluated the fair value of the collateral available to us under the Genesis Term Loan agreements and the DIP financing based on appraisals and market indicators and determined there is sufficient collateral to support the outstanding principal on each of the Genesis Term Loans and the DIP financing. Based on our determination regarding the sufficiency of the collateral, the Genesis Term Loans and the DIP financing remain on an accrual basis. As of December 31, 2025, the internal risk rating on the Genesis Term Loans and the DIP financing is a 4, which we believe appropriately reflects the risks associated with the loans as of December 31, 2025. As discussed in Note 20 – Commitments and Contingencies, the Statutory Unsecured Claimant’s Committee has filed a proposed Complaint and Preliminary Objection regarding the collateral supporting our term loans and regarding payments received by Omega under its lease and loan obligations in the 90 days prior to the Genesis bankruptcy filing date. Agemo Non-Real Estate Loans As discussed in Note 5 – Contractual Receivables and Other Receivables and Lease Inducements, in the first quarter of 2023, Omega entered into a restructuring agreement and a replacement loan agreement that modified existing Agemo loans. Under the restructuring agreement, the outstanding principal of a $ 32.0 million secured term loan was refinanced into a new $ 32.0 million loan (“Agemo Replacement Loan A”). The outstanding principal of a $ 25.0 million secured working capital loan and the aggregate rent deferred and outstanding under the Agemo lease agreement was combined and refinanced into a new $ 50.2 million loan (“Agemo Replacement Loan B” and with Agemo Replacement Loan A, the “Agemo Replacement Loans”). The Agemo Replacement Loans bore interest at 5.63 % per annum through October 2024 but increased following October 2024 to 5.71 % per annum until maturity. The Agemo Replacement Loans mature on December 31, 2036 . Beginning in January 2025, Agemo was required to make principal payments on the Agemo Replacement Loans dependent on certain metrics. These amendments were treated as loan modifications provided to a borrower experiencing financial difficulty. Both of these loans are on non-accrual status, and we are utilizing the cost recovery method, under which any payments, if received, are applied against the principal amount. The loans are reserved down to the estimated fair value of the underlying collateral. During the years ended December 31, 2025, 2024, 2023, we received $ 4.7 million, $ 4.7 million and $ 3.2 million, respectively, of interest payments from Agemo that we applied against the outstanding principal of the loans and recognized a recovery for credit loss equal to the amount of payments applied against the principal. As of December 31, 2025 and 2024, the amortized cost basis of these loans was $ 67.3 million and $ 73.1 million, respectively, which represents 15.6 % and 16.1 %, respectively, of the total amortized cost basis of all non-real estate loans receivables. As of December 31, 2025 and 2024, the total reserves related to the Agemo Replacement loans were $ 66.4 million and $ 70.9 million, respectively. $50.0 million Secured Term Loan In December 2023, the Company entered into a $ 50.0 million secured term loan with a principal of an operator that bears interest at a fixed rate of 11 % per annum and matures on December 19, 2026 . In connection with entering into this loan, we also entered into two lease amendments to extend the term of two leases with entities associated with this principal. The loan is collateralized by a pledge of equity interests in a closely held corporation of which the principal is the majority owner. The loan requires monthly interest and principal payments commencing January 19, 2024. As of December 31, 2025 and 2024, there was $ 43.9 million and $ 47.1 million, respectively, outstanding on the secured term loan. F-35 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ $45.0 million Unsecured Revolving Credit Facility On July 8, 2019, the Company entered into an unsecured revolving credit facility agreement with a principal of an operator, that has been subsequently amended multiple times in 2022, 2023, 2024 and 2025. In February 2024, we amended the revolving credit facility agreement to, among other changes, extend the maturity date to December 31, 2025 , reduce the maximum principal under the loan from $ 55.0 million to $ 45.0 million and modify the mandatory principal payments required under the loan. Additionally, the amendment increased the interest rate on principal balances exceeding $ 15.0 million to 8 % in January 2024, with further interest rate increases to 9 % and 10 % in April 2024 and June 2024, respectively. The interest rate remains at 7.5 % for borrowings that do not exceed $ 15.0 million. In December 2024, the loan was amended to increase the interest rate on the entire balance outstanding to 12.5 % per annum beginning January 1, 2025 and modify the principal payment schedule. During fourth quarter of 2025, the maturity date of this loan was extended to June 30, 2026 and required additional principal payments contingent upon the completion of certain restructuring transactions by the operator. As of December 31, 2025 and 2024, the outstanding principal on the loan was $ 32.5 million and $ 42.5 million, respectively. LaVie Non-Real Estate Loans As discussed in Note 5 – Contractual Receivables and Other Receivables and Lease Inducements, on June 2 and 3, 2024, LaVie commenced voluntary cases under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Northern District of Georgia, Atlanta Division . As described in LaVie’s filings with the Bankruptcy Court, we provided $ 10.0 million of DIP financing to LaVie in order to support sufficient liquidity to, among other things, effectively operate its facilities during bankruptcy. Another lender, also agreed to provide $ 10.0 million of DIP financing to LaVie, which is pari passu to Omega’s loan. The DIP loan bore interest at 10.0 % and was paid-in-kind in arrears on a monthly basis. The principal was due upon maturity. In addition to the DIP financing discussed above, we also had a $ 25.0 million term loan and an $ 8.3 million term loan with LaVie. Given the risks associated with the bankruptcy process, LaVie’s liquidity issues and insufficient collateral, we evaluated the risk of loss on all of Omega’s loans with LaVie on an individual basis and wrote down any remaining unreserved balances associated with these loans during the course of 2024 and 2025. We recorded provisions for credit losses of $ 4.0 million and $ 9.6 million associated with LaVie’s outstanding loans for the years ended December 31, 2025 and 2024. During the second quarter of 2025, the DIP loan and $ 8.3 million term loan were discharged as part of the LaVie plan of reorganization that was made effective on June 1, 2025 and we wrote off the principal and allowance associated with these loans. As of December 31, 2025 and 2024, the amortized cost basis of the one and three, respectively, LaVie loans outstanding was $ 24.5 million and $ 38.3 million, which represents 5.7 % and 8.4 % respectively, of the total amortized cost basis of all non-real estate loan receivables. The total reserve as of December 31, 2025 related to the remaining LaVie loan was $ 24.5 million. No interest income was recorded for any LaVie loans during the years ended December 31, 2025, 2024 and 2023 as all three loans were on non-accrual status. F-36 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ NOTE 9 – ALLOWANCE FOR CREDIT LOSSES A rollforward of our allowance for credit losses, summarized by financial instrument type and internal credit risk rating, for the years ended December 31, 2025, 2024 and 2023 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rating ​ Financial Statement Line Item Allowance for Credit Loss as of December 31, 2024 ​ Provision (recovery) for Credit Loss for the year ended December 31, 2025 (1) ​ Write-offs charged against allowance for the year ended December 31, 2025 ​ Other additions to the allowance for the year ended December 31, 2025 ​ Allowance for Credit Loss as of December 31, 2025 ​ ​ ​ (in thousands) 1 ​ Real estate loans receivable $ 312 ​ $ ( 98 ) ​ $ — ​ $ — ​ $ 214 2 ​ Real estate loans receivable ​ 492 ​ ​ ( 312 ) ​ ​ — ​ ​ — ​ ​ 180 3 ​ Real estate loans receivable ​ 10,991 ​ ​ ( 1,019 ) ​ ​ — ​ ​ — ​ ​ 9,972 4 ​ Real estate loans receivable ​ 22,528 ​ ​ ( 3,431 ) ​ ​ — ​ ​ — ​ ​ 19,097 5 ​ Real estate loans receivable ​ 25,476 ​ ​ 9,677 ​ ​ — ​ ​ — ​ ​ 35,153 6 ​ Real estate loans receivable ​ 11,450 ​ ​ ( 1,230 ) ​ ​ — ​ ​ — ​ ​ 10,220 ​ ​ Sub-total ​ 71,249 ​ ​ 3,587 (2) ​ — ​ ​ — ​ ​ 74,836 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 5 ​ Investment in direct financing leases ​ 1,605 ​ ​ — ​ ​ — ​ ​ ( 1,605 ) (3) ​ — ​ ​ Sub-total ​ 1,605 ​ ​ — ​ ​ — ​ ​ ( 1,605 ) ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2 ​ Non-real estate loans receivable ​ 37 ​ ​ 2 ​ ​ — ​ ​ — ​ ​ 39 3 ​ Non-real estate loans receivable ​ 1,868 ​ ​ ( 826 ) ​ ​ — ​ ​ — ​ ​ 1,042 4 ​ Non-real estate loans receivable ​ 2,268 ​ ​ ( 1,362 ) ​ ​ — ​ ​ — ​ ​ 906 5 ​ Non-real estate loans receivable ​ 43,287 ​ ​ ( 2,159 ) ​ ​ — ​ ​ — ​ ​ 41,128 6 ​ Non-real estate loans receivable ​ 75,335 ​ ​ 3,321 ​ ​ ( 21,509 ) (4) ​ — ​ ​ 57,147 ​ ​ Sub-total ​ 122,795 ​ ​ ( 1,024 ) (2) ​ ( 21,509 ) ​ ​ — ​ ​ 100,262 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2 ​ Unfunded real estate loan commitments ​ 1 ​ ​ ( 1 ) ​ ​ — ​ ​ — ​ ​ — 3 ​ Unfunded real estate loan commitments ​ 461 ​ ​ ( 52 ) ​ ​ — ​ ​ — ​ ​ 409 4 ​ Unfunded real estate loan commitments ​ 40 ​ ​ 4,560 ​ ​ — ​ ​ — ​ ​ 4,600 5 ​ Unfunded real estate loan commitments ​ 1,767 ​ ​ ( 1,767 ) ​ ​ — ​ ​ — ​ ​ — 2 ​ Unfunded non-real estate loan commitments ​ 13 ​ ​ ( 7 ) ​ ​ — ​ ​ — ​ ​ 6 3 ​ Unfunded non-real estate loan commitments ​ 183 ​ ​ ( 107 ) ​ ​ — ​ ​ — ​ ​ 76 4 ​ Unfunded non-real estate loan commitments ​ 433 ​ ​ ( 154 ) ​ ​ — ​ ​ — ​ ​ 279 6 ​ Unfunded non-real estate loan commitments ​ 65 ​ ​ ( 65 ) ​ ​ — ​ ​ — ​ ​ — ​ ​ Sub-total ​ 2,963 ​ ​ 2,407 ​ ​ — ​ ​ — ​ ​ 5,370 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ 198,612 ​ $ 4,970 ​ $ ( 21,509 ) ​ $ ( 1,605 ) ​ $ 180,468 (1) During the year ended December 31, 2025, we received proceeds of $ 2.1 million from the liquidating trust related to the $ 25.0 million DIP credit facility to Gulf Coast Health Care LLC (“Gulf Coast”) and proceeds of $ 0.5 million related to two other real estate loans, which resulted in a recovery for credit losses of $ 2.6 million. These loans and related reserves were previously written off, so the $ 2.6 million aggregate recovery is not included in the rollforward above. (2) These amounts include cash recoveries of $ 5.6 million related to interest payments received on loans that are written down to fair value and are being accounted for under the cost recovery method in which any payments received are applied directly against the principal balance outstanding. This amount also includes $ 2.3 million related to principal payments received on loans that were fully reserved. (3) Represents the allowance for credit losses related to an investment in a direct financing lease that was reclassified to real estate assets in connection with the termination of the lease in the first half of 2025 as discussed further in Note 3 – Real Estate Asset Acquisitions and Development. (4) Amount reflects the write-off of the reserves associated with the $ 10.0 million DIP financing and the $ 8.3 million term loan to LaVie (which were both previously fully reserved) that were discharged as part of the LaVie plan of reorganization that was made effective on June 1, 2025, along with one other non-real estate loan that was previously fully reserved. ​ F-37 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rating ​ Financial Statement Line Item Allowance for Credit Loss as of December 31, 2023 ​ Provision (recovery) for Credit Loss for the year ended December 31, 2024 (1) ​ Write-offs charged against allowance for the year ended December 31, 2024 ​ Other reductions to the allowance for the year ended December 31, 2024 ​ Allowance for Credit Loss as of December 31, 2024 ​ ​ ​ (in thousands) 1 ​ Real estate loans receivable $ 1,501 ​ $ ( 1,189 ) ​ $ — ​ $ — ​ $ 312 2 ​ Real estate loans receivable ​ 291 ​ ​ 201 ​ ​ — ​ ​ — ​ ​ 492 3 ​ Real estate loans receivable ​ 12,635 ​ ​ ( 1,644 ) ​ ​ — ​ ​ — ​ ​ 10,991 4 ​ Real estate loans receivable ​ 65,113 ​ ​ ( 42,585 ) (2) ​ — ​ ​ — ​ ​ 22,528 5 ​ Real estate loans receivable ​ — ​ ​ 25,476 (2) ​ — ​ ​ — ​ ​ 25,476 6 ​ Real estate loans receivable ​ 11,450 ​ ​ — ​ ​ — ​ ​ — ​ ​ 11,450 ​ ​ Sub-total ​ 90,990 ​ ​ ( 19,741 ) ​ ​ — ​ ​ — ​ ​ 71,249 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 5 ​ Investment in direct financing leases ​ 2,489 ​ ​ ( 884 ) ​ ​ — ​ ​ — ​ ​ 1,605 ​ ​ Sub-total ​ 2,489 ​ ​ ( 884 ) ​ ​ — ​ ​ — ​ ​ 1,605 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2 ​ Non-real estate loans receivable ​ 1,151 ​ ​ ( 1,114 ) ​ ​ — ​ ​ — ​ ​ 37 3 ​ Non-real estate loans receivable ​ 3,903 ​ ​ ( 2,035 ) ​ ​ — ​ ​ — ​ ​ 1,868 4 ​ Non-real estate loans receivable ​ 720 ​ ​ 1,548 ​ ​ — ​ ​ — ​ ​ 2,268 5 ​ Non-real estate loans receivable ​ 43,404 ​ ​ ( 117 ) ​ ​ — ​ ​ — ​ ​ 43,287 6 ​ Non-real estate loans receivable ​ 72,453 ​ ​ 16,393 ​ ​ ( 13,511 ) ​ ​ — ​ ​ 75,335 ​ ​ Sub-total ​ 121,631 ​ ​ 14,675 (3) ​ ( 13,511 ) ​ ​ — ​ ​ 122,795 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2 ​ Unfunded real estate loan commitments ​ 10 ​ ​ ( 9 ) ​ ​ — ​ ​ — ​ ​ 1 3 ​ Unfunded real estate loan commitments ​ 335 ​ ​ 126 ​ ​ — ​ ​ — ​ ​ 461 4 ​ Unfunded real estate loan commitments ​ 4,314 ​ ​ ( 4,274 ) (2) ​ — ​ ​ — ​ ​ 40 5 ​ Unfunded real estate loan commitments ​ — ​ ​ 1,767 (2) ​ — ​ ​ — ​ ​ 1,767 2 ​ Unfunded non-real estate loan commitments ​ 692 ​ ​ ( 679 ) ​ ​ — ​ ​ — ​ ​ 13 3 ​ Unfunded non-real estate loan commitments ​ 46 ​ ​ 137 ​ ​ — ​ ​ — ​ ​ 183 4 ​ Unfunded non-real estate loan commitments ​ 63 ​ ​ 370 ​ ​ — ​ ​ — ​ ​ 433 5 ​ Unfunded non-real estate loan commitments ​ 1,594 ​ ​ ( 1,594 ) ​ ​ — ​ ​ — ​ ​ — 6 ​ Unfunded non-real estate loan commitments ​ — ​ ​ 65 ​ ​ — ​ ​ — ​ ​ 65 ​ ​ Sub-total ​ 7,054 ​ ​ ( 4,091 ) ​ ​ — ​ ​ — ​ ​ 2,963 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ 222,164 ​ $ ( 10,041 ) ​ $ ( 13,511 ) ​ $ — ​ $ 198,612 (1) During the year ended December 31, 2024, we received proceeds of $ 5.3 million from the liquidating trust related to the DIP credit facility with Gulf Coast, which resulted in a recovery for credit losses of $ 5.3 million that is not included in the rollforward above since we had previously written-off the loan balance and related reserves. (2) Amount reflects the movement of reserves associated with the Maplewood Revolver due to an adjustment to the internal risk rating on the loan from 4 to 5 during the first quarter of 2024. See Note 7 – Real Estate Loans Receivable for additional information. (3) This amount includes cash recoveries of $ 4.7 million related to interest payments received on loans that are written down to fair value and are being accounted for under the cost recovery in which any payments received are applied directly against the principal balance outstanding. This amount also includes $ 0.6 million related to principal payments received on loans that were fully reserved. ​ F-38 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rating ​ Financial Statement Line Item Allowance for Credit Loss at December 31, 2022 ​ Provision (recovery) for Credit Loss for the year ended December 31, 2023 (1) ​ Write-offs charged against allowance for the year ended December 31, 2023 ​ Other additions to the allowance for the year ended December 31, 2023 ​ Allowance for Credit Loss as of December 31, 2023 ​ ​ ​ (in thousands) 1 ​ Real estate loans receivable $ 162 ​ $ 1,339 ​ $ — ​ $ — ​ $ 1,501 2 ​ Real estate loans receivable ​ 157 ​ ​ 134 ​ ​ — ​ ​ — ​ ​ 291 3 ​ Real estate loans receivable ​ 15,110 ​ ​ ( 2,475 ) ​ ​ — ​ ​ — ​ ​ 12,635 4 ​ Real estate loans receivable ​ 33,666 ​ ​ 31,447 ​ ​ — ​ ​ — ​ ​ 65,113 6 ​ Real estate loans receivable ​ 52,265 ​ ​ ( 3,860 ) ​ ​ ( 36,955 ) (2) ​ — ​ ​ 11,450 ​ ​ Sub-total ​ 101,360 ​ ​ 26,585 ​ ​ ( 36,955 ) ​ ​ — ​ ​ 90,990 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 5 ​ Investment in direct financing leases ​ 2,816 ​ ​ ( 327 ) ​ ​ — ​ ​ — ​ ​ 2,489 ​ ​ Sub-total ​ 2,816 ​ ​ ( 327 ) ​ ​ — ​ ​ — ​ ​ 2,489 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2 ​ Non-real estate loans receivable ​ 859 ​ ​ 292 ​ ​ — ​ ​ — ​ ​ 1,151 3 ​ Non-real estate loans receivable ​ 2,079 ​ ​ 1,824 ​ ​ — ​ ​ — ​ ​ 3,903 4 ​ Non-real estate loans receivable ​ 634 ​ ​ 86 ​ ​ — ​ ​ — ​ ​ 720 5 ​ Non-real estate loans receivable ​ 18,619 ​ ​ ( 415 ) ​ ​ — ​ ​ 25,200 (3) ​ 43,404 6 ​ Non-real estate loans receivable ​ 61,677 ​ ​ 10,776 ​ ​ — ​ ​ — ​ ​ 72,453 ​ ​ Sub-total ​ 83,868 ​ ​ 12,563 ​ ​ — ​ ​ 25,200 ​ ​ 121,631 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2 ​ Unfunded real estate loan commitments ​ — ​ ​ 10 ​ ​ — ​ ​ — ​ ​ 10 3 ​ Unfunded real estate loan commitments ​ — ​ ​ 335 ​ ​ — ​ ​ — ​ ​ 335 4 ​ Unfunded real estate loan commitments ​ 84 ​ ​ 4,230 ​ ​ — ​ ​ — ​ ​ 4,314 2 ​ Unfunded non-real estate loan commitments ​ 207 ​ ​ 485 ​ ​ — ​ ​ — ​ ​ 692 3 ​ Unfunded non-real estate loan commitments ​ 29 ​ ​ 17 ​ ​ — ​ ​ — ​ ​ 46 4 ​ Unfunded non-real estate loan commitments ​ — ​ ​ 63 ​ ​ — ​ ​ — ​ ​ 63 5 ​ Unfunded non-real estate loan commitments ​ — ​ ​ 1,594 ​ ​ — ​ ​ — ​ ​ 1,594 ​ ​ Sub-total ​ 320 ​ ​ 6,734 ​ ​ — ​ ​ — ​ ​ 7,054 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ 188,364 ​ $ 45,555 ​ $ ( 36,955 ) ​ $ 25,200 ​ $ 222,164 (1) During the year ended December 31, 2023, we received proceeds of $ 1.0 million from the liquidating trust related to the DIP credit facility with Gulf Coast, which resulted in a recovery for credit losses of $ 1.0 million that is not included in the rollforward above since we had previously written-off the loan balance and related reserves. (2) This amount relates to the write-off of the allowance for the Guardian mortgage note in connection with the settlement and partial forgiveness of the note in the second quarter of 2023. See Note 7 – Real Estate Loans Receivable for additional information on the write-off. (3) This amount relates to the additional $ 25.2 million allowance recorded during the first quarter of 2023 to reserve the aggregate deferred rent amount that is included within Agemo Replacement Loan B. See Note 8 – Non-Real Estate Loans Receivable for additional details. F-39 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Included below is a summary of the amortized cost basis of our financial instruments by year of origination and internal risk rating and a summary of our gross write-offs by year of origination: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rating Financial Statement Line Item 2025 2024 2023 2022 2021 2020 & older Revolving Loans Balance as of December 31, 2025 ​ ​ (in thousands) 1 Real estate loans receivable $ — $ — $ — $ 20,000 $ — $ — $ — $ 20,000 2 Real estate loans receivable ​ — ​ 29,700 ​ — ​ — ​ — ​ — ​ — ​ 29,700 3 Real estate loans receivable ​ 34,787 ​ 230,939 ​ 160,875 ​ 16,600 ​ 72,420 ​ — ​ — ​ 515,621 4 Real estate loans receivable ​ 31,010 ​ 84,877 ​ 88,154 ​ — ​ 31,713 ​ 379,438 ​ — ​ 615,192 5 Real estate loans receivable ​ — ​ — ​ — ​ — ​ — ​ — ​ 263,580 ​ 263,580 6 Real estate loans receivable ​ — ​ — ​ — ​ — ​ — ​ 11,692 ​ — ​ 11,692 ​ Sub-total ​ 65,797 ​ 345,516 ​ 249,029 ​ 36,600 ​ 104,133 ​ 391,130 ​ 263,580 ​ 1,455,785 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2 Non-real estate loans receivable ​ — ​ — ​ — ​ — ​ — ​ — ​ 10,438 ​ 10,438 3 Non-real estate loans receivable ​ 1,992 ​ 3,273 ​ 67,299 ​ 14,037 ​ — ​ 2,822 ​ 49,155 ​ 138,578 4 Non-real estate loans receivable ​ 11,698 ​ 4,411 ​ — ​ — ​ — ​ 129,610 ​ 29,725 ​ 175,444 5 Non-real estate loans receivable ​ 500 ​ 6,000 ​ — ​ — ​ — ​ 41,374 ​ — ​ 47,874 6 Non-real estate loans receivable ​ — ​ 6,386 ​ 1,500 ​ 24,457 ​ — ​ 25,907 ​ — ​ 58,250 ​ Sub-total ​ 14,190 ​ 20,070 ​ 68,799 ​ 38,494 ​ — ​ 199,713 ​ 89,318 ​ 430,584 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ 79,987 $ 365,586 $ 317,828 $ 75,094 $ 104,133 $ 590,843 $ 352,898 $ 1,886,369 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year to date gross write-offs $ — $ — $ ( 3,658 ) $ — $ ( 7,851 ) $ — $ ( 10,000 ) $ ( 21,509 ) ​ Interest Receivable on Real Estate Loans and Non-real Estate Loans We have elected the practical expedient to exclude interest receivable from our allowance for credit losses. As of December 31, 2025 and 2024, we have excluded $ 9.7 million and $ 11.1 million, respectively, of contractual interest receivables and $ 2.4 million and $ 1.8 million, respectively, of effective yield interest receivables from our allowance for credit losses. We write-off interest receivable to provision for credit losses in the period we determine the interest is no longer considered collectible. During the years ended December 31, 2025, 2024 and 2023, we recognized $ 2.6 million, $ 3.3 million and $ 1.7 million, respectively, of interest income related to loans on non-accrual status as of December 31, 2025. NOTE 10 – VARIABLE INTEREST ENTITIES We hold variable interests in several VIEs through our investing and financing activities, which are not consolidated, as we have concluded that we are not the primary beneficiary of these entities as we do not have the power to direct activities that most significantly impact the VIE’s economic performance and/or the variable interest we hold does not obligate us to absorb losses or provide us with the right to receive benefits from the VIE which could potentially be significant. F-40 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Below is a summary of our assets, liabilities, collateral and maximum exposure to loss associated with these unconsolidated VIEs as of December 31, 2025 and 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2025 ​ ​ ​ 2024 ​ ​ (in thousands) Assets ​ ​ ​ ​ ​ ​ Real estate assets – net ​ $ 1,010,790 ​ $ 1,250,131 Assets held for sale ​ ​ 4,000 ​ ​ — Real estate loans receivable – net ​ 600,543 ​ ​ 534,048 Investments in unconsolidated entities ​ ​ 346,034 ​ ​ 9,754 Non-real estate loans receivable – net ​ 20,742 ​ ​ 38,463 Contractual receivables – net ​ 1,068 ​ ​ 994 Other assets ​ ​ — ​ ​ 1,539 Total assets ​ 1,983,177 ​ 1,834,929 ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ ​ ​ Accrued expenses and other liabilities ​ ​ ( 40,579 ) ​ ​ ( 52,692 ) Total liabilities ​ ( 40,579 ) ​ ( 52,692 ) ​ ​ ​ ​ ​ ​ ​ Collateral ​ ​ ​ ​ Personal guarantee ​ ( 8,000 ) ​ ​ ( 48,000 ) Other collateral (1) ​ ( 1,270,795 ) ​ ​ ( 1,422,096 ) Total collateral ​ ( 1,278,795 ) ​ ​ ( 1,470,096 ) ​ ​ ​ ​ ​ ​ ​ Maximum exposure to loss ​ $ 663,803 ​ $ 312,141 (1) T he decrease in the balance from December 31, 2024 to December 31, 2025 primarily relates to the transition of facilities from LaVie to Avardis during the second quarter of 2025, as discussed further in Note 5 – Contractual Receivables and Ot her Receivables and Lease Inducements. In determining our maximum exposure to loss from these VIEs, we considered the underlying carrying value of the real estate subject to leases with these entities and other collateral, if any, supporting our other investments, which may include accounts receivable, security deposits, letters of credit or personal guarantees, if any, as well as other liabilities recognized with respect to these entities. The table below reflects our total revenues from the entities that are considered unconsolidated VIEs, following the date they were determined to be VIEs, for the years ended December 31, 2025, 2024 and 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ ​ 2025 ​ 2024 ​ ​ 2023 ​ ​ ​ ​ (in thousands) Revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Rental income ​ ​ ​ $ 118,746 ​ $ 106,911 ​ $ 81,900 Interest income ​ ​ ​ ​ 31,519 ​ ​ 16,414 ​ ​ 5,512 Total ​ ​ ​ $ 150,265 ​ $ 123,325 ​ $ 87,412 ​ Consolidated VIEs The Company consolidates Omega OP, a VIE in which the Company is considered the primary beneficiary. The Company, as general partner, has the power to direct the activities of Omega OP that most significantly affect Omega OP’s performance, and through its interest in Omega OP, has both the right to receive benefits from and the obligation to absorb losses of Omega OP. F-41 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Additionally, we own a partial equity interest in a JV that we have determined is a VIE. We have consolidated this VIE because we have concluded that we are the primary beneficiary of this VIE based on a combination of our ability to direct the activities that most significantly impact the JV’s economic performance and our rights to receive residual returns and obligation to absorb losses arising from the JV. Omega is not required to make any additional capital contributions to the JV. As of December 31, 2025 and 2024, this JV has $ 23.2 million and $ 24.3 million, respectively, of total assets and $ 20.9 million and $ 20.8 million, respectively, of total liabilities, which are included in our Consolidated Balance Sheets. ​ NOTE 11 – INVESTMENTS IN UNCONSOLIDATED ENTITIES Unconsolidated Entities Omega owns an interest in a number of entities which generally invest in the long-term healthcare industry. The following is a summary of our investments in unconsolidated entities (dollars in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Carrying Amount ​ ​ Ownership ​ Facility ​ Facility ​ December 31, ​ December 31, Entity ​ % (1) ​ Type ​ Count (1) ​ 2025 ​ ​ ​ 2024 SHH Holdings, LLC ​ 49 % ​ Various ​ 65 ​ $ 222,161 ​ $ — In Substance Real Estate Investments (2) ​ N/A ​ ALF ​ 12 ​ ​ 75,353 ​ ​ — Lakeway Realty, L.L.C. (3) ​ 51 % ​ Specialty facility ​ 1 ​ ​ 64,699 ​ ​ 67,541 Liberty JVs ​ 49 % ​ CCRC ​ 1 ​ ​ 42,754 ​ ​ — Other Healthcare JVs (4)(5) ​ 9 % – 25 % ​ N/A ​ N/A ​ ​ 7,429 ​ ​ 7,317 Other Real Estate JVs (4)(6)(7) ​ 20 % – 50 % ​ Various ​ 6 ​ 1,731 ​ ​ 6,736 Second Spring Healthcare Investment ​ 15 % ​ N/A ​ — ​ ​ — ​ ​ 7,117 ​ ​ ​ ​ ​ ​ ​ ​ $ 414,127 ​ $ 88,711 (1) Ownership percentages and facility counts are as of December 31, 2025. (2) During the third quarter of 2025, we entered into three mortgage loan agreements with maximum borrowings of $ 77.7 million that are secured by 12 facilities. Under the three mortgage loan agreements, we are able to participate in the residual profits of the facilities, subject to the mortgage, upon a sale or refinancing. We evaluated the characteristics of these three investments, including the associated risks and rewards, and have determined they are more similar to those associated with an investment in real estate than a loan. Arrangements with characteristics in line with real estate JVs are treated as in substance real estate investments and accounted for using the equity method. We have determined that the three borrowers under the mortgage loans are VIEs but we have not consolidated the borrowers because we are not the primary beneficiary. (3) The JV owns the Lakeway Regional Medical Center (the “Lakeway Hospital”) in Lakeway, Texas. Our initial basis difference of approximately $ 69.9 million is being amortized on a straight-line basis over 40 years to income (loss) from unconsolidated entities in the Consolidated Statements of Operations. The lessee of the Lakeway Hospital has an option to purchase the facility from the JV. The lessee also has a right of first refusal and a right of first offer in the event the JV intends to sell or otherwise transfer Lakeway Hospital. (4) As of December 31, 2025 and 2024, we had an aggregate of $ 22.0 million and $ 18.5 million, respectively, of loans outstanding with these JVs. (5) As of December 31, 2025, includes six JVs engaged in business that support the long-term healthcare industry and our operators. (6) As of December 31, 2025, includes two JVs formed for the purpose of owning or providing financing for SNFs or ALFs. (7) During the third quarter of 2024, one of the other real estate JVs, OMG Senior Holdings, LLC, sold one specialty facility to an unrelated third party for approximately $ 40.7 million in net cash proceeds and recognized a gain on sale of approximately $ 12.9 million ( $ 6.5 million of which represents the Company’s share of the gain). ​ SHH Holdings, LLC In October 2025, the Company formed a JV, SHH Holdings, LLC, with affiliates of Saber Healthcare Holdings, LLC (“Saber”) to own and lease 64 facilities. SHH Holdings, LLC was previously wholly owned by affiliates of Saber. The Company issued approximately 5.5 million Omega OP Units with a fair value of $ 222.4 million in exchange for a 49 % equity interest in the JV. Affiliates of Saber will retain a 51 % equity interest in the JV and are responsible for day-to-day operations of the JV and management of its properties, subject to obtaining approval of the Company for major decisions (including investments, dispositions, financings, major capital expenditures and annual budgets). As of the transaction date, 51 of the 64 facilities were encumbered with $ 448.6 million of mortgage debt with a weighted average interest rate of 6.1 % per annum, which is non-recourse to the Company. The JV is required to distribute a portion of its available cash from operating activities on a monthly basis in proportion to each member’s equity ownership. This JV will be accounted for as an equity method investment. Subsequent to our investment, SHH Holdings, LLC acquired an additional facility which was primarily funded through a $ 7.5 million mortgage loan, with no additional contributions from Omega. The 65 facilities now held by the JV are subject to triple net leases, with subsidiaries of Saber, that generate $ 70.2 million in contractual rent per annum. Omega’s initial basis difference was approximately $ 215.3 million which will be amortized over a weighted average life of 21 years . During the year ended December 31, 2025, we recognized income of $ 1.4 million (inclusive of basis amortization) and received distributions totaling $ 2.7 million from SHH Holdings, LLC for the two-month period following the investment closing. F-42 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Liberty-Omega HBP PropCo JV, LLC and Liberty-Omega HBP OpCo JV, LLC On December 30, 2025, the Company formed two JVs, Liberty-Omega HBP PropCo JV, LLC (the “Liberty PropCo JV”) and Liberty-Omega HBP OpCo JV, LLC (the “Liberty OpCo JV” and collectively with the Liberty PropCo JV, the “Liberty JVs”). The Liberty JVs were formed to own and operate, through a RIDEA structure, a CCRC in North Carolina. Omega acquired a 49 % equity interest in the Liberty JVs for aggregate consideration of $ 42.7 million. Affiliates of Liberty will retain the remaining 51 % of the Liberty JVs and are responsible for day-to-day operations of the JV and management of its properties, subject to obtaining Omega’s approval for certain major decisions (including investments, dispositions, financings, major capital expenditures and annual budgets). As of the transaction date, the Liberty JVs have third-party debt of approximately $ 215.3 million. The Liberty JVs will be accounted for as equity method investments. ​ NOTE 12 – GOODWILL AND OTHER INTANGIBLES The following is a summary of our goodwill: ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Balance as of December 31, 2024 ​ $ 643,664 Foreign currency translation ​ 962 Balance as of December 31, 2025 ​ $ 644,626 ​ The following is a summary of our lease intangibles as of December 31, 2025 and 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ ​ ​ 2025 ​ ​ ​ ​ 2024 ​ ​ (in thousands) Assets: ​ ​ ​ ​ ​ Above market leases ​ $ 33,977 ​ $ 31,864 Accumulated amortization ​ ( 6,816 ) ​ ( 3,800 ) Net above market leases ​ $ 27,161 ​ $ 28,064 ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ Below market leases ​ $ 33,014 ​ $ 34,723 Accumulated amortization ​ ( 26,570 ) ​ ( 26,647 ) Net below market leases ​ $ 6,444 ​ $ 8,076 ​ Above market leases, net of accumulated amortization, are included in other assets on our Consolidated Balance Sheets. Below market leases, net of accumulated amortization, are included in accrued expenses and other liabilities on our Consolidated Balance Sheets. The net amortization related to the above and below market leases is included in our Consolidated Statements of Operations as an adjustment to rental income over the estimated remaining term of the underlying leases. Should a tenant terminate the lease, the unamortized portion of the lease intangible is recognized immediately as an adjustment to rental income. For the years ended December 31, 2025, 2024 and 2023, our net amortization related to intangibles was $( 1.8 ) million, $ 1.7 million and $ 9.4 million, respectively. The estimated net amortization related to these intangibles for the subsequent five years is as follows: 2026 – $( 2.1 ) million; 2027 – $( 2.1 ) million; 2028 – $( 2.1 ) million; 2029 – $( 2.2 ) million; 2030 – $( 2.2 ) million and $( 10.0 ) million thereafter. As of December 31, 2025, the weighted average remaining amortization period of both above market lease assets and below market lease liabilities is approximately nine years . F-43 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ NOTE 13 – CONCENTRATION OF RISK Property and Investment Concentration As of December 31, 2025, our portfolio of real estate investments consisted of 1,027 operating healthcare facilities (including properties associated with mortgages, direct financing leases, assets held for sale and consolidated JVs), along with other real estate loans receivable (excluding mortgages) of $ 482.6 million and $ 414.1 million of investments in 15 unconsolidated entities. These healthcare facilities are located in 42 states, Washington, D.C., the U.K. and Jersey, and are operated or managed by 89 third-party operators or managers. Our investment in these facilities, net of impairments and allowances, totaled approximately $ 10.5 billion at December 31, 2025, with approximately 98 % of our real estate investments related to long-term healthcare facilities. Our portfolio is made up of (i) 561 SNFs, 339 ALFs, 19 ILFs, 16 specialty facilities and one CCRC, (ii) fixed rate mortgages on 47 SNFs, 42 ALFs and two ILFs and (iii) one property adjacent to one of our existing facilities that is held for sale. At December 31, 2025, our total investments also include non-real estate loans receivable of $ 330.3 million, consisting primarily of secured loans to third-party operators of our facilities. Operator Concentration At December 31, 2025 and 2024, we had investments with one operator/or manager that approximated or exceeded 10% of our total investments: Maplewood. Maplewood generated approximately 6.6 %, 5.2 % and 5.4 % of our total revenues for the years ended December 31, 2025, 2024 and 2023, respectively. The revenue associated with Maplewood for the year ended December 31, 2023 reflects a reduction of revenue of $ 12.5 million related to a termination fee payment made by Omega as discussed in Note 5 – Contractual Receivables and Other Receivables and Lease Inducements. During the years ended December 31, 2025, 2024 and 2023, we also have one operator with total revenues that exceeded 10% of our total revenues: CommuniCare Health Services, Inc. (“CommuniCare”). CommuniCare generated approximately 10.3 %, 11.8 % and 11.7 % of our total revenues for the years ended December 31, 2025, 2024 and 2023, respectively. As of December 31, 2025, CommuniCare represented approximately 7.2 % of our total investments. Geographic Concentration At December 31, 2025, the three geographic locations in which we had our highest concentration of real estate assets and mortgages (before accumulated depreciation and allowances) were the U.K ( 17.7 %), Texas ( 8.5 %) and Indiana ( 6.0 %). F-44 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ NOTE 14 - BORROWING ARRANGEMENTS The following is a summary of our long-term borrowings: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Annual ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest Rate ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ as of ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ December 31, ​ December 31, ​ ​ ​ ​ Maturity ​ ​ ​ 2025 ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) Secured borrowings: ​ ​ ​ ​ ​ ​ ​ 2026 Mortgage Loan (1) 2026 N/A ​ ​ $ — ​ $ 231,148 Deferred financing costs – net ​ ​ ​ ​ — ​ ( 3,753 ) Premium – net (2) ​ ​ ​ ​ — ​ 15,915 Total secured borrowings ​ ​ ​ ​ ​ ​ ​ — ​ ​ 243,310 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unsecured borrowings: ​ ​ ​ ​ ​ ​ ​ Revolving Credit Facility (3) 2029 SOFR + 1.05 % ​ 242,000 ​ — ​ ​ ​ ​ ​ ​ ​ ​ 242,000 ​ ​ — Senior notes and other unsecured borrowings: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2025 notes (3)(4) 2025 N/A ​ ​ — ​ 400,000 2026 notes (3)(5) 2026 N/A ​ ​ — ​ 600,000 2027 notes (3) 2027 4.50 % ​ 700,000 ​ 700,000 2028 notes (3) 2028 4.75 % ​ 550,000 ​ 550,000 2029 notes (3) 2029 3.63 % ​ 500,000 ​ 500,000 2030 notes (3) ​ 2030 ​ 5.20 % ​ ​ 600,000 ​ ​ — 2031 notes (3) ​ 2031 ​ 3.38 % ​ ​ 700,000 ​ ​ 700,000 2033 notes (3) ​ 2033 ​ 3.25 % ​ ​ 700,000 ​ ​ 700,000 2026 Term Loan (3) ​ 2026 N/A ​ ​ — ​ 428,500 OP Term Loan (7) 2025 N/A ​ ​ — ​ 50,000 2028 Term Loan (6) ​ 2028 ​ 5.22 % ​ ​ 300,000 ​ ​ — Deferred financing costs – net ​ ​ ​ ​ ( 17,451 ) ​ ( 14,843 ) Discount – net ​ ​ ​ ​ ( 18,538 ) ​ ( 18,108 ) Total senior notes and other unsecured borrowings – net ​ ​ ​ ​ 4,014,011 ​ 4,595,549 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total unsecured borrowings – net ​ ​ ​ ​ 4,256,011 ​ 4,595,549 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total secured and unsecured borrowings – net (8)(9) ​ ​ ​ ​ $ 4,256,011 ​ $ 4,838,859 (1) Wholly owned subsidiaries of Omega OP were the obligors on this loan (the “2026 Mortgage Loan”). The 2026 Mortgage Loan was denominated in GBP. (2) Represents the remaining fair value adjustment associated with the 2026 Mortgage Loan that was assumed as part of an asset acquisition in July 2024, which was being amortized over the remaining contractual term of the loan. Any remaining unamortized portion of the adjustment along with the unamortized deferred financing fees associated with the 2026 Mortgage Loan were reflected in net gain on debt extinguishment following the repayment in November 2025. (3) Guaranteed by Omega OP. (4) The Company repaid the $ 400 million of 4.50 % senior notes that matured on January 15, 2025 using available cash. (5) On October 15, 2025, the Company redeemed, at par value, the $ 600.0 million of aggregate principal outstanding under its 5.250 % Senior Notes with a scheduled maturity of January 15, 2026. The notes were repaid using proceeds from the issuance of the 2030 Senior Notes (defined below). (6) Reflects the impact of interest rate swaps on the 2028 Term Loan which effectively fix the SOFR-based portion of the interest rate at 4.019 % . (7) Omega OP was the obligor on this borrowing. (8) All borrowings are direct borrowings of Parent unless otherwise noted. (9) Certain of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of December 31, 2025 and December 31, 2024, we were in compliance with all applicable covenants for our borrowings. F-45 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Secured Borrowings 2026 Mortgage Loan As discussed in Note 3 – Real Estate Asset Acquisitions and Development, we assumed the 2026 Mortgage Loan as part of our acquisition of the remaining 51 % interest in the Cindat Joint Venture. The 2026 Mortgage Loan was scheduled to mature in August 2026 but could be repaid without a prepayment penalty beginning November 2025. The 2026 Mortgage Loan bore interest at the Sterling Overnight Index Average (“SONIA”) plus an applicable margin of 5.38 %. We incurred $ 4.9 million of deferred costs in connection with the assumption of the 2026 Mortgage Loan. The initial fair value adjustment on the 2026 Mortgage Loan was $ 20.7 million and was being amortized into interest expense over the remaining contractual term of the loan. The 2026 Mortgage loan was repaid in full in November 2025 using proceeds from the 2028 Term Loan (defined below). In connection with the repayment, we recognized a gain on extinguishment of $ 5.6 million primarily related to the remaining amortized premium associated with the fair value adjustment. Unsecured Borrowings Revolving Credit Facility and 2028 Term Loan On April 30, 2021, Omega entered into a credit agreement for a new $ 1.45 billion senior unsecured multicurrency revolving credit facility (the “2021 Revolving Credit Facility”), replacing our previous unsecured multicurrency revolving credit facility and the related credit agreement. The 2021 Revolving Credit Facility bore interest at SOFR plus an adjustment of 0.11448 % per annum (or in the case of loans denominated in GBP, the SONIA reference rate plus an adjustment of 0.1193 % per annum, and in the case of loans denominated in Euros, the Euro interbank offered rate, or EURIBOR ) plus an applicable percentage (with a range of 95 to 185 basis points) based on our credit ratings. The 2021 Revolving Credit Facility could be drawn in Euros, GBP, Canadian Dollars (collectively, “Alternative Currencies”) or USD, with a $ 1.15 billion tranche available in USD and a $ 300 million tranche available in Alternative Currencies. The 2021 Revolving Credit Facility was set to mature on April 30, 2025 , but in January 2025, Omega elected to utilize one of two six-month options to extend the maturity date to October 30, 2025. On September 30, 2025, Omega entered into a credit agreement (the “2025 Omega Credit Agreement”) consisting of a new $ 2.0 billion senior unsecured multicurrency revolving credit facility (the “Revolving Credit Facility”) and a $ 300.0 million delayed draw term loan facility (the “2028 Term Loan”), replacing our previous 2021 Revolving Credit Facility. The 2025 Omega Credit Agreement contains an accordion feature permitting us, subject to compliance with customary conditions, to increase the maximum aggregate commitments thereunder to $ 3.0 billion, by requesting an increase in the aggregate commitments under the Revolving Credit Facility or by adding one or more tranches of term loans. The Revolving Credit Facility may be drawn in Alternative Currencies or USD, with a $ 600.0 million sublimit for loans in Alternative Currencies and the 2028 Term Loan may be drawn in USD. The Revolving Credit Facility bears interest at SOFR (or in the case of loans denominated in Alternative Currencies, the applicable reference rate) plus (i) an applicable percentage (with a range of 72.5 to 140 basis points) based on the Company’s debt ratings and (ii) a facility fee based on the same ratings (with a range of 12.5 to 30 basis points). The 2028 Term Loan bears interest at SOFR plus an applicable percentage (with a range of 80 to 160 basis points) based on the Company’s debt ratings. The Revolving Credit Facility matures on September 28, 2029 , subject to Omega’s option to extend such maturity for two consecutive six-month periods. The 2028 Term Loan Credit Facility matures on September 29, 2028 , subject to Omega’s option to extend such maturity for two consecutive twelve-month periods. We incurred $ 19.8 million of deferred costs in connection with the 2025 Omega Credit Agreement, of which $ 2.0 million related to the 2028 Term Loan. Deferred costs associated with the Revolving Credit Facility are reflected within Other Assets on the Consolidated Balance Sheets. F-46 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ $600 Million Senior Note Issuance On June 20, 2025, Omega issued $ 600 million of Senior Notes due 2030 (the “2030 Senior Notes”) that mature on July 1, 2030 and bear interest at a fixed rate of 5.200 % per annum, payable semi-annually on January 1 and July 1 of each year, commencing on January 1, 2026. The 2030 Senior Notes were sold at an issue price of 99.118 % of their face value, resulting in a discount of $ 5.3 million. We incurred $ 5.6 million of deferred costs in connection with the issuance. The net proceeds from the issuance will be used for general corporate purposes, which may include, among other things, repayment of our existing indebtedness and future acquisition or investment opportunities in healthcare-related real estate properties and to pay certain fees and expenses related to the offering. 2026 Term Loan On August 8, 2023, Omega entered into a $ 400 million senior unsecured term loan facility (the “2026 Term Loan”). On September 27, 2023, Omega exercised an accordion feature to increase the aggregate commitment under the 2026 Term Loan by $ 28.5 million. The 2026 Term Loan bore interest at SOFR plus an adjustment of 0.1 % per annum plus an applicable percentage (with a range of 85 to 185 basis points) based on our credit rating. The 2026 Term Loan had an original maturity date of August 8, 2025 , subject to Omega’s option to extend such maturity date for two sequential 12-month periods. We recorded $ 3.3 million of deferred financing costs and a $ 1.4 million discount in connection with the 2026 Omega Credit Agreement. In July 2025, the maturity date of the 2026 Term Loan was extended from August 8, 2025 to August 8, 2026 following Omega’s election to utilize one of two 12-month extension options. On September 30, 2025, Omega amended the 2026 Term Loan to, among other things, modify the interest rate margins to align with the 2028 Term Loan (a reduction of 35 basis points) and remove the 0.100 % pricing step-up in each of the extension periods. During the fourth quarter of 2025, Omega fully repaid the 2026 Term Loan using available cash, proceeds from the 2028 Term Loan and the Revolving Credit Facility. OP Term Loan On April 30, 2021, Omega OP entered into a $ 50 million unsecured term loan facility (the “OP Term Loan”). The OP Term Loan bore interest at SOFR plus an adjustment of 0.11448 % per annum plus an applicable percentage (with a range of 85 to 185 basis points) based on our credit ratings. The OP Term Loan was set to mature on April 30, 2025 , subject to Omega OP’s option to extend such maturity date for two , six-month periods. Omega previously provided notification in January 2025 to extend the maturity date from April 30, 2025 to October 30, 2025 . On April 29, 2025, Omega repaid OP Term Loan using available cash prior to its original maturity date. General Parent and Omega OP, on a combined basis, have no material assets, liabilities or operations other than financing activities (including borrowings under the senior unsecured revolving and term loan credit facility, OP term loan and the outstanding senior notes) and their investments in non-guarantor subsidiaries. Substantially all of our assets are held by non-guarantor subsidiaries. The required principal payments, excluding the premium or discount and deferred financing costs on our secured and unsecured borrowings, for each of the five years following December 31, 2025 and the aggregate due thereafter are set forth below: ​ ​ ​ ​ ​ ​ ​ ​ (in thousands) 2026 $ — 2027 ​ 700,000 2028 ​ 850,000 2029 ​ 742,000 2030 ​ 600,000 Thereafter ​ 1,400,000 Total ​ $ 4,292,000 ​ ​ F-47 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ NOTE 15 – DERIVATIVES AND HEDGING We are exposed to, among other risks, the impact of changes in foreign currency exchange rates as a result of our investments in the U.K. and interest rate risk related to our capital structure. As a matter of policy, we do not use derivatives for trading or speculative purposes. Our risk management program is designed to manage the exposure and volatility arising from these risks, and utilizes foreign currency forward contracts, interest rate swaps and debt issued in foreign currencies to offset a portion of these risks. Derivatives Designated as Hedging Instruments As of December 31, 2025, we have nine interest rate swaps with $ 300.0 million in notional value. The swaps are designated as cash flow hedges of the interest payments on one of Omega’s variable interest loans. Additionally, we have 11 foreign currency forward contracts with £ 258.0 million in notional value issued at a weighted average GBP-USD forward rate of 1.2899 that are designated as net investment hedges. Cash Flow Hedges of Interest Rate Risk We enter into interest rate swaps in order to maintain a capital structure containing targeted amounts of fixed and floating-rate debt and manage interest rate risk. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for our fixed-rate payments. These interest rate swap agreements are used to hedge the variable cash flows associated with variable-rate debt. On March 27, 2020 , we entered into five forward starting swaps totaling $ 400 million, indexed to 3-month LIBOR, that were issued at a weighted average fixed rate of approximately 0.8675 % and were subsequently designated as cash flow hedges of interest rate risk associated with interest payments on a forecasted issuance of fixed rate long-term debt, initially expected to occur within the next five years . The swaps had an effective date of August 1, 2023 and an expiration date of August 1, 2033 . In conjunction with the October 2020 issuance of $ 700 million of 3.375 % Senior Notes due 2031 and the March 2021 issuance of $ 700 million aggregate principal amount of our 3.25 % Senior Notes due 2033 , we applied hedge accounting for these five forward starting swaps and began amortization. Simultaneously, we re-designated these swaps in new cash flow hedging relationships of interest rate risk associated with interest payments on another forecasted issuance of long-term debt. We were hedging our exposure to the variability in future cash flows for forecasted transactions over a maximum period of 46 months (excluding forecasted transactions related to the payment of variable interest on existing financial instruments). As a result of these transactions, the aggregate unrealized gain of $ 41.2 million ($ 9.5 million gain related to the October 2020 issuance and $ 31.7 million gain related to the March 2021 issuance) included within accumulated other comprehensive income at the time of the bond issuances is being ratably reclassified as a reduction to interest expense, net over 10 years. On May 30, 2023, the five forward starting swaps were terminated, and Omega received a net cash settlement of $ 92.6 million from the swap counterparties. The incremental $ 51.4 million of gains related to the forward swaps, recorded in accumulated other comprehensive income, were frozen at the time of termination and will be recognized ratably over 10 years in earnings when the next qualifying debt issuance occurs. Consistent with our accounting policy and historical practice, the $ 92.6 million net cash settlement from the forward swap termination is reflected within net cash used in financing activities in the Consolidated Statements of Cash Flows. The $ 600 million of 2030 Senior Notes that were issued in June 2025, as discussed further in Note 14 – Borrowing Arrangements, were determined to be a qualifying issuance, and amortization of the $ 51.4 million began as of the issuance date of the 2030 Senior Notes. The amortization is recorded as a reduction to interest expense. F-48 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ In August 2023, we entered into ten interest rate swaps with $ 400.0 million in notional value. The swaps are effective August 14, 2023 and terminate on August 6, 2027 . The interest rate swaps were originally designated as hedges against our exposure to changes in interest payment cash flows as a result of the variable interest rate on the 2026 Term Loan. In September 2023, in connection with the exercise of the accordion feature on the 2026 Term Loan, we entered into one additional interest rate swap with $ 28.5 million in notional value to hedge the additional $ 28.5 million under the 2026 Term Loan. This swap was effective September 29, 2023 and terminates on August 6, 2027 . These 11 interest rate swap contracts effectively converted our $ 428.5 million 2026 Term Loan to a new combined aggregate fixed rate of approximately 5.597 % until the 2026 Term Loan was amended in the third quarter of 2025 to reduce the interest rate margins by 35 basis points, resulting in a new combined aggregate fixed rate of approximately 5.247 % . Upon the repayment of the 2026 Term Loan in the fourth quarter of 2025, we redesignated nine of the interest rate swaps, with $ 300 million of notional value, as hedges against our exposure to changes in interest payment cash flows on the 2028 Term Loan. These nine interest rate swap contracts effectively convert our 2028 Term Loan to a new combined aggregate fixed rate of approximately 5.219 % through its maturity. We terminated two of the interest rates swaps with notional value of $ 128.5 million and paid our swap counterparty $ 1.7 million that is recorded within other income – net in the Consolidated Statements of Operations for the year ended December 31, 2025. Foreign Currency Forward Contracts and Debt Designated as Net Investment Hedges We have historically used debt denominated in GBP and foreign currency forward contracts to hedge a portion of our net investments, including certain intercompany loans, in the U.K. against fluctuations in foreign exchange rates. In March 2021, we entered into four foreign currency forward contracts with notional amounts totaling £ 174.0 million, that matured on March 8, 2024 , to hedge a portion of our net investments in the U.K., including an intercompany loan and an investment in our U.K. JV, effectively replacing the terminated net investment hedge. The forwards were issued at a weighted average GBP-USD forward rate of 1.3890 . On December 27, 2023, we terminated two of these foreign currency forward contracts with notional amounts totaling £ 104.0 million. Omega received a net cash settlement of $ 11.4 million as a result of termination, which is included within net cash used in investing activities in the Consolidated Statements of Cash Flows. On February 27, 2024, we terminated the remaining two foreign currency forward contracts that were entered into in March 2021 with notional amounts totaling £ 70.0 million. Omega received a net cash settlement of $ 8.4 million as a result of termination. Both cash settlements are included within net cash used in investing activities in the Consolidated Statements of Cash Flows. The aggregate $ 19.8 million related to the terminations will remain in accumulated other comprehensive income until the underlying hedged items are liquidated. On May 17, 2022, we entered into two foreign currency forward contracts with notional amounts totaling £ 76.0 million and a GBP-USD forward rate of 1.3071 , each of which mature on May 21, 2029 . On December 27, 2023, we entered into six foreign currency forward contracts with notional amounts totaling £ 104.0 million and a GBP-USD forward rate of 1.2916 , each of which mature between March 8, 2027 and March 8, 2030 . On February 27, 2024, we entered into three foreign currency forward contracts with notional amounts totaling £ 78.0 million and a GBP-USD forward rate of 1.2707 , each of which mature between March 8, 2027 and March 7, 2031 . The aforementioned foreign currency forward contracts hedge a portion of our net investments in U.K. subsidiaries, including an intercompany loan. Derivatives Not Designated as Hedging Instruments We enter into foreign currency exchange swap agreements to reduce the effects of currency exchange rate fluctuations between the USD, our reporting currency, and GBP. These derivative contracts generally mature within one year and are not designated as hedge instruments for accounting purposes. In connection with funding a $ 344.2 million acquisition in the U.K. (see Note 3 – Real Estate Asset Acquisitions and Development), in April 2025, Omega entered a GBP/USD currency forward with a notional value of £ 90.0 million and a GBP-USD forward rate of 1.2733 . The swap was settled on the closing date of the acquisition, and we recorded a $ 5.2 million gain from its termination within other income – net in the Consolidated Statements of Operations for the year ended December 31, 2025. F-49 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ In the third quarter of 2025, Omega entered into six GBP/USD currency forwards with notional amounts totaling £ 108.0 million and a weighted average GBP-USD rate of 1.3600 , each of which mature between October 2, 2025 and January 5, 2027 . We recognized unrealized gains of $ 1.0 million and realized gains of $ 0.9 million related to these swaps that are recorded within other income – net in the Consolidated Statements of Operations for the year ended December 31, 2025. As of December 31, 2025, we have five GBP/USD currency forwards remaining with notional amounts totaling £ 81.0 million and a weighted average GBP-USD rate of 1.3615 , each of which mature between January 5, 2026 and January 5, 2027 . The location and the fair value of derivative instruments designated as hedges, at the respective balance sheet dates, were as follows: ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ 2025 ​ ​ ​ 2024 Cash flow hedges: (in thousands) Other assets $ — ​ $ 381 Accrued expenses and other liabilities $ 3,402 ​ $ 554 ​ ​ ​ ​ ​ ​ Net investment hedges: ​ ​ ​ ​ ​ Other assets $ — ​ $ 8,434 Accrued expenses and other liabilities $ 10,258 ​ $ — ​ ​ ​ ​ ​ ​ Derivative instruments not designated: ​ ​ ​ ​ ​ Other assets $ 1,729 ​ $ — ​ The fair value of the interest rate swaps and foreign currency forwards is derived from observable market data such as yield curves and foreign exchange rates and represents a Level 2 measurement on the fair value hierarchy. NOTE 16 - FINANCIAL INSTRUMENTS The net carrying amount of cash and cash equivalents, restricted cash, contractual receivables, other assets and accrued expenses and other liabilities reported in the Consolidated Balance Sheets approximates fair value because of the short maturity of these instruments (Level 1). F-50 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ At December 31, 2025 and 2024, the net carrying amounts and fair values of other financial instruments were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2025 ​ December 31, 2024 ​ Carrying ​ ​ ​ Fair ​ ​ ​ Carrying ​ ​ ​ Fair ​ Amount ​ ​ ​ Value ​ ​ ​ Amount ​ ​ ​ Value ​ (in thousands) Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Investments in direct financing leases – net $ — ​ $ — ​ ​ ​ $ 9,453 ​ $ 9,453 Real estate loans receivable – net 1,380,949 ​ ​ 1,412,106 ​ ​ 1,428,298 ​ ​ 1,447,262 Non-real estate loans receivable – net 330,322 ​ ​ 331,970 ​ ​ 332,274 ​ ​ 340,025 Total $ 1,711,271 ​ $ 1,744,076 ​ $ 1,770,025 ​ $ 1,796,740 Liabilities: ​ ​ ​ ​ ​ ​ ​ Revolving Credit Facility $ 242,000 ​ $ 242,000 ​ ​ ​ $ — ​ $ — 2026 Mortgage Loan — ​ ​ — ​ ​ 243,310 ​ ​ 247,063 2026 Term Loan ​ — ​ ​ — ​ ​ 427,044 ​ ​ 428,500 OP Term Loan — ​ ​ — ​ ​ 49,966 ​ ​ 50,000 2028 Term Loan 298,118 ​ ​ 300,000 ​ ​ — ​ ​ — 4.50 % notes due 2025 – net — ​ ​ — ​ ​ 399,968 ​ ​ 399,856 5.25 % notes due 2026 – net — ​ ​ — ​ ​ 599,259 ​ ​ 600,714 4.50 % notes due 2027 – net 698,231 ​ ​ 702,303 ​ ​ 696,766 ​ ​ 691,040 4.75 % notes due 2028 – net 547,941 ​ ​ 554,307 ​ ​ 546,933 ​ ​ 542,553 3.63 % notes due 2029 – net ​ 495,517 ​ ​ 484,105 ​ ​ 494,308 ​ ​ 461,180 5.20 % notes due 2030 – net ​ 590,190 ​ ​ 610,608 ​ ​ — ​ ​ — 3.38 % notes due 2031 – net ​ 690,752 ​ ​ 653,527 ​ ​ 688,962 ​ ​ 620,809 3.25 % notes due 2033 – net ​ 693,262 ​ ​ 622,272 ​ ​ 692,343 ​ ​ 585,389 Total $ 4,256,011 ​ $ 4,169,122 ​ $ 4,838,859 ​ $ 4,627,104 ​ Fair value estimates are subjective in nature and are dependent on a number of important assumptions, including estimates of future cash flows, risks, discount rates and relevant comparable market information associated with each financial instrument (see Note 2 – Summary of Significant Accounting Policies). The use of different market assumptions and estimation methodologies may have a material effect on the reported estimated fair value amounts. The following methods and assumptions were used in estimating fair value disclosures for financial instruments. ​ ● Real estate loans receivable: The fair value of the real estate loans receivable are estimated using a discounted cash flow analysis, using current interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3). ● Non-real estate loans receivable: Non-real estate loans receivable are primarily comprised of notes receivable. The fair values of notes receivable are estimated using a discounted cash flow analysis, using current interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3). ● Revolving Credit Facility, OP Term Loan, 2026 Term Loan and 2028 Term Loan: The carrying amount of these approximate fair value because the borrowings are interest rate adjusted. Differences between carrying value and the fair value in the table above are due to the inclusion of deferred financing costs in the carrying value. ● 2026 Mortgage Loan: The 2026 Mortgage Loan was recorded at fair market value in July 2024, as of the date we assumed it as part of our acquisition of the remaining 51 % interest in the Cindat Joint Venture. The fair market value was determined by discounting the remaining contractual cash flows using a current market interest rate of comparable debt instruments. Differences between carrying value and the fair value in the table above are due to the inclusion of deferred financing costs in the carrying value. ● Senior notes: The fair value of the senior unsecured notes payable was estimated based on publicly available trading prices (Level 1). F-51 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ NOTE 17 – TAXES Omega and Omega OP, including their wholly owned subsidiaries were organized, have operated, and intend to continue to operate in a manner that enables Omega to qualify for taxation as a REIT under Sections 856 through 860 of the Code. On a quarterly and annual basis we perform several analyses to test our compliance within the REIT taxation rules. If we fail to meet the requirements for qualification as a REIT in any tax year, we will be subject to federal income tax on our taxable income at regular corporate rates and may not be able to qualify as a REIT for the four subsequent years, unless we qualify for certain relief provisions that are available in the event we fail to satisfy any of the requirements. We are also subject to federal taxation of 100 % of the net income derived from the sale or other disposition of property, other than foreclosure property, that we held primarily for sale to customers in the ordinary course of a trade or business. We believe that we do not hold assets for sale to customers in the ordinary course of business and that none of the assets currently held for sale or that have been sold would be considered a prohibited transaction within the REIT taxation rules. As a REIT under the Code, we generally will not be subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions. In 2025, 2024 and 2023, we distributed dividends in excess of our taxable income. We currently own stock in certain subsidiary REITs. These subsidiary entities are required to individually satisfy all of the rules for qualification as a REIT. If we fail to meet the requirements for qualification as a REIT for any of the subsidiary REITs, it may cause the Parent REIT to fail the requirements for qualification as a REIT also. We have elected to treat certain of our active subsidiaries as TRSs. Our domestic TRSs are subject to federal, state and local income taxes at the applicable corporate rates. Our foreign TRSs are subject to foreign income taxes and may be subject to current-year income inclusion relating to ownership of a controlled foreign corporation for U.S. income tax purposes. Under current law, net operating loss (“NOL”) carry-forwards generated up through December 31, 2017 may be carried forward for no more than 20 years, and NOL carry-forwards generated in taxable years ended after December 31, 2017, may be carried forward indefinitely. We do not anticipate that such changes will materially impact the computation of Omega’s taxable income, or the taxable income of any Omega entity, including our TRSs. Our foreign subsidiaries are subject to foreign income taxes and withholding taxes. The majority of our U.K. portfolio elected to enter the U.K. REIT regime with an effective date of April 1, 2023. U.K. NOLs have no expiration date and may be available to offset future taxable income. We believe these foreign NOLs are realizable under a “more likely than not” measurement and have not recorded a valuation allowance against the deferred tax asset. The Organization for Economic Co-operation and Development (OECD) has a framework to implement a global minimum corporate tax of 15% for companies with global revenues and profits above certain thresholds (referred to as Pillar 2), with certain aspects of Pillar 2 effective January 1, 2024 and other aspects effective January 1, 2025. While it is uncertain whether the U.S. will enact legislation to adopt Pillar 2, the U.K. has adopted legislation. Pillar 2 has not had a material impact on our effective tax rate or our consolidated results of operation, financial position and cash flows. The following is a summary of our income taxes paid (net of refunds received): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ 2023 ​ ​ (in thousands) Federal income taxes paid ​ $ 204 ​ $ 596 ​ $ 1,030 State and local income taxes paid ​ ​ 784 ​ ​ 945 ​ ​ 935 Foreign income taxes paid (1) ​ ​ 3,324 ​ ​ 6,873 ​ ​ 1,650 Total income taxes paid ​ $ 4,312 ​ $ 8,414 ​ $ 3,615 (1) The total foreign income taxes paid for the years ended December 31, 2025, 2024 and 2023 related to income taxes paid in the U.K. F-52 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ The following is a summary of our provision for income taxes: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ 2023 ​ ​ (in thousands) Federal income tax (benefit) expense (1) ​ $ ( 1,473 ) ​ $ 527 ​ $ 976 State and local income tax expense ​ ​ 616 ​ ​ 945 ​ ​ 989 Foreign income tax expense ​ ​ 15,605 ​ ​ 9,386 ​ ​ 4,290 Total income tax expense (2) ​ $ 14,748 ​ $ 10,858 ​ $ 6,255 (1) During the fourth quarter of 2025, we reversed the full valuation allowance associated with our U.S. federal NOL carryforward as a result of new investments that will have sufficient taxable income to fully utilize the NOLs. (2) The above amounts do not include gross income receipts or franchise taxes payable to certain states and municipalities. The following is a summary of our income before income tax expense disaggregated between domestic and foreign operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ 2023 ​ ​ (in thousands) Income before income tax expense related to domestic operations ​ $ 553,245 ​ $ 396,043 ​ $ 237,797 Income before income tax expense related to foreign operations ​ ​ 70,970 ​ ​ 32,619 ​ ​ 17,254 Total income before income tax expense ​ $ 624,215 ​ $ 428,662 ​ $ 255,051 ​ The following is a summary of deferred tax: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ ​ (in thousands) U.S. federal net operating loss carryforward ​ $ 1,800 ​ $ 2,048 Valuation allowance on deferred tax asset (1) ​ — ​ ( 1,925 ) Foreign net operating loss carryforward ​ ​ 18,834 ​ ​ 19,101 Foreign deferred tax asset (2) ​ ​ 1,899 ​ ​ 200 Net deferred tax asset ​ $ 22,533 ​ $ 19,424 (1) During the fourth quarter of 2025, we reversed the full valuation allowance associated with our U.S. federal NOL carryforward as a result of new investments that will have sufficient taxable income to fully utilize the NOLs. (2) The deferred tax asset resulted from book to tax differences recorded in the U.S. relating to depreciation and revenue recognition in the U.K. ​ NOTE 18 – STOCKHOLDERS’ EQUITY Stock Repurchase Program On January 27, 2022, the Company authorized the repurchase of up to $ 500 million of our outstanding common stock from time to time, which expired in March 2025. Omega did no t repurchase any of its outstanding common stock under this announced program during 2023, 2024 or 2025. At-The-Market Offering Program During the second quarter of 2021, we entered into a new “at-the-market” (“ATM”) Equity Offering Sales Agreement pursuant to which shares of common stock having an aggregate gross sales price of up to $ 1.0 billion (the “2021 ATM Program”) could be sold. During the third quarter of 2024, we terminated the 2021 ATM Program and entered into a new ATM Equity Offering Sales Agreement pursuant to which shares of common stock having an aggregate gross sales price of up to $ 1.25 billion (the “2024 ATM Program”) could be sold. F-53 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ During the fourth quarter of 2025, we terminated the 2024 ATM Program and entered into a new ATM Equity Offering Sales Agreement pursuant to which shares of common stock having an aggregate gross sales price of up to $ 2.0 billion (the “2025 ATM Program,” and together with the 2024 ATM Program and the 2021 ATM Program, the “ATM Program”) may be sold from time to time (i) by Omega through several financial institutions acting as a sales agent or directly to the financial institutions as principals, or (ii) by several financial institutions acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. Under the 2025 ATM Program, compensation for sales of the shares will not exceed 2 % of the gross sales price per share for shares sold through each financial institution. The use of forward sales under the 2025 ATM Program generally allows Omega to lock in a price on the sale of shares of common stock when sold by the forward sellers but defer receiving the net proceeds from such sales until the shares of our common stock are issued at settlement on a later date. We did not utilize the forward provisions under the ATM Program during 2025, 2024 or 2023. The following is a summary of the shares issued under our ATM Program for each of the years ended December 31, 2025, 2024 and 2023 (in thousands except average price per share): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average Net Price ​ ​ ​ ​ ​ ​ Period Ended Shares issued ​ Per Share (1) ​ Gross Proceeds ​ Net Proceeds December 31, 2025 7,493 ​ $ 36.97 ​ $ 280,887 ​ $ 277,031 December 31, 2024 28,714 ​ ​ 36.49 ​ ​ 1,058,080 ​ ​ 1,047,767 December 31, 2023 7,243 ​ ​ 30.25 ​ ​ 221,732 ​ ​ 219,140 (1) Represents the average price per share after commissions. Dividend Reinvestment and Common Stock Purchase Plan We have a Dividend Reinvestment and Common Stock Purchase Plan (the “DRCSPP”) that allows for the reinvestment of dividends and the optional purchase of our common stock. The table below presents information regarding the shares issued under the DRCSPP for each of the years ended December 31, 2025, 2024, and 2023 (in thousands): ​ ​ ​ ​ ​ ​ Period Ended Shares issued ​ Gross Proceeds December 31, 2025 8,783 ​ $ 331,243 December 31, 2024 5,078 ​ ​ 187,969 December 31, 2023 3,715 ​ ​ 117,259 ​ Dividends The Board of Directors has declared common stock dividends as set forth below: ​ ​ ​ ​ ​ ​ ​ Record Date ​ ​ ​ Payment Date ​ ​ ​ Dividend per Common Share February 10, 2025 ​ February 18, 2025 ​ $ 0.67 May 5, 2025 ​ May 15, 2025 ​ ​ 0.67 August 4, 2025 ​ August 15, 2025 ​ ​ 0.67 November 3, 2025 ​ November 17, 2025 ​ ​ 0.67 February 9, 2026 ​ February 17, 2026 ​ ​ 0.67 ​ F-54 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Per Share Distributions Per share distributions by our Company were characterized in the following manner for income tax purposes (unaudited): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Common ​ ​ ​ 2025 ​ ​ ​ 2024 ​ ​ ​ 2023 Ordinary income ​ $ 2.255 ​ $ 1.862 ​ $ 2.258 Return of capital ​ 0.214 ​ 0.712 ​ 0.212 Capital gains ​ 0.211 ​ 0.106 ​ 0.210 Total dividends paid ​ $ 2.680 ​ $ 2.680 ​ $ 2.680 ​ Pursuant to Treasury Regulation Section 1.1061-6(c), Omega Healthcare Investors Inc. is disclosing the following information to its shareholders. “One Year Amounts Disclosure” is zero percent of the capital gain distributions allocated to each shareholder and “Three Year Amounts Disclosure” is zero percent of the capital gain distributions allocated to each shareholder. All capital gain distributions reported are related to Section 1231 gain. For additional information regarding dividends, see Note 17 – Taxes. Accumulated Other Comprehensive Income (Loss) The following is a summary of our accumulated other comprehensive income (loss), net of tax as of December 31, 2025 and 2024: ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ 2025 ​ ​ ​ 2024 ​ (in thousands) Foreign currency translation ​ 20,353 ​ ​ ​ ​ ( 66,110 ) Derivative instruments designated as cash flow hedges (1) ​ 66,916 ​ ​ 76,713 Derivative instruments designated as net investment hedges ( 6,794 ) ​ 11,898 Total accumulated other comprehensive income before noncontrolling interest 80,475 ​ 22,501 Add: portion included in noncontrolling interest ( 1,438 ) ​ 230 Total accumulated other comprehensive income for Omega $ 79,037 ​ $ 22,731 (1) During the years ended December 31, 2025, 2024 and 2023, we reclassified $ 5.5 million, $ 9.6 million and $ 6.7 million, respectively, of net realized gains out of accumulated other comprehensive income into interest expense or other income - net on our Consolidated Statements of Operations associated with our cash flow hedges. ​ NOTE 19 – STOCK-BASED COMPENSATION At December 31, 2025, we maintained several stock-based compensation plans as described below. For the years ended December 31, 2025, 2024 and 2023, we recognized stock-based compensation of $ 44.2 million, $ 36.7 million and $ 35.1 million, respectively, related to these plans. Stock-based compensation expense for the year ended December 31, 2025 includes $ 6.6 million of non-cash stock-based compensation expense associated with the transition discussed in the “Leadership Transition” section below. Stock-based compensation expense is included within general and administrative expenses on our Consolidated Statements of Operations. For purposes of measuring stock-based compensation expense, we consider whether an adjustment to the observable market price is necessary to reflect material nonpublic information that is known to us at the time the award is granted. No adjustments were deemed necessary for the years ended December 31, 2025, 2024 or 2023. F-55 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Time-Based Restricted Equity Awards Restricted stock, restricted stock units (“RSUs”) and profits interest units (“PIUs”) are subject to forfeiture if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of service or a change in control of the Company. Prior to vesting, ownership of the shares/units cannot be transferred. The restricted stock has the same dividend and voting rights as our common stock. RSUs accrue dividend equivalents but have no voting rights. PIUs accrue distributions, which are equivalent to dividend equivalents, but have no voting rights. Once vested, each RSU is settled by the issuance of one share of Omega common stock and each PIU is settled by the issuance of one Omega OP Unit, subject to certain conditions. Restricted stock and RSUs are valued at the price of our common stock on the date of grant. The PIUs are valued using a Monte Carlo model to estimate fair value. We expense the cost of these awards ratably over their vesting period. Performance-Based Restricted Equity Awards Performance-based restricted equity awards include performance restricted stock units (“PRSUs”) and PIUs. PRSUs and PIUs are subject to forfeiture if the performance requirements are not achieved or if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change in control of the Company. PRSUs and PIUs have varying degrees of performance requirements to achieve vesting, and each PRSU and PIU award represents the right to a variable number of shares of common stock or partnership units. Each PIU once earned is convertible into one Omega OP Unit in Omega OP, subject to certain conditions. The vesting requirements are based on either the (i) total shareholder return (“TSR”) of Omega or (ii) Omega’s TSR relative to other REITs in the FTSE NAREIT Equity Health Care Index (“Relative TSR”). We expense the cost of these awards ratably over their service period. Prior to vesting and the distribution of shares or Omega OP Units, ownership of the PRSUs or PIUs cannot be transferred. Dividend equivalents on the PRSUs are accrued and paid to the extent the applicable performance requirements are met. While each PIU is unearned, the employee receives a partnership distribution equal to 10 % of the quarterly approved regular periodic distributions per Omega OP Unit. Partnership distributions (which in the case of normal periodic distributions is equal to the total approved quarterly dividend on Omega’s common stock), less the 10 % already paid, on the PIUs accumulate, and if the PIUs are earned, the accumulated distributions are paid. We used a Monte Carlo model to estimate the fair value for the PRSUs and PIUs granted to the employees. The following are the significant assumptions used in estimating the value of the awards for grants made on the following dates: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ January 1, ​ January 1, ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ 2023 Closing price on date of grant ​ $ 37.85 ​ ​ $ 30.66 ​ ​ $ 27.95 ​ Dividend yield ​ 7.08 % ​ ​ 8.74 % ​ ​ 9.59 % Risk free interest rate at time of grant ​ 4.49 % ​ ​ 4.15 % ​ ​ 4.28 % Expected volatility (1) ​ 23.61 % ​ ​ 25.27 % ​ ​ 40.28 % (1) Expected volatility is using 50 % historical volatility and 50 % implied volatility. ​ F-56 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ The following table summarizes the activity in restricted stock, RSUs, PRSUs, and PIUs for the years ended December 31, 2023, 2024 and 2025: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Time-Based ​ Performance-Based ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted - ​ ​ ​ ​ ​ ​ ​ Weighted - ​ ​ ​ Total ​ ​ Number of ​ Average Grant- ​ Number of ​ Average Grant- ​ Compensation ​ ​ Shares/Omega ​ Date Fair Value ​ Shares/Omega ​ Date Fair Value ​ Cost (1) ​ ​ ​ ​ OP Units ​ ​ ​ per Share ​ OP Units ​ ​ ​ per Share ​ ​ ​ (in millions) Non-vested at December 31, 2022 408,024 ​ ​ 31.93 ​ 3,215,946 ​ ​ 17.16 ​ ​ Granted during 2023 309,927 ​ 28.15 ​ 2,139,421 ​ 13.42 ​ $ 37.40 Cancelled during 2023 — ​ — ​ ( 1,228 ) ​ 11.35 ​ ​ Forfeited during 2023 ​ — ​ — ​ ( 539,312 ) ​ 17.50 ​ ​ ​ Vested during 2023 ( 208,119 ) ​ 34.31 ​ ( 482,772 ) ​ 21.52 ​ ​ Non-vested at December 31, 2023 509,832 ​ ​ 28.66 ​ 4,332,055 ​ ​ 14.78 ​ ​ Granted during 2024 306,526 ​ 30.73 ​ 2,368,170 ​ 13.22 ​ $ 40.70 Cancelled during 2024 — ​ — ​ ( 20,811 ) ​ 12.98 ​ ​ Vested during 2024 ( 251,457 ) ​ 29.56 ​ ( 578,763 ) ​ 19.93 ​ ​ Non-vested at December 31, 2024 564,901 ​ ​ 29.38 ​ 6,100,651 ​ ​ 13.69 ​ ​ Granted during 2025 263,477 ​ 37.53 ​ 1,924,305 ​ 16.93 ​ $ 42.50 Cancelled during 2025 — ​ — ​ ( 16,182 ) ​ 12.34 ​ ​ Forfeited during 2025 — ​ — ​ ( 827,111 ) ​ 13.10 ​ ​ Vested during 2025 (2) ( 305,120 ) ​ 28.50 ​ ( 1,609,459 ) ​ 14.75 ​ ​ Non-vested at December 31, 2025 523,258 ​ $ 34.00 ​ 5,572,204 ​ $ 14.60 ​ ​ (1) Total compensation cost to be recognized on the awards based on grant date fair value . (2) PRSUs and performance PIUs are shown as vesting in the year that the Compensation Committee determines the level of achievement of the applicable performance measures . As of December 31, 2025, unrecognized compensation costs related to unvested awards to employees is as follows: ● $ 4.6 million on RSUs and PIUs expected to be recognized over a weighted average period of approximately 26 months . ● $ 1.5 million on RSUs and PIUs expected to be recognized over a weighted average period of approximately 12 months . ● $ 17.1 million on TSR PRSUs and PIUs expected to be recognized over a weighted average period of approximately 42 months . ● $ 20.9 million on Relative TSR PRSUs and PIUs expected to be recognized over a weighted average period of approximately 42 months . In addition, we have a deferred stock compensation plan that allows employees and directors the ability to defer the receipt of stock awards (units). The deferred stock awards (units) participate in future dividend equivalents as well as the change in the value of the Company’s common stock. As of December 31, 2025 and 2024, the Company had 680,840 and 667,986 deferred stock units outstanding. Tax Withholding for Stock Compensation Plans Stock withheld to pay tax withholdings for equity instruments granted under stock-based payment arrangements for the years ended December 31, 2025, 2024 and 2023, was $ 1.8 million, $ 0.3 million and $ 0.6 million, respectively. F-57 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Shares Available for Issuance for Compensation Purposes On June 8, 2018, at the Annual Meeting of Stockholders, our stockholders approved the 2018 Stock Incentive Plan (the “2018 Plan”), which amended and restated the Company’s 2013 Stock Incentive Plan (the “2013 Plan”). The 2018 Plan is a comprehensive incentive compensation plan that allows for various types of equity-based compensation, including RSUs (including PRSUs), stock awards (including restricted stock), deferred RSUs, incentive stock options, non-qualified stock options, stock appreciation rights, dividend equivalent rights, performance unit awards, certain cash-based awards (including performance-based cash awards), PIUs and other stock-based awards. The 2018 Plan increased the number of shares of common stock available for issuance under the 2013 Plan by 4.5 million. On June 5, 2023, our stockholders approved an amendment to the 2018 Plan to increase the number of shares of common stock authorized for issuance from 10.5 million shares to 17.2 million shares, an increase of 6.7 million shares. As of December 31, 2025, approximately 2.6 million shares of common stock were reserved for issuance to our employees, directors and consultants under our stock incentive plans. ​ Leadership Transition In January 2025, the Company and Daniel J. Booth, Chief Operating Officer, mutually agreed that Mr. Booth’s employment agreement with the Company would terminate effective January 2, 2025. The Company entered into a Transition Agreement and Release (the “Transition Agreement”) as of January 1, 2025 with Mr. Booth in connection with his departure and transitioning of his responsibilities. The Transition Agreement provides that Mr. Booth will be entitled to receive the payments and benefits due in connection with a termination of employment by the Company without cause pursuant to his Employment Agreement, as amended, dated effective January 1, 2024, provided that vesting of his previously granted equity incentives shall be prorated through January 1, 2026, and he shall be entitled to certain continued benefits under his supplemental life insurance policy. In connection with the transition discussed above and the modification of certain of Mr. Booth’s equity awards, the Company incurred incremental non-cash stock-based compensation expense of $ 6.6 million, which is reflected within general and administrative expense within the Consolidated Statements of Operations in the first quarter of 2025. General and administrative expense also includes the accrual of $ 2.2 million of transition payments to Mr. Booth to be made over the 24-month period and other costs incurred related to the transaction. NOTE 20 – COMMITMENTS AND CONTINGENCIES Litigation Gulf Coast Subordinated Debt In August 2021, we filed suit in the Circuit Court for Baltimore County against the holders of certain Subordinated Debt (the “Gulf Coast Debt Holders”) associated with our Gulf Coast master lease agreement, following an assertion by the Gulf Coast Debt Holders that our prior exercise of offset rights in connection with Gulf Coast’s non-payment of rent had resulted in defaults under the terms of the Subordinated Debt. The suit sought a declaratory judgment to, among other items, declare that the aggregate amount of unpaid rent due from Gulf Coast under the master lease agreement exceeds all amounts which otherwise would be due and owing by an indirect subsidiary of Omega (the “Omega Gulf Coast Obligor”) under the Subordinated Debt, and that all principal and interest due and owing under the Subordinated Debt may be (and was) offset in full as of December 31, 2021. In October 2021, the Gulf Coast Debt Holders filed a motion to dismiss for lack of personal jurisdiction, which was granted in November 2022 and upheld on appeal in January 2026. F-58 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ In January 2023, the Gulf Coast Debt Holders served a lawsuit against the Omega Gulf Coast Obligor in the Superior Court of the State of Delaware, asserting claims for (i) breach of the instruments evidencing the Subordinated Debt, (ii) declaratory judgment and (iii) unjust enrichment, all claims that are factually based on the claims that were the subject of the Omega Gulf Coast Obligor’s lawsuit in Maryland. In February 2023, the Omega Gulf Coast Obligor filed a motion to dismiss or, in the alternative, to stay this action pending the outcome of the above-referenced lawsuit in Maryland, and in July 2023, the Delaware court case stayed the proceeding pending further developments in the Maryland litigation. In July 2025, the Delaware state court requested that Omega file an answer to the lawsuit by August 19, 2025, while allowing the stay to remain in place, subject to further orders of the court. Omega timely filed its answer and affirmative defenses, denying the claims and relief sought by the Gulf Coast Debt Holders in the Delaware state court. It is anticipated that the Delaware case stay will be lifted based on the denial of the appeal that was issued in January 2026 in the Maryland case. While Omega believes the Omega Gulf Coast Obligor is entitled to enforcement of the offset rights that are the subject of these actions, Omega cannot predict the ultimate outcome of the litigation. Genesis Bankruptcy - Claim of Statutory Unsecured Claimants’ Committee On December 4, 2025, the Genesis Statutory Unsecured Claimants’ Committee (“UCC”) filed its (a) Motion for Leave, Standing, And Authority To Prosecute Certain Claims On Behalf Of The Debtors’ Estates And For Related Relief which attached a proposed Complaint against a subsidiary of the Company, and (b) Preliminary Objection To Determine The Secured Status Of Prepetition Term Loan Claims. Both the proposed Complaint and Preliminary Objection seek a determination that the Prepetition Term Loan(s) to which our subsidiary is a co-lender is, in part, unsecured. The proposed Complaint also alleges a preference action against the agent under the Prepetition Term Loan(s) in respect of payments made to said agent within the ninety (90) days of the Genesis bankruptcy filing (“Petition Date”), certain of which payments were dispersed to our subsidiary. Finally, the proposed Complaint alleges a preference action against other subsidiar(ies) of the Company, in respect of lease payments made to such subsidiar(ies) under a master lease with Genesis within ninety (90) days of the Petition Date. On January 23, 2026, the UCC and the Debtors in the proceeding entered into an unopposed stipulation (“Stipulation”) that the Bankruptcy Court’s consideration of the Standing Motion shall be continued to the date of an order confirming a chapter 11 plan in accordance with section 1129 of the Bankruptcy Code, whereupon the Standing Motion shall be granted. The Bankruptcy Court approved the Stipulation by order dated January 26, 2026. While Omega believes that the claims asserted against our subsidiaries are without merit and intends to vigorously defend against them, Omega cannot predict the ultimate outcome of this action. Other In addition to the matters above, we are subject to various other legal proceedings, claims and other actions arising out of the normal course of business. While any legal proceeding or claim has an element of uncertainty, management believes that the outcome of each lawsuit, claim or legal proceeding that is pending or threatened, or all of them combined, will not have a material adverse effect on our consolidated financial position or results of operations. Indemnification Agreements In connection with certain facility transitions, we have agreed to indemnify certain operators in certain events. As of December 31, 2025, our maximum funding commitment under these indemnification agreements was approximately $ 8.0 million. Claims under these indemnification agreements generally may be made within 18 months to 72 months of the transition date. These indemnification agreements were provided to certain operators in connection with facility transitions and generally would be applicable if the prior operators do not perform under their transition agreements. F-59 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ Commitments We have committed to fund the construction of new leased and mortgaged facilities, capital improvements and other commitments. We expect the funding of these commitments to be completed over the next several years. Our remaining commitments at December 31, 2025, are outlined in the table below (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Lessor construction and capital commitments under lease agreements ​ $ 207,762 Non-real estate loan commitments ​ 37,392 Real estate loan commitments ​ 90,891 Total remaining commitments (1) ​ $ 336,045 (1) Includes finance costs. ​ Canadian Loan Commitment On December 12, 2025, we entered into a loan agreement with a borrower to fund the development of several long-term care facilities in Canada. The maximum commitment under the loan agreement is $ 87.6 million Canadian dollars, which will be funded in several advances as needed by the borrower. As of December 31, 2025, no advances had been made on the loan, and the full commitment is reflected within “Real estate loan commitments” in the table above. The loan bears interest at 10.0 % per annum and has a maturity date of December 12, 2035. At Omega’s option, the loan is convertible into a 34.9 % equity stake in the borrower. NOTE 21 – SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS The following are supplemental disclosures to the consolidated statements of cash flows for the years ended December 31, 2025, 2024 and 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ ​ ​ 2023 ​ (in thousands) Reconciliation of cash and cash equivalents and restricted cash: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 27,024 ​ ​ ​ $ 518,340 ​ ​ ​ $ 442,810 Restricted cash ​ 27,539 ​ 30,395 ​ 1,920 Cash, cash equivalents and restricted cash at end of year ​ $ 54,563 ​ $ 548,735 ​ $ 444,730 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental information: ​ ​ ​ ​ ​ ​ Interest paid during the year, net of amounts capitalized ​ $ 224,046 ​ $ 230,993 ​ $ 234,453 Taxes paid during the year ​ $ 4,312 ​ $ 8,414 ​ $ 3,615 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Non-cash investing activities ​ ​ ​ ​ ​ ​ Non-cash acquisition of real estate (see Note 3) ​ $ ( 10,081 ) ​ $ ( 344,008 ) ​ $ — Non-cash collection of real-estate loan receivable principal (see Note 3) ​ $ 10,081 ​ $ — ​ $ — Non-cash investment in non-real estate loans receivables (See Note 3) ​ $ — ​ $ ( 1,632 ) ​ $ — Non-cash investment in unconsolidated entities (See Note 11) ​ $ ( 222,375 ) ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Non-cash financing activities ​ ​ ​ ​ ​ ​ Assumption of debt (see Note 3 and Note 14) ​ $ — ​ $ 263,989 ​ $ — ​ ​ F-60 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ NOTE 22 - EARNINGS PER SHARE The following tables set forth the computation of basic and diluted earnings per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ ​ ​ 2023 ​ ​ (in thousands, except per share amounts) Numerator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income ​ $ 609,467 ​ $ 417,804 ​ $ 248,796 Less: adjustments to basic numerator (1) ​ ( 37,437 ) ​ ( 11,478 ) ​ ( 6,616 ) Net income available to common stockholders – basic ​ $ 572,030 ​ $ 406,326 ​ $ 242,180 Add: net income attributable to OP Units ​ 19,356 ​ 12,060 ​ 7,077 Net income available to common stockholders – diluted ​ $ 591,386 ​ $ 418,386 ​ $ 249,257 Denominator: ​ ​ ​ ​ ​ ​ Denominator for basic earnings per share ​ 291,648 ​ 258,118 ​ 240,493 Effect of dilutive securities: ​ ​ ​ ​ ​ ​ Common stock equivalents ​ 3,614 ​ 4,664 ​ 2,923 Noncontrolling interest – Omega OP Units ​ 9,690 ​ 7,668 ​ 7,035 Denominator for diluted earnings per share ​ 304,952 ​ 270,450 ​ 250,451 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Earnings per share – basic: ​ ​ ​ ​ ​ ​ Net income available to common stockholders ​ $ 1.96 ​ $ 1.57 ​ $ 1.01 Earnings per share – diluted: ​ ​ ​ ​ ​ ​ Net income available to common stockholders ​ $ 1.94 ​ $ 1.55 ​ $ 1.00 ​ (1) Includes adjustments to remove income related to non-controlling interests and participating shares including time-based and performance-based PIUs and time-based and performance-based RSUs. NOTE 23 – SEGMENTS We conduct our operations and report financial results as one business segment. The presentation of financial results as one reportable segment is consistent with the way we operate our business and is consistent with the manner in which our CODM, our Chief Executive Officer, evaluates performance and makes resource and operating decisions for the business. The reportable segment derives revenues from operators primarily through providing financing and capital to the long-term healthcare industry. Our core portfolio consists of long-term “triple net” leases and real estate loans with our operators. In addition to our core investments, we make loans to operators and/or their principals. From time to time, we also acquire equity interests in JVs or entities that support the long-term healthcare industry and our operators. Additionally, during the fourth quarter of 2025, we began utilizing the RIDEA structure. Omega manages the business activities on a consolidated basis. The accounting policies of the business segment are the same as those described in the summary of significant accounting policies. F-61 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – Continued ​ The CODM evaluates performance and makes resource and operating decisions for the business based on net income that is reported on the Consolidated Statements of Operations. The measure of segment assets is reported on the Consolidated Balance Sheets as total assets. The CODM uses net income to evaluate whether to make new investments, borrow or pay-off debt and/or issue or repurchase equity. The Company’s CODM periodically reviews interest expense and treats it as a significant segment expense. Interest expense is the largest recurring cash expense of the Company because debt is one of our primary sources of funds for new investments. Dependent on market conditions, our CODM seeks to mitigate the effects of fluctuations in interest rates by matching the terms of new investments with long-term fixed rate borrowings to the extent possible. Additionally, the CODM also utilizes hedging instruments as discussed in Note 15 – Derivatives and Hedging, to help manage interest rate risk and limit significant fluctuations in interest expense for variable rate borrowings. Interest expense related to the Company’s reportable segment is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2025 ​ ​ ​ 2024 ​ ​ ​ 2023 ​ (in thousands) Interest expense $ 209,072 ​ $ 211,319 ​ $ 221,832 Interest – amortization of deferred financing costs (1) 5,963 ​ 10,397 ​ 13,697 Interest expense – net $ 215,035 ​ $ 221,716 ​ $ 235,529 (1) Includes amortization of deferred financing costs, discounts and premiums. ​ ​ NOTE 24 – SUBSEQUENT EVENTS Saber OpCo JV On January 1, 2026, Omega acquired a 9.9 % equity interest in Saber, an operating company that Omega leased 53 operating facilities to as of December 31, 2025. Under the agreement, Omega funded $ 92.6 million in cash consideration. Omega will receive minimum quarterly cash distributions equivalent to an annualized yield of 8 % on its investment. 2026 Acquisitions In January 2026, we acquired one facility in Alabama for a contractual purchase price of $ 10.3 million. The Company will operate the facility, through a new third-party property manager, utilizing a RIDEA structure. In February 2026, we acquired 13 facilities in Georgia for a contractual purchase price of $ 108.5 million and leased them to one existing operator. ​ ​ ​ ​ ​ ​ F-62 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. ​ SC HEDULE III – REAL ESTATE AND ACCUMULATED DEPRECIATI ON (in thousands) December 31, 2025 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross Amount at ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial Cost to ​ Cost Capitalized ​ Which Carried at ​ ​ ​ ​ ​ ​ ​ ​ Life on Which ​ ​ Company ​ Subsequent to ​ Close of Period (2) (4) ​ ​ ​ ​ ​ ​ ​ ​ Depreciation ​ ​ ​ ​ ​ ​ ​ ​ Acquisition ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (3) ​ ​ ​ (6) ​ in Latest ​ ​ ​ ​ ​ Buildings and ​ ​ ​ ​ Carrying ​ (5) ​ (7) ​ Buildings and ​ ​ ​ ​ Accumulated ​ Date of ​ Date ​ Income Statements Description (1) Encumbrances Land ​ ​ ​ Improvements ​ ​ ​ Improvements ​ ​ ​ Cost ​ ​ ​ Other ​ ​ ​ Land ​ ​ ​ Improvements ​ ​ ​ Total ​ ​ ​ Depreciation ​ ​ ​ Construction ​ ​ ​ Acquired ​ ​ ​ is Computed Alabama (SNF) ​ $ 1,817 ​ $ 33,356 ​ $ 15,611 ​ $ — ​ $ — ​ $ 1,817 ​ $ 48,967 ​ $ 50,784 ​ $ ( 43,814 ) 1960 - 1982 ​ 1992 - 1997 ​ 31 years - 33 years Arizona (ALF, ILF, SNF) ​ 11,502 ​ 117,878 ​ 4,831 ​ — ​ ​ — ​ 11,502 ​ 122,709 ​ 134,211 ​ ( 42,613 ) 1949 - 1999 ​ 2005 - 2021 ​ 25 years - 40 years Arkansas (ALF, SNF) 2,810 ​ 48,765 ​ 5,696 ​ — ​ ​ ( 36 ) ​ 2,810 ​ 54,425 ​ 57,235 ​ ( 35,004 ) 1967 - 1988 ​ 1992 - 2014 ​ 25 years - 31 years California (ALF, SF, SNF) ​ 86,313 ​ 481,310 ​ 16,270 ​ — ​ ​ ( 478 ) ​ 86,313 ​ 497,102 ​ 583,415 ​ ( 194,703 ) 1938 - 2013 ​ 1997 - 2025 ​ 5 years - 35 years Colorado (ILF, SNF) ​ 11,283 ​ 88,830 ​ 8,188 ​ — ​ ​ ( 10 ) ​ 11,272 ​ 97,019 ​ 108,291 ​ ( 59,488 ) 1925 - 1975 ​ 1998 - 2016 ​ 20 years - 39 years Connecticut (ALF) ​ 25,063 ​ 252,417 ​ 12,323 ​ 1,319 ​ ​ — ​ 25,063 ​ 266,059 ​ 291,122 ​ ( 93,458 ) 1968 - 2019 ​ 2010 - 2017 ​ 30 years - 33 years Florida (ALF, ILF, SNF) ​ 59,103 ​ 406,535 ​ 31,810 ​ 38 ​ ​ ( 24,067 ) ​ 58,113 ​ 415,306 ​ 473,419 ​ ( 222,160 ) 1942 - 2018 ​ 1993 - 2021 ​ 2 years - 39 years Georgia (ALF, SNF) ​ 3,740 ​ 47,689 ​ 2,478 ​ — ​ ​ — ​ 3,740 ​ 50,167 ​ 53,907 ​ ( 21,253 ) 1967 - 1997 ​ 1998 - 2016 ​ 30 years - 40 years Idaho (SNF) ​ ​ 5,735 ​ ​ 47,530 ​ ​ 1,920 ​ ​ — ​ ​ ( 542 ) ​ ​ 5,193 ​ ​ 49,450 ​ ​ 54,643 ​ ​ ( 26,757 ) ​ 1920 - 2008 ​ 1997 - 2014 ​ 25 years - 39 years Illinois (ALF) ​ ​ 1,830 ​ ​ 13,967 ​ ​ 1,903 ​ ​ — ​ ​ — ​ ​ 1,830 ​ ​ 15,870 ​ ​ 17,700 ​ ​ ( 3,876 ) ​ 1999 ​ 2021 ​ 25 years Indiana (ALF, ILF, SF, SNF) ​ 48,224 ​ 571,751 ​ 17,305 ​ — ​ ​ ( 7,453 ) ​ 48,130 ​ 581,697 ​ 629,827 ​ ( 261,640 ) 1942 - 2015 ​ 1992 - 2025 ​ 20 years - 40 years Iowa (ALF, SNF) ​ 1,964 ​ 51,759 ​ 1,809 ​ — ​ ​ — ​ 1,964 ​ 53,568 ​ 55,532 ​ ( 24,144 ) 1961 - 1998 ​ 2010 - 2014 ​ 23 years - 33 years Jersey (ALF) ​ ​ 7,965 ​ 34,366 ​ — ​ — ​ ​ 644 ​ 8,086 ​ 34,889 ​ 42,975 ​ ( 1,045 ) 1800 - 2004 ​ 2025 ​ 25 years Kansas (SNF) ​ 4,092 ​ 38,693 ​ 14,532 ​ 1 ​ ​ ( 4,390 ) ​ 4,092 ​ 48,836 ​ 52,928 ​ ( 31,625 ) 1957 - 1977 ​ 2005 - 2011 ​ 25 years Kentucky (ALF, SNF) ​ 15,556 ​ 130,819 ​ 7,517 ​ — ​ ​ — ​ 15,556 ​ 138,336 ​ 153,892 ​ ( 68,790 ) 1964 - 2002 ​ 1999 - 2016 ​ 20 years - 33 years Louisiana (ALF, SNF) ​ 5,846 ​ 113,351 ​ 6,920 ​ 448 ​ ​ ( 1,752 ) ​ 5,846 ​ 118,967 ​ 124,813 ​ ( 39,817 ) 1951 - 2020 ​ 1997 - 2024 ​ 22 years - 39 years Maryland (SNF) ​ 21,486 ​ 131,741 ​ 27,158 ​ 135 ​ ​ — ​ 17,526 ​ 162,994 ​ 180,520 ​ ( 54,527 ) 1921 - 2016 ​ 2008 - 2025 ​ 25 years - 30 years Massachusetts (ALF, SNF) ​ 19,041 ​ 113,728 ​ 27,800 ​ — ​ ​ ( 693 ) ​ 19,041 ​ 140,835 ​ 159,876 ​ ( 57,982 ) 1988 - 2017 ​ 2014 ​ 30 years - 33 years Michigan (SNF) ​ 1,535 ​ 29,465 ​ — ​ — ​ ​ — ​ 1,535 ​ 29,465 ​ 31,000 ​ ( 2,168 ) 1950 ​ 2024 ​ 25 years Minnesota (ALF, ILF, SNF) ​ 10,502 ​ 52,585 ​ 5,972 ​ — ​ ​ — ​ 10,502 ​ 58,557 ​ 69,059 ​ ( 28,471 ) 1966 - 1983 ​ 2014 ​ 33 years Mississippi (SNF) ​ 8,803 ​ 191,448 ​ 827 ​ — ​ ​ — ​ 8,803 ​ 192,275 ​ 201,078 ​ ( 66,603 ) 1965 - 2008 ​ 2009 - 2019 ​ 20 years - 30 years Missouri (SNF) ​ 255 ​ 4,956 ​ — ​ — ​ ​ ( 120 ) ​ 247 ​ 4,844 ​ 5,091 ​ ( 3,958 ) 1989 ​ 1999 ​ 33 years Montana (SNF) ​ 1,319 ​ 11,698 ​ 432 ​ — ​ ​ — ​ 1,319 ​ 12,130 ​ 13,449 ​ ( 5,008 ) 1963 - 1971 ​ 2005 ​ 33 years Nebraska (SNF) ​ 530 ​ 13,712 ​ 768 ​ — ​ ​ — ​ 530 ​ 14,480 ​ 15,010 ​ ( 6,721 ) 1966 - 1969 ​ 2012 - 2015 ​ 20 years - 33 years Nevada (SNF, SF) ​ 8,811 ​ 92,797 ​ 8,350 ​ — ​ ​ — ​ 8,811 ​ 101,147 ​ 109,958 ​ ( 45,548 ) 1972 - 2012 ​ 2009 - 2017 ​ 25 years - 33 years New Hampshire (ALF, SNF) ​ 1,782 ​ 19,837 ​ 1,463 ​ — ​ ​ — ​ 1,782 ​ 21,300 ​ 23,082 ​ ( 13,523 ) 1963 - 1999 ​ 1998 - 2006 ​ 33 years - 39 years New Jersey (ALF, CCRC) ​ ​ 23,603 ​ ​ 129,088 ​ ​ 2,268 ​ ​ 1,559 ​ ​ — ​ ​ 23,603 ​ ​ 132,915 ​ ​ 156,518 ​ ​ ( 13,597 ) ​ 1997 - 2021 ​ 2019 - 2025 ​ 25 years New Mexico (SNF) ​ 11,023 ​ 72,298 ​ 1,318 ​ — ​ ​ — ​ 11,023 ​ 73,616 ​ 84,639 ​ ( 19,421 ) 1960 - 1990 ​ 2005 - 2025 ​ 25 years - 33 years New York (ALF) ​ ​ 113,145 ​ ​ 176,921 ​ ​ 4,878 ​ ​ 40,543 ​ ​ ( 5,900 ) ​ ​ 113,145 ​ ​ 216,442 ​ ​ 329,587 ​ ​ ( 52,104 ) ​ 2020 ​ 2015 ​ 25 years North Carolina (ALF, SNF) ​ 29,063 ​ 369,884 ​ 12,110 ​ 336 ​ ​ ( 902 ) ​ 28,876 ​ 381,615 ​ 410,491 ​ ( 147,782 ) 1963 - 2019 ​ 1994 - 2024 ​ 25 years - 36 years Ohio (ALF, SNF, SF) ​ ​ 28,026 ​ ​ 332,613 ​ ​ 25,350 ​ ​ 345 ​ ​ ( 28,680 ) ​ ​ 27,776 ​ ​ 329,878 ​ ​ 357,654 ​ ​ ( 120,745 ) ​ 1955 - 2021 ​ 1994 - 2020 ​ 25 years - 39 years Oklahoma (SNF) ​ ​ 1,280 ​ ​ 11,190 ​ ​ 573 ​ ​ — ​ ​ — ​ ​ 1,280 ​ ​ 11,763 ​ ​ 13,043 ​ ​ ( 9,247 ) ​ 1965 - 1993 ​ 2010 ​ 20 years Oregon (ALF, ILF, SNF) ​ ​ 8,740 ​ ​ 128,799 ​ ​ 13,550 ​ ​ — ​ ​ — ​ ​ 8,740 ​ ​ 142,349 ​ ​ 151,089 ​ ​ ( 39,273 ) ​ 1959 - 2007 ​ 2005 - 2024 ​ 25 years - 33 years Pennsylvania (ALF, ILF, SNF) ​ ​ 25,301 ​ ​ 345,548 ​ ​ 24,733 ​ ​ — ​ ​ ( 31,316 ) ​ ​ 25,296 ​ ​ 338,970 ​ ​ 364,266 ​ ​ ( 140,785 ) ​ 1873 - 2012 ​ 2004 - 2022 ​ 20 years - 39 years Rhode Island (SNF) ​ ​ 3,299 ​ ​ 23,487 ​ ​ 3,805 ​ ​ — ​ ​ — ​ ​ 3,299 ​ ​ 27,292 ​ ​ 30,591 ​ ​ ( 18,064 ) ​ 1965 - 1981 ​ 2006 ​ 39 years South Carolina (ALF, SNF) ​ ​ 11,640 ​ ​ 82,262 ​ ​ 2,889 ​ ​ — ​ ​ ( 26 ) ​ ​ 11,614 ​ ​ 85,151 ​ ​ 96,765 ​ ​ ( 36,576 ) ​ 1959 - 2007 ​ 2014 - 2025 ​ 20 years - 33 years Tennessee (ALF, SNF, SF) ​ ​ 12,976 ​ ​ 268,846 ​ ​ 9,986 ​ ​ — ​ ​ — ​ ​ 12,976 ​ ​ 278,832 ​ ​ 291,808 ​ ​ ( 138,683 ) ​ 1968 - 2018 ​ 1992 - 2021 ​ 20 years - 31 years Texas (ALF, ILF, SNF, SF) ​ ​ 68,421 ​ ​ 793,991 ​ ​ 48,456 ​ ​ — ​ ​ ( 7,259 ) ​ ​ 70,994 ​ ​ 832,615 ​ ​ 903,609 ​ ​ ( 281,368 ) ​ 1949 - 2016 ​ 1997 - 2025 ​ 20 years - 40 years United Kingdom (ALF) ​ ​ 353,872 ​ ​ 1,318,226 ​ ​ 21,898 ​ ​ — ​ ​ 25,748 ​ ​ 361,678 ​ ​ 1,358,066 ​ ​ 1,719,744 ​ ​ ( 199,100 ) ​ 1650 - 2012 ​ 2015 - 2025 ​ 25 years - 30 years Vermont (SNF) ​ ​ 318 ​ ​ 6,005 ​ ​ 602 ​ ​ — ​ ​ — ​ ​ 318 ​ ​ 6,607 ​ ​ 6,925 ​ ​ ( 3,913 ) ​ 1971 ​ 2004 ​ 39 years Virginia (ALF, SNF) ​ 32,632 ​ 343,936 ​ 11,554 ​ 190 ​ ​ 1,141 ​ 31,612 ​ 357,841 ​ 389,453 ​ ( 118,726 ) 1964 - 2017 ​ 2016 - 2023 ​ 25 years - 30 years Washington (ALF, SNF) ​ 12,914 ​ 162,575 ​ 9,351 ​ — ​ ​ ( 2 ) ​ 12,912 ​ 171,926 ​ 184,838 ​ ( 56,759 ) 1951 - 2004 ​ 1999 - 2021 ​ 25 years - 33 years Washington DC (ALF) ​ ​ 68,017 ​ ​ 135,298 ​ ​ — ​ ​ 16,217 ​ ​ — ​ ​ 68,017 ​ ​ 151,515 ​ ​ 219,532 ​ ​ ( 5,988 ) ​ 2025 ​ 2021 ​ 25 years West Virginia (SNF) ​ 3,475 ​ 202,085 ​ 7,069 ​ — ​ ​ — ​ 3,475 ​ 209,154 ​ 212,629 ​ ( 69,525 ) 1850 - 2016 ​ 1994 - 2024 ​ 25 years - 39 years Wisconsin (ALF, SNF) ​ 1,440 ​ 13,791 ​ 2,153 ​ — ​ ​ — ​ 1,440 ​ 15,944 ​ 17,384 ​ ( 4,259 ) 1974 - 1999 ​ 2005 - 2025 ​ 25 years - 33 years Total ​ $ 1,176,092 ​ $ 8,057,826 ​ $ 424,426 ​ $ 61,131 ​ $ ( 86,093 ) ​ $ 1,179,497 ​ $ 8,453,885 ​ $ 9,633,382 ​ $ ( 2,930,611 ) ​ ​ ​ ​ (1) The real estate included in this schedule is being used in either the operation of skilled nursing facilities (“SNF”), assisted living facilities (“ALF”), including care homes in the U.K., independent living facilities (“ILF”), specialty facilities (“SF”) (consisting of specialty hospitals, long-term acute care hospitals, independent rehabilitation facilities, behavioral health substance facilities, behavioral health psychology facilities, traumatic brain injury facilities and other healthcare facilities) or continuing care retirement communities (“CCRCs”), located in the states or country indicated. F-63 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. SCHEDULE III – REAL ESTATE AND ACCUMULATED DEPRECIATION — continued (in thousands) December 31, 2025 (2) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ ​ ​ 2023 Balance at beginning of period ​ $ 9,060,174 ​ $ 8,372,419 ​ $ 8,860,264 Acquisitions (a) ​ 693,111 ​ 740,661 ​ 262,453 Impairment ​ ( 29,932 ) ​ ( 23,728 ) ​ ( 89,985 ) Improvements ​ 79,188 ​ 114,610 ​ 87,760 Disposals/other ​ ( 169,159 ) ​ ( 143,788 ) ​ ( 748,073 ) Balance at close of period ​ $ 9,633,382 ​ $ 9,060,174 ​ $ 8,372,419 ​ (a) Includes approximately $ 10.1 million and $ 344.0 million of non-cash consideration exchanged and/or valuation adjustments during the year ended December 31, 2025 and 2024, respectively. Also includes certain land purchases and other acquisitions not reflected in Note 3 – Real Estate Asset Acquisitions and Development. (3) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ ​ ​ 2023 Balance at beginning of period ​ $ 2,721,016 ​ $ 2,469,893 ​ $ 2,322,773 Provisions for depreciation ​ 322,710 ​ 302,088 ​ 317,536 Dispositions/other ​ ( 113,115 ) ​ ( 50,965 ) ​ ( 170,416 ) Balance at close of period ​ $ 2,930,611 ​ $ 2,721,016 ​ $ 2,469,893 ​ ​ (4) The reported amount of our real estate at December 31, 2025 is greater than the tax basis of the real estate by approximately $ 675.6 million (unaudited). (5) Reflects bed sales, impairments (including the write-off of accumulated depreciation), land easements and impacts from foreign currency exchange rates. (6) To the extent that we acquired an entity previously owning the underlying facility, the acquisition date reflects the date that the entity acquired the facility. (7) Includes $ 4.9 million of construction in progress related to land, all other amounts related to construction in progress are reflected in buildings and improvements. ​ ​ ​ ​ F-64 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. ​ SCHEDULE IV – MORTGAGE LOANS ON REAL ESTATE (in thousands) December 31, 2025 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Carrying ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount of ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Loans ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Face ​ ​ Carrying Subject to ​ ​ ​ ​ ​ ​ ​ ​ Final ​ ​ ​ ​ ​ Amount ​ ​ Amount Delinquent ​ ​ ​ ​ Interest ​ Fixed/ ​ Maturity ​ ​ ​ Prior ​ of ​ ​ of Principal Grouping ​ ​ ​ Description (1) ​ ​ ​ Rate ​ ​ ​ Variable ​ ​ ​ Date ​ ​ ​ Periodic Payment Terms ​ ​ ​ Liens ​ ​ ​ Mortgages ​ ​ ​ ​ Mortgages (3) (4) (6) ​ ​ ​ or Interest ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ First Mortgages ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1 Michigan (33 SNFs and 1 ALF) 11.78 % F (2) 2030 Interest plus approximately $ 112.6 of principal payable monthly with $ 426,322 due at maturity None ​ $ 621,749 ​ $ 433,544 ​ $ — ​ 2 Ohio (8 SNFs) 10.50 % F (2) 2037 Interest payable monthly until maturity None ​ 72,420 ​ 72,420 ​ — ​ 3 ​ Maryland (1 SNF) ​ 10.00 % F ​ 2026 ​ Interest payable monthly until maturity ​ None ​ ​ 4,623 ​ ​ 4,623 ​ ​ — ​ 4 ​ Ohio (2 SNFs) ​ 10.00 % F ​ 2027 ​ Interest payable monthly until maturity ​ None ​ ​ 7,300 ​ ​ 7,300 ​ ​ — ​ 5 Illinois (2 ALFs, 1 SNF and 1 ILF) 10.00 % F 2028 Interest payable monthly until maturity None ​ 60,000 ​ 53,750 ​ — ​ 6 Pennsylvania (4 ALFs) 10.00 % F 2027 Interest payable monthly until maturity None ​ 38,626 ​ 37,382 ​ — ​ 7 Michigan (1 ALF) 10.00 % F 2027 Interest payable monthly until maturity None ​ 8,000 ​ 8,000 ​ — ​ 8 ​ South Carolina (1 ILF) ​ 10.00 % F ​ 2028 ​ Interest payable monthly until maturity ​ None ​ ​ 11,844 ​ ​ 11,844 ​ ​ — ​ 9 ​ Florida (1 ALF) ​ 10.00 % F ​ 2027 ​ Interest payable monthly until maturity ​ None ​ ​ 8,332 ​ ​ 8,332 ​ ​ — ​ 10 Tennessee (1 ALF) 8.00 % F 2026 Interest payable monthly until maturity None ​ 8,680 ​ 8,680 ​ — ​ 11 Oregon (1 ALF) 9.00 % F 2027 Interest payable monthly until maturity None ​ 5,450 ​ 5,450 ​ — ​ 12 Massachusetts (1 specialty facility) 9.00 % F 2029 Interest plus $ 250 of principal payable quarterly with $ 2,436 due at maturity None ​ 9,000 ​ — ​ — (5) 13 Tennessee (1 SNF) 8.35 % F 2015 Past due None ​ 6,377 ​ 1,472 ​ 1,472 (5) 14 ​ Georgia (2 ALFs) ​ 10.00 % F ​ 2029 ​ Interest payable monthly until maturity ​ None ​ ​ 9,551 ​ ​ 9,551 ​ ​ — ​ 15 ​ Georgia (2 SNFs, 1 ALF), Florida (1 SNF) ​ 10.00 % F ​ 2027 ​ Interest payable monthly until maturity ​ None ​ ​ 29,700 ​ ​ 29,700 ​ ​ — ​ 16 ​ Florida (1 ALF ) ​ 10.00 % F ​ 2030 ​ Interest payable monthly until maturity ​ None ​ ​ 10,400 ​ ​ 10,400 ​ ​ — ​ 17 ​ United Kingdom (15 ALFs) ​ 10.00 % F ​ 2026 ​ Interest payable monthly until maturity ​ None ​ ​ 39,069 ​ ​ 39,069 ​ ​ — ​ 18 ​ United Kingdom (11 ALFs) ​ 10.00 % F ​ 2026 ​ Interest payable monthly until maturity ​ None ​ ​ 61,742 ​ ​ 61,742 ​ ​ — ​ 19 ​ Florida (1 ALF) ​ 10.00 % F ​ 2027 ​ Interest payable monthly until maturity ​ None ​ ​ 11,891 ​ ​ 11,891 ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital Expenditure Mortgages ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 20 ​ Ohio ​ 10.25 % F (2) ​ 2037 ​ Interest plus approximately $ 27.2 of principal payable monthly with $ 82 due at maturity ​ None ​ ​ 7,200 ​ ​ 6,543 ​ ​ — ​ 21 Michigan 10.51 % F (2) 2030 Interest payable monthly until maturity None ​ 560 ​ 362 ​ — ​ 22 ​ Michigan ​ 10.25 % F (2) ​ 2030 ​ No interest due on the first $ 300 , then interest payable monthly until maturity ​ None ​ ​ 500 ​ ​ 391 ​ ​ — ​ 23 ​ Michigan ​ 10.50 % F (2) ​ 2030 ​ Interest plus approximately $ 1.9 of principal payable monthly with $ 1,356 due at maturity ​ ​ ​ ​ 3,835 ​ ​ 1,458 ​ ​ ​ ​ 24 ​ Michigan ​ 11.91 % F (2) ​ 2030 ​ Interest plus approximately $ 6.1 of principal payable monthly with $ 43,864 due at maturity ​ None ​ ​ 54,223 ​ ​ 44,272 ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Construction Mortgages ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 25 United Kingdom (1 ALF) 10.00 % F 2026 Interest payable monthly until maturity None ​ 53,220 ​ 53,220 ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance for credit loss on mortgage loans (7) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ( 23,078 ) ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 1,144,292 ​ $ 898,318 ​ $ 1,472 ​ (1) Loans included in this schedule represent first mortgages, capital expenditure mortgages and construction mortgages on facilities used in the delivery of long-term healthcare of which such facilities are located in the states indicated. Includes 3 facilities that are not currently operating. (2) Interest on the loans escalates at a fixed rate. (3) The aggregate cost for federal income tax purposes is approximately $ 931.6 million (unaudited). ​ ​ ​ ​ F-65 Table of Contents OMEGA HEALTHCARE INVESTORS, INC. SCHEDULE IV – MORTGAGE LOANS ON REAL ESTATE — continued (in thousands) December 31, 2025 (4) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ ​ 2025 ​ ​ ​ 2024 ​ ​ ​ 2023 Balance at beginning of period ​ $ 942,765 ​ $ 698,776 ​ $ 648,130 Additions during period - new mortgage loans or additional fundings (a) ​ 48,367 ​ 292,722 ​ 102,332 Deductions during period - collection of principal/other (b) ​ ( 99,078 ) ​ ( 63,876 ) ​ ( 79,418 ) Allowance for credit loss on mortgage loans ​ 6,264 ​ 15,143 ​ 27,732 Balance at close of period ​ $ 898,318 ​ $ 942,765 ​ $ 698,776 (a) The 2024 and 2023 amounts include $ 1.5 million and $ 2.3 million, respectively, of non-cash PIK interest. The 2024 amount includes $ 7.3 million of non-cash placement of mortgage capital. (b) The 2025 and 2023 amounts include $ 0.9 million and $ 3.9 million, respectively, of interest payments that were directly applied against the principal balance outstanding using the cost recovery method. The 2025 and 2023 amounts also include $ 28.5 million and $ 37.0 million, respectively, of non-cash principal reductions. ​ (5) Mortgage written down to the fair value of the underlying collateral. (6) Mortgages included in the schedule which were extended during 2025 aggregated approximately $ 168.2 million. (7) The allowance for credit loss on mortgage loans represents the allowance calculated utilizing a PD and LGD methodology. For mortgages that the risk of loss was evaluated on an individual basis, the allowance is included as a reduction to the carrying amount of the mortgage. ​ ​ ​ ​ F-66 Table of Contents INDEX TO EXHIBITS TO 2025 FORM 10-K ​ ​ EXHIBIT NUMBER DESCRIPTION 3.1 Articles of Amendment and Restatement of the Company, as amended through June 6, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K, filed June 6, 2025). 3.2 Amended and Restated Bylaws of the Company as of October 21, 2022 (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed October 21, 2022). 4.0 See Exhibits 3.1 to 3.2. 4.1 Indenture, dated as of March 18, 2015, by and among the Company, the subsidiary guarantors named therein and U.S. Bank National Association, governing the Company’s 4.500% Senior Notes due 2027 (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed March 24, 2015). 4.1A First Supplemental Indenture, dated as of April 1, 2015, among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association (Incorporated by reference to Exhibit 4.5A to the Company’s Quarterly Report on Form 10-Q, filed May 8, 2015). 4.1B Second Supplemental Indenture, dated as of August 4, 2015, among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association (Incorporated by reference to Exhibit 4.2A to the Company’s Registration Statement on Form S-4, filed October 6, 2015). 4.1C Third Supplemental Indenture, dated as of November 9, 2015, among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association (Incorporated by reference to Exhibit 4.2B to the Amendment to the Company’s Registration Statement on Form S-4/A, filed November 12, 2015). 4.1D Fourth Supplemental Indenture, dated as of March 29, 2016, among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association (Incorporated by reference to Exhibit 4.4 to the Company’s Quarterly Report on Form 10-Q, filed May 6, 2016). 4.1E Fifth Supplemental Indenture, dated as of May 13, 2016, among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association (Incorporated by reference to Exhibit 4.4 to the Company’s Quarterly Report on Form 10-Q, filed August 5, 2016). 4.1F Sixth Supplemental Indenture, dated as of August 9, 2016, among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association (Incorporated by reference to Exhibit 4.4 to the Company’s Quarterly Report on Form 10-Q, filed November 8, 2016). 4.1G Seventh Supplemental Indenture, dated as of November 10, 2016, among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association (Incorporated by reference to Exhibit 4.4G to the Company’s Annual Report on Form 10-K, filed February 24, 2017 ). 4.1H Eighth Supplemental Indenture, dated as of March 17, 2017, among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association (Incorporated by reference to Exhibit 4.4 to the Company’s Quarterly Report on Form 10-Q, filed May 5, 2017). 4.1I Ninth Supplemental Indenture, dated as of May 11, 2017, among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association (Incorporated by reference to Exhibit 4.3 to the Company’s Quarterly Report on Form 10-Q, filed August 9, 2017). 4.1J Tenth Supplemental Indenture, dated as of May 25, 2017, among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association (Incorporated by reference to Exhibit 4.3A to the Company’s Quarterly Report on Form 10-Q, filed August 9, 2017). 4.2 Indenture, dated as of April 4, 2017, by and among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association, governing the Company’s 4.750% Senior Notes due 2028 (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed April 4, 2017). 4.2A First Supplemental Indenture, dated as of May 11, 2017, among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association (Incorporated by reference to Exhibit 4.6A to the Company’s Quarterly Report on Form 10-Q, filed August 9, 2017). 4.2B Second Supplemental Indenture, dated as of May 25, 2017, among the Company, each of the subsidiary guarantors listed therein and U.S. Bank National Association (Incorporated by reference to Exhibit 4.6B to the Company’s Quarterly Report on Form 10-Q, filed August 9, 2017). 4.3 Indenture, dated as of September 20, 2019, among the Company, OHI Healthcare Properties Limited Partnership and U.S. Bank National Association, governing the Company’s 3.625% Senior Notes due 2029 (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed September 20, 2019). I-1 Table of Contents 4.4 Indenture, dated as of October 9, 2020, among the Company, OHI Healthcare Properties Limited Partnership and U.S. Bank National Association, governing the Company’s 3.375% Senior Notes due 2031 (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed October 9, 2020). 4.4A First Supplemental Indenture, dated as of October 30, 2020, among the Company, OHI Healthcare Properties Limited Partnership and U.S. Bank National Association (Incorporated by reference to Exhibit 4.2 to the Company’s Quarterly Report on Form 10-Q, filed November 3, 2020). 4.5 Indenture, dated as of March 10, 2021, among the Company, OHI Healthcare Properties Limited Partnership and U.S. Bank National Association, governing the Company’s 3.250% Senior Notes due 2033 (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed March 10, 2021). 4.6 Indenture dated as of June 20, 2025, among the Company and U.S. Bank Trust Company, National Association (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed June 20, 2025). 4.6A First Supplemental Indenture, dated as of June 20, 2025, among the Company, OHI Healthcare Properties Limited Partnership and U.S. Bank Trust Company, National Association, governing the Company’s 5.200% Senior Notes due 2030 (Incorporated by reference to Exhibit 4.2 to the Company’s Form 8-K, filed June 20, 2025). 4.7 Description of Securities registered under Section 12 of the Securities Exchange Act of 1934.* 10.1 Form of Directors and Officers Indemnification Agreement (Incorporated by reference to Exhibit 10.1 to the Company’s Annual Report on Form 10-K, filed February 23, 2018). 10.2 Amended and Restated Deferred Stock Plan, dated October 16, 2012, and forms of related agreements (Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed November 7, 2012). 10.3 Amended and Restated Credit Agreement, dated as of September 30, 2025, by and among the Company, as a borrower, OHI UK Healthcare Properties Ltd., as a U.K. borrower, certain of Omega’s subsidiaries identified therein, as guarantors, a syndicate of financial institutions, as lenders, and Bank of America, N.A., as administrative agent (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed October 1, 2025). 10.4 Credit Agreement, dated as of April 30, 2021, among OHI Healthcare Properties Limited Partnership, the lenders named therein and Bank of America, N.A., as administrative agent for such lenders (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed May 4, 2021). 10.4A Conforming Changes Amendment to Credit Agreement, dated as of June 7, 2023, amending the Credit Agreement dated April 30, 2021, between OHI Healthcare Properties Limited Partnership and Bank of America, N.A., as administrative agent (Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q, filed August 3, 2023). 10.5 Credit Agreement, dated as of August 8, 2023, among Omega Healthcare Investors, Inc., certain subsidiaries of Omega Healthcare Investors, Inc. identified therein as guarantors, the lenders named therein and Bank of America, N.A., as administrative agent for such lenders (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed August 11, 2023). 10.5A First Amendment to Credit Agreement dated September 30, 2025, amending the Credit Agreement dated August 8, 2023, by and among Omega, as borrower, certain of Omega’s subsidiaries identified from time to time therein, as guarantors, a syndicate of financial institutions, as lenders, and Bank of America, N.A., as administrative agent (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed October 1, 2025). 10.6 At-the Market Equity Offering Sales Agreement, dated November 3, 2025, among the Company, the Sales Agents, the Forward Sellers and the Forward Purchasers (Incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K, filed November 3, 2025). 10.7 Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed June 11, 2018). + 10.7A Amendment to Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan, effective June 5, 2023 (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed June 5, 2023). + 10.7B Form of Time-Based Restricted Stock Units Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan (commencing 2022) (Incorporated by reference to Exhibit 10.6M to the Company’s Annual Report on Form 10-K, filed February 17, 2022). + 10.7C Form of Time-Based Profits Interest Units Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan (2022 through 2024) (Incorporated by reference to Exhibit 10.6N to the Company’s Annual Report on Form 10-K, filed February 17, 2022). + 10.7D Form of Time-Based Profits Interest Units Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan (commencing 2025) (Incorporated by reference to Exhibit 10.6D to the Company’s Annual Report on Form 10-K, filed February 13, 2025). + I-2 Table of Contents 10.7E Form of TSR-Based Performance Restricted Stock Units Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan (2022 through 2024) (Incorporated by reference to Exhibit 10.6O to the Company’s Annual Report on Form 10-K, filed February 17, 2022). + 10.7F Form of TSR-Based Performance Restricted Stock Units Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan (commencing 2025) (Incorporated by reference to Exhibit 10.6F to the Company’s Annual Report on Form 10-K, filed February 13, 2025). + 10.7G Form of TSR-Based Performance Profits Interest Units Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan (2022 through 2024) (Incorporated by reference to Exhibit 10.6P to the Company’s Annual Report on Form 10-K, filed February 17, 2022). + 10.7H Form of TSR-Based Performance Profits Interest Units Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan (commencing 2025) (Incorporated by reference to Exhibit 10.6H to the Company’s Annual Report on Form 10-K, filed February 13, 2025). + 10.7I Form of Relative TSR-Based Performance Restricted Stock Units Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan (2022 through 2024) (Incorporated by reference to Exhibit 10.6Q to the Company’s Annual Report on Form 10-K, filed February 17, 2022). + 10.7J Form of Relative TSR-Based Performance Restricted Stock Units Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan (commencing 2025) (Incorporated by reference to Exhibit 10.6J to the Company’s Annual Report on Form 10-K, filed February 13, 2025). + 10.7K Form of Relative TSR-Based Performance Profits Interest Units Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan (2022 through 2024) (Incorporated by reference to Exhibit 10.6R to the Company’s Annual Report on Form 10-K, filed February 17, 2022). + 10.7L Form of Relative TSR-Based Performance Profits Interest Units Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan (commencing 2025) (Incorporated by reference to Exhibit 10.6L to the Company’s Annual Report on Form 10-K, filed February 13, 2025).+ 10.7M Form of Director Time-Based Profits Interest Units Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan. (Incorporated by reference to Exhibit 10.6M to the Company’s Annual Report on Form 10-K, filed February 13, 2025). + 10.7N Form of Director Restricted Stock Award Agreement pursuant to the Omega Healthcare Investors, Inc. 2018 Stock Incentive Plan. (Incorporated by reference to Exhibit 10.6N to the Company’s Annual Report on Form 10-K, filed February 13, 2025). + 10.8 Form of Officer Deferred Performance Restricted Stock Unit Agreement (Incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q, filed August 5, 2013). + 10.9 Form of Employment Agreement for Company’s executive officers. (Incorporated by reference to Exhibit 10.8 to the Company’s Annual Report on Form 10-K, filed February 13, 2025). + 10.10 Omega Healthcare Investors, Inc. Deferred Cash Compensation Plan with form of Deferral Agreement pursuant to the Omega Healthcare Investors, Inc. Deferred Cash Compensation Plan (June 30, 2018) (Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed August 8, 2018). + 10.11 Third Amended and Restated Agreement of Limited Partnership of OHI Healthcare Properties Limited Partnership as of February 11, 2025 (Incorporated by reference to Exhibit 3.5 to the Company’s Annual Report on Form 10-K, filed February 13, 2025). 19.1 Omega Healthcare Investors, Inc. Insider Trading Policy (Incorporated by reference to Exhibit 19.1 to the Company’s Annual Report on Form 10-K, filed February 13, 2025). 21.1 Subsidiaries of the Registrant.* 22.1 Subsidiary guarantors of guaranteed securities.* 23.1 Consent of Independent Registered Public Accounting Firm for Omega Healthcare Investors, Inc.* 31.1 Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer of Omega Healthcare Investors, Inc.* 31.2 Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer of Omega Healthcare Investors, Inc.* 32.1 Section 1350 Certification of the Chief Executive Officer of Omega Healthcare Investors, Inc.* 32.2 Section 1350 Certification of the Chief Financial Officer of Omega Healthcare Investors, Inc.* 97.1 Omega Healthcare Investors, Inc. Incentive Compensation Recovery Policy (Incorporated by reference to Exhibit 97.1 to the Company’s Annual Report on Form 10-K, filed February 12, 2024). + I-3 Table of Contents 101 The following financial statements from the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Comprehensive Income, (iv) Consolidated Statements of Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101). * Exhibits that are filed or furnished herewith. + Management contract or compensatory plan, contract or arrangement. ​ ​ ​ ​ ​ I-4 Table of Contents SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ​ ​ ​ ​ ​ ​ ​ OMEGA HEALTHCARE INVESTORS, INC. ​ Registrant ​ ​ ​ ​ Date: February 9, 2026 ​ By: /s/ C. Taylor Pickett ​ ​ ​ C. Taylor Pickett ​ ​ ​ Chief Executive Officer ​ ​ ​ ​ ​ ​ ​ I-5 Table of Contents Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Omega Healthcare Investors, Inc., for itself and in the capacities on the date indicated. ​ ​ ​ ​ ​ Signatures ​ ​ ​ Title ​ ​ ​ Date ​ ​ ​ ​ ​ /s/ C. Taylor Pickett ​ Chief Executive Officer ​ February 9, 2026 C. Taylor Pickett ​ (Principal Executive Officer) ​ ​ ​ ​ ​ ​ ​ /s/ Robert O. Stephenson ​ Chief Financial Officer ​ February 9, 2026 Robert O. Stephenson ​ (Principal Financial Officer) ​ ​ ​ ​ ​ ​ ​ /s/ Neal A. Ballew ​ Chief Accounting Officer ​ February 9, 2026 Neal A. Ballew ​ (Principal Accounting Officer) ​ ​ ​ ​ ​ ​ ​ /s/ Craig R. Callen ​ Chair of the Board ​ February 9, 2026 Craig R. Callen ​ ​ ​ ​ ​ ​ ​ ​ ​ /s/ Kapila K. Anand ​ Director ​ February 9, 2026 Kapila K. Anand ​ ​ ​ ​ ​ ​ ​ ​ ​ /s/ Dr. Lisa C. Egbuonu-Davis ​ Director ​ February 9, 2026 Dr. Lisa C. Egbuonu-Davis ​ ​ ​ ​ ​ ​ ​ ​ ​ /s/ Barbara B. Hill ​ Director ​ February 9, 2026 Barbara B. Hill ​ ​ ​ ​ ​ ​ ​ ​ ​ /s/ Kevin J. Jacobs ​ Director ​ February 9, 2026 Kevin J. Jacobs ​ ​ ​ ​ ​ ​ ​ ​ ​ /s/ C. Taylor Pickett ​ Director ​ February 9, 2026 C. Taylor Pickett ​ ​ ​ ​ ​ ​ ​ ​ ​ /s/ Stephen D. Plavin ​ Director ​ February 9, 2026 Stephen D. Plavin ​ /s/ Burke W. Whitman ​ Director ​ February 9, 2026 Burke W. Whitman ​ ​ ​ ​ ​ ​ ​ ​ I-6